<PAGE>
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
------------------------
/X/ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
FOR THE FISCAL YEAR ENDED DECEMBER 31, 1999
OR
/ / TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM TO
------------------------
COMMISSION FILE NUMBER 333-17827
INTERNATIONAL SPECIALTY PRODUCTS INC.
(Exact name of registrant as specified in its charter)
<TABLE>
<S> <C>
DELAWARE 51-0376469
(State of Incorporation) (I.R.S. Employer Identification No.)
300 DELAWARE AVENUE
SUITE 303
WILMINGTON, DELAWARE 19801
(Address of Principal Executive Offices) (Zip Code)
</TABLE>
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE:
(302) 427-5715
SECURITIES REGISTERED PURSUANT TO SECTION 12(B) OF THE ACT:
<TABLE>
<S> <C>
NAME OF EACH EXCHANGE ON
TITLE OF EACH CLASS WHICH REGISTERED
Common Stock, par value $.01 per share New York Stock Exchange
</TABLE>
SECURITIES REGISTERED PURSUANT TO SECTION 12(G) OF THE ACT: None
------------------------
Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes X No _
Indicate by check mark if disclosure of delinquent filers pursuant to
Item 405 of Regulation S-K is not contained herein, and will not be contained,
to the best knowledge of International Specialty Products Inc., in definitive
proxy or information statements incorporated by reference in Part III of this
Form 10-K or any amendment to this Form 10-K. X
As of March 24, 2000, 68,844,702 shares of common stock of the registrant
were outstanding. The aggregate market value of the voting stock held by
non-affiliates of the registrant as of March 24, 2000 was $98,647,523. The
aggregate market value was computed by reference to the closing price on the New
York Stock Exchange of common stock of the registrant on such date ($6.50). For
purposes of the computation, voting stock held by executive officers and
directors of the registrant has been excluded. Such exclusion is not intended,
and shall not be deemed, to be an admission that such executive officers and
directors are affiliates of the registrant.
DOCUMENTS INCORPORATED BY REFERENCE
The Proxy Statement for the 2000 Annual Meeting of Stockholders of
International Specialty Products Inc. to be filed within 120 days after the
registrant's fiscal year-end (the "Proxy Statement") is incorporated by
reference in Part III, Items 10, 11, 12 and 13.
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
<PAGE>
PART I
ITEM 1. BUSINESS
GENERAL
International Specialty Products Inc. (formerly ISP Holdings Inc.) ("ISP")
is a leading multinational manufacturer of specialty chemicals and mineral
products.
We operate our business exclusively through our direct and indirect
subsidiaries, including ISP Opco Holdings Inc., ISP Chemicals Inc., ISP
Technologies Inc., ISP Van Dyk Inc., ISP Fine Chemicals Inc., ISP Freetown Fine
Chemicals Inc. and ISP Alginates Inc. We were incorporated in Delaware in 1996.
On July 15, 1998, International Specialty Products Inc. ("Old ISP") merged
with and into our company (then known as ISP Holdings Inc. ("ISP Holdings")). In
connection with the merger, each share of common stock of Old ISP (other than
those held by ISP Holdings) was automatically converted into one share of common
stock of the surviving corporation, substantially all of the assets and
liabilities of Old ISP were transferred to our subsidiary, ISP Opco Holdings
Inc., and we changed our name to International Specialty Products Inc.
Approximately 76% of our outstanding common stock is owned beneficially (as
defined in Rule 13d-3 of the Securities Exchange Act of 1934) by Samuel J.
Heyman, our Chairman of the Board of Directors.
Prior to January 1, 1997, ISP Holdings was a wholly-owned subsidiary of GAF
Corporation ("GAF"). On January 1, 1997, GAF effected a series of transactions
involving its subsidiaries that resulted in, among other things, the capital
stock of ISP Holdings being distributed to the stockholders of GAF. As a result
of this distribution, we are no longer a subsidiary of GAF, and the assets and
liabilities of other subsidiaries of GAF, including G-I Holdings Inc., Building
Materials Corporation of America, U.S. Intec, Inc., and GAF Fiberglass
Corporation are no longer included in our assets and liabilities.
On October 15, 1999, we acquired substantially all of the assets of the
Kelco Alginates division of Monsanto Company. Our alginates business
manufactures sodium alginate, propylene glycol alginate and other alginate
derivatives at our San Diego, California and Girvan, Scotland plants. Algin is a
naturally occurring hydrocolloid derived from brown seaweed and is used in food,
pharmaceutical and industrial applications. As part of the transaction, we also
acquired a research and administrative center in Tadworth, England and equity
investments in three seaweed processing joint ventures located in Ireland,
Iceland and Tasmania.
Prior to October 1, 1999, we manufactured and sold filter products,
consisting of pressure filter vessels, filter bags and filter systems, primarily
to the paint, automotive, chemical, pharmaceutical, petroleum and food and
beverage industries. Effective October 1, 1999, we sold the stock of our filter
products subsidiaries to Hayward Industrial Products, Inc.
The address and telephone number of our principal executive offices are 300
Delaware Avenue, Suite 303, Wilmington, Delaware 19801, (302) 427-5715.
Financial information concerning our industry segments and foreign and
domestic operations required by Item 1 is included in Notes 15 and 16 to
Consolidated Financial Statements contained in this Annual Report on Form 10-K.
SPECIALTY CHEMICALS
Products and Markets. We manufacture a broad spectrum of specialty
chemicals having numerous applications in consumer and industrial products. We
use proprietary technology to convert various raw materials, through a chain of
one or more processing steps, into increasingly complex and higher value-added
specialty chemicals specifically developed to meet customer requirements.
1
<PAGE>
Our specialty chemicals business is organized based upon the markets for
our products. Accordingly, we manage our specialty chemicals in the following
three business segments:
o Personal Care--whose products are sold to the skin care and hair
care markets;
o Pharmaceutical, Food and Beverage--whose products are sold to these
three government-regulated industries; and
o Performance Chemicals, Fine Chemicals and Industrial--whose products
are sold to numerous consumer and industrial markets.
For the year ended December 31, 1999, sales of specialty chemicals
represented approximately 89% of our revenues. Most of our specialty chemical
products fall within the following categories:
o vinyl ether monomers--includes several products for use in specialty
and radiation-cured coatings. Our vinyl ether monomers are marketed
by the Performance Chemicals group of our Performance Chemicals,
Fine Chemicals and Industrial business segment.
o vinyl ether copolymers--includes our GANTREZ(R) line of products.
These products serve as a bioadhesive resin in such consumer
products as tartar-control toothpaste, denture adhesives and facial
pore strips. Vinyl ether copolymers are marketed by our Personal
Care and Pharmaceutical, Food and Beverage business segments.
o polyvinyl pyrrolidone (PVP) polymers and copolymers--represents our
largest product group. These polymers and copolymers are marketed by
all of our business segments. Our PLASDONE(R), POLYCLAR(R) and
GAFQUAT(R) product lines, which are used as tablet binders, beverage
clarifiers and hair fixative resins, respectively, are included in
this group.
o intermediates--includes butanediol, butenediol, butynediol, and
propargyl alcohol for use in numerous industrial applications.
Intermediates are marketed by our Performance Chemicals, Fine
Chemicals and Industrial business segment. Our largest selling
intermediate product is butanediol, which is utilized by industrial
companies to manufacture spandex fibers and polybutylene
terephthalate (PBT) plastics for use in automobiles.
o solvents--includes our M-PYROL(R) brand of N-methyl pyrrolidone
(NMP), for use in metal degreasing and paint stripping, BLO(R) brand
of gamma-butyrolactone, for use by electronics companies in the
manufacture of semiconductors and micro-processing chips, and
tetrahydrofuran (THF), which is used in the manufacture and
installation of PVC pipe. Solvents are also marketed by our
Performance Chemicals, Fine Chemicals and Industrial business
segment.
o alginates--includes sodium alginate, propylene glycol alginate and
other alginate derivatives for use as thickeners, stabilizers and
viscosity modifiers. These products are marketed by our
Pharmaceutical, Food and Beverage business segment, with the
majority of our sales to the food industry.
The balance of our specialty chemical products includes fine chemicals
(marketed by our Performance Chemicals, Fine Chemicals and Industrial business
segment), sunscreens, preservatives, emollients (each marketed by our Personal
Care business segment) and advanced materials (marketed by our Pharmaceutical,
Food and Beverage business segment and our Performance Chemicals, Fine Chemicals
and Industrial business segment).
Personal Care. Our Personal Care business segment markets numerous
specialty chemicals that serve as critical ingredients in the formulation of
many well-known skin care, hair care, toiletry and cosmetic products.
Our skin care ingredients include:
o ultraviolet (UV) light absorbing chemicals, which serve as
sunscreens;
o emollients, which provide skin softness;
o moisturizers, which enhance the skin's water balance;
2
<PAGE>
o waterproofing agents, which enhance the performance of eye-liners
and sunscreens in wet environments; and
o preservatives, which extend the shelf life of aqueous-based cosmetic
formulations by preventing the growth of harmful bacteria.
Our ESCALOL(R) sunscreen actives serve as the primary active ingredient in
many of the most popular sunscreens today and increasingly find applications in
many other products such as lipsticks and facial creams. Our CERAPHYL(R) line of
emollients and moisturizers provide a variety of popular bath products with
their softening and moisturizing characteristics. We produce a growing number of
specialty preservatives, including GERMALL(R) PLUS, a patented product that
offers broad-spectrum anti-microbial activity, and SUTTOCIDE(R) A, a
preservative gentle enough for infant care products.
Our hair care ingredients, marketed under the GANTREZ(R), GAFQUAT(R), and
PVP/VA family of products, include a number of specially formulated fixative
resins which provide hairsprays, mousses and gels with their holding power, as
well as thickeners and stabilizers for shampoos and conditioners. Utilizing our
combined expertise in hair care and sunscreen applications, we developed the
world's first high performance hair protectant, ESCALOL(R) HP-610, to prevent
sun damage to hair.
On April 2, 1999, we sold our pearlescent pigments business, a non-core
product line that was part of the Personal Care business segment.
Pharmaceutical, Food and Beverage. Our specialty chemicals for the
Pharmaceutical, Food and Beverage markets provide a number of end-use products
with their unique properties while enabling these products to meet increasingly
strict regulatory requirements.
In the pharmaceutical market, our specialty chemicals serve as key
ingredients in the following types of products:
o prescription and over-the-counter tablets;
o injectable prescription drugs and serums;
o cough syrups;
o antiseptics;
o toothpastes; and
o denture adhesives.
Our PLASDONE(R) and POLYPLASDONE(R) polymers for tablet binders and tablet
disintegrants are established excipients for use in the production of wet
granulated tablets, and our GANTREZ(R) bioadhesive polymers serve as critical
ingredients in denture adhesives and tartar control toothpastes.
Our advanced materials product line includes the FERRONYL(R) brand of
dietary iron supplement, which is marketed to the pharmaceutical industry.
In the food and beverage markets, our alginates and acetylene-derived
polymers serve as critical ingredients in the manufacture of numerous consumer
products, including salad dressings, cheese sauces, fruit fillings, beer and
health drinks. For example, our alginates products, marketed under the
KELCOLOID(R) tradename, are used as stabilizers in many well-known consumer
products, while our acetylene-based specialty polymers, marketed under the
POLYCLAR(R) tradename, serve the beverage market by assuring the clarity and
extending the shelf life of beer, wine and fruit juices.
Performance Chemicals, Fine Chemicals and Industrial. Our Performance
Chemicals business includes acetylene-based polymers, vinyl ether monomers and
advanced materials for consumer, agricultural and industrial applications. Our
acetylene-based chemistry produces a number of Performance Chemicals for use in
a wide range of markets including:
o coatings;
o agriculture;
3
<PAGE>
o imaging;
o detergents;
o electronics; and
o metalworking.
We believe that we are a leading producer of inert ingredients for the
agricultural industry, where our solvents and polymers are used for the
formulation of safer and more effective crop treatment products. For example,
our AGRIMER(R) line of specialty polymers are EPA-approved inert ingredients
which are used in seed-coating, crop dusting products, and as binders and
disintegrants for a variety of pesticide tablets, pellets and granules.
Our advanced materials product line includes high-purity carbonyl iron
powders, sold under the MICROPOWDER(R) name, for use in the aerospace, defense,
electronics and powder metallurgy industries.
Our Fine Chemicals business focuses on the production of a variety of
highly specialized products sold to the pharmaceutical, biotechnology,
agricultural and imaging markets. We also offer custom manufacturing services
for these industries.
We manufacture a broad range of fine chemicals under U.S. FDA current good
manufacturing practices (cGMP) at our Columbus, Ohio facility. These fine
chemicals include:
o bulk pharmaceuticals, such as flunixin meglumine, a veterinary drug,
and mitotane, a cancer treatment drug;
o pharmaceutical intermediates, manufactured under contract for
well-known pharmaceutical companies whose end products treat heart
and kidney diseases, viral infections, and lower cholesterol; and
o pheromones, for use in insect population measurement and control.
We expanded our presence in the fine chemicals market with the February
1998 acquisition of our Freetown, Massachusetts manufacturing facility from
Polaroid Corporation. We are expanding the facility's production capabilities to
allow for the manufacture of certain specialty chemical product lines for our
Personal Care business segment and to offer custom manufacturing capability to
the pharmaceutical, biotechnology, agricultural and chemical process industries.
As part of the acquisition of this facility, we entered into a multi-year
agreement to supply the imaging dyes and polymers used by Polaroid in its
instant film business.
In our Industrial business, we market several intermediate and solvent
products, such as butanediol, tetrahydrofuran (THF) and N-methyl pyrrolidone
(NMP), for use in a variety of industries, including:
o high performance plastics;
o lubricating oil and chemical processing;
o electronics cleaning; and
o coatings.
In addition, we offer a family of environmentally friendly products that
can replace chlorinated and other volatile solvents for a variety of industrial
uses, including cleaning, stripping and degreasing.
Effective April 1, 1998, we acquired the remaining 50% interest in GAF-Huls
Chemie GmbH, now known as ISP Marl GmbH ("ISP Marl"), our joint venture with a
subsidiary of Huls AG, based in Marl, Germany. As part of the transaction, we
also acquired the fully-dedicated, modern production facility that provides ISP
Marl with its primary raw material, acetylene. We believe that the production
costs for butanediol and THF at ISP Marl are among the most competitive in the
industry. We believe that this acquisition provides us with continued access to
a low-cost supply of butanediol that is critical to the manufacture of many of
our downstream polymers.
4
<PAGE>
During 1999, based on a review of our entire butanediol manufacturing
network, which includes the Texas City, Texas; Calvert City, Kentucky; and Marl,
Germany plants, we shut down the butanediol production unit at our Calvert City
plant, writing off the associated assets, and evaluated curtailing production of
butanediol at our Texas City plant. As a result of this evaluation, we wrote
down to fair value certain butanediol assets at our Texas City and Seadrift,
Texas manufacturing facilities and may shut down the butanediol production units
at these facilities in the near future. We continue to produce polymers at our
Calvert City and Texas City plants.
Marketing and Sales. We market our specialty chemicals using a worldwide
marketing and sales force, typically chemists or chemical engineers, who work
closely with our customers to familiarize themselves with our customers'
products, manufacturing processes and markets. We conduct our domestic marketing
and sales efforts from our facility in Wayne, New Jersey and regional offices
strategically located throughout the United States.
International Operations. We conduct our international operations through
39 subsidiaries and 45 sales offices located in Europe, Canada, Latin America
and the Asia-Pacific region. We also use the services of local distributors to
reach markets that might otherwise be unavailable to us.
International sales of our specialty chemicals in 1999 were approximately
48% of our total sales for that period. Approximately 37% of our specialty
chemicals sales in 1999 were in Europe and Japan. Sales in these regions are
subject to exchange rate fluctuation risks. For a discussion of our policy
regarding the management of these risks, see Item 7, "Management's Discussion
and Analysis of Financial Condition and Results of Operations--Liquidity and
Financial Condition." Other countries in which we have sales are subject to
additional risks, including high rates of inflation, exchange controls,
government expropriation and general instability.
We own and operate ISP Marl, primarily a butanediol manufacturing facility,
and ISP Acetylene GmbH, an acetylene production plant. Both production
facilities are located at Huls' Chemiepark site in Marl, Germany, and each
relies upon Huls to provide certain services, including utilities, rail
transport and waste handling. ISP Marl is the most modern butanediol production
facility in our butanediol manufacturing network. ISP Acetylene, which employs
electric arc technology for the production of acetylene from various hydrocarbon
feedstocks, was built in 1992 to replace an older facility and utilizes
state-of-the-art gas separation technology. ISP Acetylene's entire production is
dedicated to fulfilling ISP Marl's requirements and has no third-party sales.
In October 1999, we acquired an alginates manufacturing plant in Girvan,
Scotland and a research and administrative center in Tadworth, England. In
addition, we acquired equity investments in three seaweed processing joint
ventures located in Ireland, Iceland and Tasmania. These joint ventures serve to
provide our alginates business with a steady supply of its primary raw material,
seaweed.
Raw Materials. Because of the multi-step processes required to manufacture
our specialty chemicals, we believe that our raw materials costs represent a
smaller percentage of the cost of goods sold than for most other chemical
companies. We estimate that approximately one-third of our manufacturing costs
are for raw materials (including energy and packaging). As a result, we believe
that fluctuations in the price of raw materials have less of an impact on our
specialty chemicals business than on those chemical companies for which raw
materials costs represent a larger percentage of manufacturing costs.
The principal raw materials used in the manufacture of our acetylene-based
specialty chemicals are acetylene, methanol and methylamine. Most of the raw
materials for consumption in the United States are obtained from third party
sources pursuant to supply agreements. Acetylene, a significant raw material
used in the production of most of our specialty chemicals, is obtained by us for
domestic use from two unaffiliated suppliers pursuant to supply contracts. At
our Texas City and Seadrift, Texas plants, acetylene is supplied via pipeline by
a neighboring large multinational company that generates this raw material as a
by-product from the manufacture of ethylene. At our Calvert City, Kentucky
facility, acetylene is supplied via pipeline by a neighboring company that
generates it from calcium carbide.
Due to the nature of the manufacturing process, electricity and hydrocarbon
feedstocks (primarily butane) are critical raw materials for the production of
acetylene at our operations in Marl, Germany, where
5
<PAGE>
methanol is also a principal raw material. Electricity, butane and methanol for
our Marl, Germany operations are supplied by Huls pursuant to a long-term supply
agreement.
We believe that the diversity of our acetylene supply sources and our use
of a number of acetylene production technologies (ethylene by-product, calcium
carbide and electric arc technology) provide us with a reliable supply of
acetylene. In the event of a substantial interruption in the supply of acetylene
from current sources, or, in the case of ISP Marl, electricity and hydrocarbon
feedstocks, we cannot assure that we would be able to obtain as much acetylene
from other sources as would be necessary to meet our supply requirements. To
date, we have not experienced an interruption of our acetylene supply that has
had a material adverse effect on our sales of specialty chemicals.
The principal raw material used in the manufacture of alginates is certain
select species of seaweed. We process seaweed in both wet and dry forms. We use
our own specially designed vessels to harvest, under government license, wet
seaweed from leased kelp beds in the Pacific Ocean to supply our San Diego,
California facility. Our Girvan, Scotland facility processes primarily dry
seaweed purchased from our joint ventures in Iceland, Ireland and Tasmania, as
well as from independent suppliers in South America. We believe that the species
of seaweed required to manufacture alginates will remain readily available and
that we will have adequate access to this seaweed to provide us with adequate
supplies of this raw material for the foreseeable future.
Availability of other raw materials, including methanol and methylamine,
remained adequate during 1999. We believe that, in the event of a supply
interruption, we could obtain adequate supplies of such raw materials from
alternate sources.
We use natural gas and raw materials derived from petroleum in many of our
manufacturing processes and, consequently, the price and availability of natural
gas and petroleum could be material to our operations. During 1999, crude oil
and natural gas supplies remained adequate and the impact of rising crude oil
prices was mitigated through operational efficiencies.
MINERAL PRODUCTS
Products and Markets. We manufacture mineral products consisting of
ceramic-coated colored roofing granules, which are produced from rock deposits
that are mined and crushed at our quarries and are colored and coated using a
proprietary process. We sell our mineral roofing granules primarily to the North
American roofing industry for use in the manufacture of asphalt roofing
shingles. The granules help to provide weather resistance, decorative coloring,
heat deflection and increased weight in the shingle. We are the second largest
of only three major suppliers of colored roofing granules in North America.
We estimate that more than 80% of the asphalt shingles currently produced
by the roofing industry are sold for the reroofing/replacement market, in which
demand is driven not by the pace of new home construction but by the needs of
homeowners to replace existing roofs. Homeowners generally replace their roofs
either because they are worn, thereby creating concerns as to weather-tightness,
or because of the homeowners' desire to upgrade the appearance of their homes.
We estimate that the balance of the roofing industry's asphalt shingle
production historically has been sold primarily for use in new housing
construction. Sales of our colored mineral granules have benefited from a trend
toward the increased use of heavyweight, three-dimensional laminated roofing
shingles which results in both functional and aesthetic improvements. These
shingles require, on average, approximately 60% more granules than traditional
three-tab, lightweight roofing shingles.
Sales to Building Materials Corporation of America ("BMCA"), an affiliate,
and its subsidiaries constituted approximately 66% of our mineral products net
sales in 1999. See Item 13, "Certain Relationships and Related Transactions" and
Note 14 to Consolidated Financial Statements. See also Item 7, "Management's
Discussion and Analysis of Financial Condition and Results of
Operations--Results of Operations--1999 Compared with 1998."
Raw Materials. We own rock deposits that have specific performance
characteristics, including weatherability, the ability to reflect UV light,
abrasion-resistance, non-staining characteristics and the ability
6
<PAGE>
to absorb pigments. We own three quarries, each with proven reserves, based on
current production levels, of more than 20 years.
COMPETITION
We believe that we are either the first or second largest seller, based on
revenues, worldwide of our specialty chemicals derived from acetylene, other
than butanediol and tetrahydrofuran, and the second largest seller, based on
revenues, of alginates.
In each end-use market, there are a limited number of companies that
produce substitutable products for our acetylene-derived specialty chemicals.
These companies compete with us in the personal care, pharmaceutical, beverage
and industrial markets and have the effect of limiting our market penetration
and pricing flexibility. For our specialty chemicals not derived from acetylene,
including alginates, sunscreens, emollients, moisturizers and fine chemicals, a
number of world-wide competitors can provide similar products or services. We
compete on quality, customer service and price in these markets.
Butanediol, which we produce primarily for use as a raw material, is also
manufactured by a limited number of companies throughout the world for both
their captive use or to supply the merchant market. We believe that there are
four competitors of significance for merchant market butanediol. One of these
competitors sources the merchant market from its plants in the United States and
in Europe. Two other competitors each source the merchant market from their
single manufacturing plants, one in the United States and the other in Europe.
We believe the fourth competitor is nearing completion of its single plant in
the United States and is expected to begin commercial production of butanediol
during 2000. Tetrahydrofuran is manufactured by a number of companies throughout
the world.
With regard to our mineral products, we have only one larger and one
smaller competitor and believe that competition has been limited by:
o the substantial capital expenditures associated with the
construction of new mineral processing and coloring plants and the
acquisition of suitable rock reserves;
o the limited availability of proven rock sources;
o the complexity associated with the construction of a mineral
processing and coloring plant, together with the technical know-how
required to operate such a plant;
o the need to obtain, prior to commencing operations, reliable data
over a substantial period of time regarding the weathering of
granules in order to assure the quality and durability of the
product; and
o the difficulty in obtaining the necessary permits to mine and
operate a quarry.
Competition is largely based upon product and service quality, technology,
distribution capability and price. We believe that we are well-positioned in the
marketplace as a result of our broad product lines, sophisticated technology and
worldwide distribution network.
RESEARCH AND DEVELOPMENT
Our worldwide research and development expenditures were $26.9, $25.9 and
$23.0 million in 1997, 1998 and 1999, respectively.
Our research and development activities are conducted primarily at our
worldwide technical center and laboratories in Wayne, New Jersey. Additional
research and development is conducted at plant sites in Calvert City, Kentucky;
Texas City, Texas; Chatham, New Jersey; Belleville, New Jersey; Freetown,
Massachusetts; Columbus, Ohio; San Diego, California; and Girvan, Scotland, as
well as at technical centers in the United Kingdom, Germany, China and
Singapore. Our mineral products research and development facility, together with
our customer design and color center, is located in Hagerstown, Maryland.
7
<PAGE>
ENVIRONMENTAL SERVICES
We have received site designation for the construction of a hazardous waste
treatment, storage and disposal facility at our Linden, New Jersey property and
have received approval from the New Jersey Turnpike Authority for a direct
access ramp from the New Jersey Turnpike to the site. If we are successful in
securing the necessary permits to construct and operate the hazardous waste
facility, we intend to develop and operate the facility in a separate
subsidiary, either on our own or in a joint venture with a suitable partner. We
estimate that the cost of constructing the facility will be approximately $100
million and, if approved, the facility is anticipated to be in operation three
years after commencement of construction. We anticipate utilizing internally
generated cash and/or seeking project or other independent financing for this
project. We also are investigating other development opportunities at this site.
PATENTS AND TRADEMARKS
As of December 31, 1999, we owned or licensed approximately 350 domestic
and 460 foreign patents or patent applications and owned or licensed
approximately 150 domestic and 1,890 foreign trademark registrations or
applications related to our business. While we believe the patent protection
covering certain of our products is material to those products, we do not
believe that any single patent, patent application or trademark is material to
our business or operations. We believe that the duration of the existing patents
and patent licenses is consistent with our business needs.
ENVIRONMENTAL COMPLIANCE
Since 1970, a wide variety of federal, state and local environmental laws
and regulations relating to environmental matters have been adopted and amended.
By reason of the nature of our operations and the operations of our predecessor
and certain of the substances that are or have been used, produced or discharged
at our or its plants or at other locations, we are affected by these
environmental laws and regulations. We have made capital expenditures of less
than $4.0 million in each of the three years ended December 31, 1999, in order
to comply with these laws and regulations. These expenditures are included in
additions to property, plant and equipment. We anticipate that aggregate capital
expenditures relating to environmental compliance in 2000 and 2001 will be
approximately $7.0 and $9.0 million, respectively.
The environmental laws and regulations deal with air and water emissions or
discharges into the environment, as well as the generation, storage, treatment,
transportation and disposal of solid and hazardous waste, and the remediation of
any releases of hazardous substances and materials to the environment. We
believe that our manufacturing facilities comply in all material respects with
applicable environmental laws and regulations, and, while we cannot predict
whether more burdensome requirements will be adopted in the future, we believe
that any potential liability for compliance with environmental laws and
regulations will not materially affect our business, liquidity, results of
operations, cash flows or financial position.
We believe that we operate our manufacturing facilities in compliance in
all material respects with applicable environmental, health and safety laws and
regulations, but we cannot predict whether more burdensome requirements will be
imposed by governmental authorities in the future.
EMPLOYEES
At December 31, 1999, we employed approximately 2,650 people worldwide.
Approximately 780 employees in the United States were subject to seven union
contracts. We believe that our relations with our employees and their unions are
satisfactory.
OTHER DEVELOPMENTS
On January 27, 2000, we announced that we had notified Dexter Corporation
of our intent to present at Dexter's 2000 Annual Meeting of Shareholders, and
solicit proxies in favor of, a series of resolutions designed to facilitate our
business combination proposal. Under the proposal, as amended on March 23, 2000,
Dexter shareholders would receive at least $50 per share in cash, subject to the
execution of a mutually acceptable merger agreement. We have filed with the
Securities and Exchange Commission a preliminary
8
<PAGE>
proxy statement in connection with Dexter's Annual Meeting. We beneficially own
approximately 10% of the outstanding shares of Dexter common stock and
approximately 14% of the outstanding shares of the common stock of Life
Technologies, Inc., a majority-owned subsidiary of Dexter. See Item 7,
"Management's Discussion and Analysis of Financial Condition and Results of
Operations--Liquidity and Financial Condition" and Note 18 to Consolidated
Financial Statements.
ITEM 2. PROPERTIES
Our corporate headquarters and principal research and development
laboratories are located at a 100-acre campus-like office and research park
owned by one of our subsidiaries at 1361 Alps Road, Wayne, New Jersey 07470. The
premises are subject to a first mortgage.
The principal domestic and foreign real properties either owned by, or
leased to, us are described below. Unless otherwise indicated, the properties
are owned in fee. In addition to the principal facilities listed below, we
maintain sales offices and warehouses in the United States and abroad,
substantially all of which are in leased premises under relatively short-term
leases.
<TABLE>
<CAPTION>
LOCATION FACILITY PRODUCT LINE
- ----------------------------------------- ----------------------------------- -----------------------
<S> <C> <C>
DOMESTIC
Alabama
Huntsville............................. Plant* Specialty Chemicals
California
San Diego.............................. Plant* Specialty Chemicals
Kentucky
Calvert City........................... Plant Specialty Chemicals
Maryland
Hagerstown............................. Research Center, Design Center, Mineral Products
Sales Office
Massachusetts
Freetown............................... Plant, Research Center Specialty Chemicals
Missouri
Annapolis.............................. Plant, Quarry Mineral Products
New Jersey
Belleville............................. Plant, Sales Office, Research Specialty Chemicals
Center
Bridgewater............................ Sales Office* Specialty Chemicals
Chatham................................ Plant, Sales Office, Research Specialty Chemicals
Center
Wayne.................................. Headquarters, Corporate Specialty Chemicals
Administrative Offices, Research
Center
Ohio
Columbus............................... Plant, Research Center, Sales Specialty Chemicals
Office
Pennsylvania
Blue Ridge Summit...................... Plant, Quarry Mineral Products
Texas
Seadrift............................... Plant Specialty Chemicals
Texas City............................. Plant Specialty Chemicals
Wisconsin
Pembine................................ Plant, Quarry Mineral Products
</TABLE>
9
<PAGE>
<TABLE>
<CAPTION>
LOCATION FACILITY PRODUCT LINE
- ----------------------------------------- ----------------------------------- -----------------------
<S> <C> <C>
INTERNATIONAL
Belgium
Sint-Niklaas........................... Sales Office, Distribution Center Specialty Chemicals
Brazil
Sao Paulo.............................. Sales Office*, Distribution Center* Specialty Chemicals
Canada
Mississauga, Ontario................... Sales Office*, Distribution Center* Specialty Chemicals
England
Guildford.............................. European Headquarters*, Research Specialty Chemicals
Center*
Manchester............................. Sales Office**, Distribution Specialty Chemicals
Center**
Tadworth............................... Research Center*, Sales Office* Specialty Chemicals
Germany
Cologne................................ Research Center*, Sales Office* Specialty Chemicals
Marl................................... Plants**, Sales Office** Specialty Chemicals
India
Nagpur................................. Plant** Specialty Chemicals
Japan
Tokyo.................................. Sales Office* Specialty Chemicals
Scotland
Girvan................................. Plant Specialty Chemicals
Singapore................................ Sales Office*, Distribution Specialty Chemicals
Center*, Asia-Pacific
Headquarters*, Warehouse*
</TABLE>
- ------------------
* Leased property
** Long-term ground lease
We believe that our plants and facilities, which are of varying ages and
are of different construction types, have been satisfactorily maintained, are in
good condition, are suitable for their respective operations and generally
provide sufficient capacity to meet production requirements. Each plant has
adequate transportation facilities for both raw materials and finished products.
In 1999, we made capital expenditures in the amount of $69.2 million relating to
plant, property and equipment.
ITEM 3. LEGAL PROCEEDINGS
Our company, together with other companies, is a party to a variety of
proceedings and lawsuits involving environmental matters ("Environmental
Claims") under the Comprehensive Environmental Response Compensation and
Liability Act ("CERCLA") and similar state laws, in which recovery is sought for
the cost of cleanup of contaminated sites, a number of which are in the early
stages or have been dormant for protracted periods.
We estimate that our liability in respect of all Environmental Claims
(including those relating to our closed Linden, New Jersey plant described
below), and certain other environmental compliance expenses, as of December 31,
1999, is $22.5 million, before reduction for insurance recoveries reflected on
our balance sheet (discussed below) of $11.1 million that relate to both past
expenses and estimated future liabilities ("estimated recoveries"). In the
opinion of management, the resolution of such matters should not be material to
our business, liquidity, results of operations, cash flows or financial
position. However, adverse decisions or events, particularly as to the liability
and the financial responsibility of our insurers and of the other parties
involved at each site and their insurers, could cause us to increase our
estimate of our liability in respect of such matters. It is not currently
possible to estimate the amount or range of any additional liability.
After considering the relevant legal issues and other pertinent factors, we
believe that we will receive the estimated recoveries and that the recoveries
could be well in excess of the current estimated liability for all
10
<PAGE>
Environmental Claims, although there can be no assurance in this regard. We
believe we are entitled to substantially full defense and indemnity under our
insurance policies for most Environmental Claims, although our insurers have not
affirmed a legal obligation under the policies to provide indemnity for such
claims.
In March 1995, GAF Corporation commenced litigation on behalf of itself and
its predecessors, successors, subsidiaries and related corporate entities in the
United States District Court for the District of New Jersey seeking amounts
substantially in excess of the estimated recoveries. The court dismissed the
action in December 1997 for lack of federal jurisdiction, and defendant insurers
appealed the dismissal. The appeal was denied by the Third Circuit Court of
Appeals in March 1999. In June 1997, GAF Corporation filed a similar action
against the insurers in the Superior Court of New Jersey, Somerset County, which
action is pending. While we believe that our claims are meritorious, we cannot
be certain that we will prevail in our efforts to obtain amounts equal to, or in
excess of, the estimated recoveries.
In June 1989, we entered into a Consent Order with the New Jersey
Department of Environmental Protection ("NJDEP") requiring the development of a
remediation plan for our closed Linden, New Jersey plant and the maintenance of
financial assurances (currently $7.5 million) to guarantee our performance. This
Consent Order does not address any potential natural resource damage claims. In
April 1993, NJDEP issued orders which require the prevention of discharge of
contaminated groundwater and stormwater from the site and the elimination of
other potential exposure concerns. We believe, although we cannot be certain,
that, taking into account our plans for development of the site, we can comply
with the NJDEP order at a cost of no more than $7.5 million. See Item 1,
"Business--Environmental Services."
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
None.
EXECUTIVE OFFICERS OF THE REGISTRANT
The following table sets forth the name, age, position and other
information with respect to ISP's executive officers. Under ISP's By-laws, each
director and executive officer continues in office until ISP's next annual
meeting of stockholders and until his or her successor is elected and qualified.
As used in this section, "ISP" refers to both Old ISP prior to the merger of Old
ISP into ISP Holdings and ISP subsequent to the merger.
<TABLE>
<CAPTION>
PRESENT PRINCIPAL OCCUPATION
NAME AND POSITION HELD AGE OR EMPLOYMENT AND FIVE-YEAR EMPLOYMENT HISTORY
- -------------------------------- --- ------------------------------------------------------------------------
<S> <C> <C>
Samuel J. Heyman ............... 61 Mr. Heyman has been a director and Chairman of the Board of ISP since
Chairman of the Board its formation and was Chief Executive Officer of ISP and certain of
its subsidiaries from their formation to June 1999. Mr. Heyman also
has been a director, Chairman of the Board, President and Chief
Executive Officer of GAF Corporation and certain of its subsidiaries
for more than five years. He has been a director and Chairman of the
Board of BMCA since its formation, and has served as Chief Executive
Officer of BMCA and certain of its subsidiaries since June 1999, which
position he also held from June 1996 to January 1999. He is also the
Chief Executive Officer, Manager and General Partner of a number of
closely held real estate development companies and partnerships whose
investments include commercial real estate and a portfolio of publicly
traded securities.
Sunil Kumar .................... 50 Mr. Kumar has been a director, President and Chief Executive Officer of
President and Chief Executive ISP and President and Chief Executive Officer of certain of its
Officer subsidiaries since June 1999. Mr. Kumar was a director, President and
Chief Executive Officer of BMCA and certain of its subsidiaries from
May 1995, July 1996 and January 1999, respectively, to June 1999. He
also was Chief Operating Officer of BMCA and certain of its
subsidiaries from March 1996
</TABLE>
11
<PAGE>
<TABLE>
<CAPTION>
PRESENT PRINCIPAL OCCUPATION
NAME AND POSITION HELD AGE OR EMPLOYMENT AND FIVE-YEAR EMPLOYMENT HISTORY
- -------------------------------- --- ------------------------------------------------------------------------
<S> <C> <C>
to January 1999. Mr. Kumar was President, Commercial Roofing Products
Division, and Vice President of BMCA from February 1995 to March 1996.
From 1992 to February 1995, he was Executive Vice President of
Bridgestone/Firestone Inc., a retail distributor and manufacturer of
tires and provider of automobile services.
Andrew G. Mueller .............. 57 Mr. Mueller has been Executive Vice President--Operations of ISP and
Executive Vice President-- certain of its subsidiaries since May 1997. He was employed by BASF
Operations Corporation as Group Vice President, Colorants & Textile/Leather
Chemicals from December 1995 to April 1997 and as Vice President,
Fiber Intermediates for more than five years until November 1995.
Richard A. Weinberg ............ 40 Mr. Weinberg has been Executive Vice President, General Counsel and
Executive Vice President, Secretary of ISP and its subsidiaries since May 1998 and was Senior
General Counsel and Secretary Vice President, General Counsel and Secretary of ISP and its
subsidiaries from May 1996 to May 1998. Mr. Weinberg has held the same
positions during the same time periods with GAF Corporation and
certain of its subsidiaries, including BMCA. He has been a director of
certain of ISP's subsidiaries since May 1996 and a director of GAF
Corporation since February 2000. He was Vice President and General
Counsel of BMCA from September 1994 to May 1996.
Randall R. Lay ................. 45 Mr. Lay has been Executive Vice President and Chief Financial Officer of
Executive Vice President and ISP and its subsidiaries since July 1999, was Senior Vice President
Chief Financial Officer and Chief Financial Officer of ISP and its subsidiaries from December
1998 to July 1999 and was Vice President and Chief Financial Officer
of ISP and its subsidiaries from April 1995 to December 1998. From
August 1993 to April 1995, he served as Controller, Specialty
Derivatives of ISP.
Susan B. Yoss .................. 41 Ms. Yoss has been Senior Vice President and Treasurer of ISP and its
Senior Vice President and subsidiaries since July 1999 and was Vice President and Treasurer of
Treasurer ISP and its subsidiaries from February 1998 to June 1999. She also has
been Senior Vice President and Treasurer of BMCA and its subsidiaries
and Senior Vice President, Chief Financial Officer and Treasurer of
GAF Corporation and certain of its subsidiaries since July 1999. Ms.
Yoss was Vice President and Treasurer of BMCA from February 1998 to
June 1999. She was Assistant Treasurer of Joseph E. Seagram & Sons,
Inc., a global beverage and entertainment company for more than five
years until February 1998.
Ronald E. Brandt ............... 52 Mr. Brandt has been Senior Vice President, Sales and Commercial
Senior Vice President, Sales Director--Americas of ISP and certain of its subsidiaries since July
and Commercial Director-- 1999 and was Senior Vice President, Personal Care and Fine Chemicals
Americas Group of ISP and certain of its subsidiaries from December 1998 to
July 1999. He served as Vice President and General Manager,
Performance and Fine Chemicals of ISP and certain of its subsidiaries
from July 1998 to December 1998 and as Vice President, Performance and
Fine Chemicals of ISP and certain of its subsidiaries from October
1997 to July 1998. From July 1996 to January 1997, Mr. Brandt was
Senior Vice President of Lawson Mardon Wheaton, a packaging
manufacturer, and from 1992 to June 1996, he served as Senior Vice
President of Lonza Inc., a chemicals manufacturer.
</TABLE>
12
<PAGE>
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
The following information pertains to ISP's common stock, which is traded
on the New York Stock Exchange. As of March 24, 2000, there were 209 holders of
record of ISP's outstanding common stock. For purposes of this section, "ISP"
refers to both Old ISP for the periods prior to the merger of Old ISP into ISP
Holdings and ISP for the periods subsequent to the merger.
<TABLE>
<CAPTION>
1999 BY QUARTER
----------------------------------------------------------
FIRST SECOND THIRD FOURTH
----------- ----------- ----------- ----------
<S> <C> <C> <C> <C>
Price Range of Common Stock:
High.................................. $ 13 13/16 $ 10 5/16 $ 10 1/4 $ 10 3/16
Low................................... 7 1/2 7 8 9/16 7
<CAPTION>
1998 BY QUARTER
---------------------------------------------------
FIRST SECOND THIRD FOURTH
------- ---------- ---------- ----------
<S> <C> <C> <C> <C>
Price Range of Common Stock:
High.................................. $ 18 1/2 $ 20 1/2 $ 18 13/16 $ 15 7/16
Low................................... 13 9/16 16 13/16 12 9 9/16
</TABLE>
ISP announced in the second quarter of 1995 that its Board of Directors had
eliminated the 2 1/2 cents per share semi-annual dividend on ISP's common stock.
The declaration and payment of dividends is at the discretion of the Board of
Directors of ISP. See Item 7, "Management's Discussion and Analysis of Financial
Condition and Results of Operations" and Note 11 to Consolidated Financial
Statements for information regarding restrictions on the payment of dividends
set forth on pages F-2 to F-10 and page F-28, respectively. Any decision to
resume the payment of dividends, and the timing and amount thereof, is dependent
upon, among other things, ISP's results of operations, financial condition, cash
requirements, prospects and other factors deemed relevant by the Board of
Directors. Accordingly, there can be no assurance that the Board of Directors
will resume the declaration and payment of dividends or as to the amount
thereof.
ITEM 6. SELECTED FINANCIAL DATA
See page F-11.
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
See page F-2.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
See Item 7, "Management's Discussion and Analysis of Financial Condition
and Results of Operations--Liquidity and Financial Condition--Market Sensitive
Instruments and Risk Management" on page F-8.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
See Index on page F-1 and Financial Statements and Supplementary Data on
pages F-13 to F-45.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
None.
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
The information relating to the directors of ISP to be contained in the
Proxy Statement under the heading "Election of Directors" is incorporated by
reference herein. For information relating to the executive officers of ISP, see
"Executive Officers of the Registrant" in Part I of this report.
13
<PAGE>
ITEM 11. EXECUTIVE COMPENSATION
The information to be contained in the Proxy Statement under the headings
"Compensation of Executive Officers of the Company" and "Election of Directors"
is incorporated by reference herein.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The information to be contained in the Proxy Statement under the heading
"Security Ownership of Certain Beneficial Owners and Management" is incorporated
by reference herein.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
The information to be contained in the Proxy Statement under the captions
"Election of Directors" and "Certain Transactions" is incorporated by reference
herein.
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K
The following documents are filed as part of this report:
(a)(1) Financial Statements: See Index on page F-1.
(a)(2) Financial Statement Schedules: See Index on page F-1.
(a)(3) Exhibits:
<TABLE>
<CAPTION>
EXHIBIT
NUMBER DESCRIPTIONS
- ------ ---------------------------------------------------------------------------------------------------------
<S> <C>
3.1 -- Amended and Restated Certificate of Incorporation of ISP (incorporated by reference to Exhibit 4.1 to
Post-Effective Amendment No. 1 of Form S-8 to the Registration Statement on Form S-4 of ISP
(Registration No. 333-53709) (the "ISP Registration Statement")).
3.2 -- By-laws of ISP (incorporated by reference to Exhibit 99.2 to the ISP Registration Statement).
4.1 -- 9% Note Indenture, dated as of October 18, 1996, between ISP Holdings and The Bank of New York, as
trustee (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-4 of ISP
Holdings (Registration No. 333-17827) (the "Holdings Registration Statement")).
4.2 -- 9 3/4% Note Indenture, dated as of October 18, 1996, between ISP Holdings and The Bank of New York, as
trustee (incorporated by reference to Exhibit 4.2 to the Holdings Registration Statement).
10.1 -- Amended and Restated Management Agreement, dated as of January 1, 1999, among GAF Corporation, G-I
Holdings Inc., G Industries Corp., Merick Inc., GAF Fiberglass Corporation, ISP, GAF Building
Materials Corporation, GAF Broadcasting Company, Inc., Building Materials Corporation of America and
ISP Opco Holdings Inc. (the "Management Agreement") (incorporated by reference to Exhibit 10.1 to
BMCA's Annual Report on Form 10-K for the fiscal year ended December 31, 1998).
10.2 -- Amendment No. 1 to the Management Agreement, dated as of January 1, 2000.
10.3 -- Indemnification Agreement, dated as of October 18, 1996, among GAF Corporation, G-I Holdings Inc., ISP
Holdings, G Industries Corp. and GAF Fiberglass Corporation (incorporated by reference to
Exhibit 10.7 to the Holdings Registration Statement).
10.4 -- Tax Sharing Agreement, dated as of January 1, 1997, among ISP Holdings, International Specialty
Products Inc. and certain subsidiaries of International Specialty Products Inc. (incorporated by
reference to Exhibit 10.8 to the Holdings Registration Statement).
</TABLE>
14
<PAGE>
<TABLE>
<S> <C>
10.5 -- Non-Qualified Retirement Plan Letter Agreement (incorporated by reference to Exhibit 10.11 to the
Registration Statement on Form S-1 of International Specialty Products Inc. (Registration
No. 33-40351)).*
10.6 -- International Specialty Products Inc. 1991 Incentive Plan for Key Employees and Directors, as amended
(incorporated by reference to Exhibit 4.3 to Post-Effective Amendment No. 1 on Form S-8 to the ISP
Registration Statement).*
10.7 -- Agreement, dated July 30, 1993, between International Specialty Products Inc. and Carl R. Eckardt
(incorporated by reference to Exhibit 10.16 to the Registration Statement on Form S-4 of G-I Holdings
Inc. (Registration No. 33-72220)).*
10.8 -- Letter Agreement, dated September 29, 1999, between International Specialty Products Inc. and Sunil
Kumar (incorporated by reference to Exhibit 10 to the ISP Quarterly Report on Form 10-Q for the
fiscal quarter ended October 3, 1999).*
10.9 -- Compensation and Indemnification Agreement among Charles M. Diker, Burt Manning and ISP, dated
October 10, 1997 (incorporated by reference to Exhibit 10.23 to the ISP Registration Statement).*
10.10 -- Consulting Agreement, dated November 23, 1999, between Carl R. Eckardt and ISP.*
10.11 -- Agreement and Plan of Merger between ISP Holdings and International Specialty Products Inc., dated as
of March 30, 1998 (incorporated by reference to Exhibit A to Amendment No. 2 to ISP Holdings Schedule
13D with respect to the common stock of International Specialty Products Inc. filed with the
Securities and Exchange Commission on April 1, 1998).
21 -- Subsidiaries of ISP.
23 -- Consent of Arthur Andersen LLP.
27 -- Financial Data Schedule for fiscal year 1999, which is submitted electronically to the Securities and
Exchange Commission for information only.
</TABLE>
- ------------------
* Management and/or compensation plan or arrangement.
(b) Reports on Form 8-K
No reports on Form 8-K were filed in the fourth quarter of 1999.
15
<PAGE>
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
INTERNATIONAL SPECIALTY PRODUCTS INC.
By: /s/ RANDALL R. LAY
---------------------------------
Randall R. Lay
Executive Vice President and Chief
Financial Officer
Date: March 29, 2000
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below on March 29, 2000, by the following persons on
behalf of the Registrant and in the capacities indicated.
<TABLE>
<CAPTION>
SIGNATURE TITLE
- ------------------------------------------------------- -------------------------------------------------------
<S> <C>
/s/ SAMUEL J. HEYMAN Chairman of the Board; Director
- ------------------------------------------------------
Samuel J. Heyman
/s/ SUNIL KUMAR President and Chief Executive Officer; Director
- ------------------------------------------------------ (Principal Executive Officer)
Sunil Kumar
/s/ CARL R. ECKARDT Director
- ------------------------------------------------------
Carl R. Eckardt
/s/ HARRISON J. GOLDIN Director
- ------------------------------------------------------
Harrison J. Goldin
/s/ CHARLES M. DIKER Director
- ------------------------------------------------------
Charles M. Diker
/s/ SANFORD KAPLAN Director
- ------------------------------------------------------
Sanford Kaplan
/s/ BURT MANNING Director
- ------------------------------------------------------
Burt Manning
/s/ RANDALL R. LAY Executive Vice President and Chief Financial Officer
- ------------------------------------------------------ (Principal Financial and Accounting Officer)
Randall R. Lay
</TABLE>
16
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
FORM 10-K
INDEX TO MANAGEMENT'S DISCUSSION AND ANALYSIS, CONSOLIDATED
FINANCIAL STATEMENTS AND SCHEDULES
<TABLE>
<CAPTION>
PAGE
----
<S> <C>
Management's Discussion and Analysis of Financial Condition and Results of Operations...................... F-2
Selected Financial Data.................................................................................... F-11
Report of Independent Public Accountants................................................................... F-12
Consolidated Statements of Income for the three years ended December 31, 1999.............................. F-13
Consolidated Balance Sheets as of December 31, 1998 and 1999............................................... F-14
Consolidated Statements of Cash Flows for the three years ended December 31, 1999.......................... F-15
Consolidated Statements of Stockholders' Equity for the three years ended December 31, 1999................ F-17
Notes to Consolidated Financial Statements................................................................. F-18
Supplementary Data (Unaudited):
Quarterly Financial Data (Unaudited)..................................................................... F-45
SCHEDULES
Consolidated Financial Statement Schedules:
Schedule II--Valuation and Qualifying Accounts........................................................... S-1
</TABLE>
F-1
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
On July 15, 1998, International Specialty Products Inc. ("Old ISP") merged
(the "Merger") with and into ISP Holdings Inc. ("ISP Holdings"). In connection
with the Merger, ISP Holdings changed its name to International Specialty
Products Inc. (the "Company"). In the Merger, each outstanding share of Old
ISP's common stock, other than those held by ISP Holdings, was converted into
one share of common stock of the Company, and the outstanding shares of Old
ISP's common stock which were held by ISP Holdings were converted into an
aggregate of 53,833,333 shares (or approximately 78%) of the outstanding shares
of common stock of the Company. The financial statements presented herein for
periods prior to the Merger represent the results of the former ISP Holdings.
In October 1999, the Company sold the stock of its filter products ("Filter
Products") subsidiaries (see Note 3 to Consolidated Financial Statements).
Accordingly, the results of operations and assets and liabilities of the Filter
Products subsidiaries have been classified as a "Discontinued Operation" within
the Consolidated Financial Statements for all periods presented. The following
discussion is on a continuing operations basis.
RESULTS OF OPERATIONS
1999 Compared With 1998
The Company recorded income from continuing operations in 1999 of $49.6
million ($.72 diluted earnings per share) compared with $2.8 million ($.05
diluted earnings per share) in 1998. Including income from discontinued
operations of $25.3 million, which reflected an after-tax gain of $23.5 million
from the sale of Filter Products, net income in 1999 was $74.9 million ($1.09
diluted earnings per share) versus net income of $4.8 million ($.08 diluted
earnings per share) in 1998.
The results for 1999 include an $8.5 million pre-tax gain from the sale of
the Company's pearlescent pigments business, a non-core product line. The
results for 1998 reflected a restructuring and impairment loss of $73.0 million
and $12.8 million of charges related to the Merger. In 1999, the Company
reversed previously recorded restructuring reserves in the amount of $1.9
million and also established a staff reduction program for which a pre-tax
provision for severance of $2.3 million was recorded (see Note 5 to Consolidated
Financial Statements and "Results of Operations--1998 Compared With 1997"). In
1998, the Company also recorded a pre-tax gain of $1.2 million from the sale of
its tennis court materials business, which was part of the Mineral Products
business segment. Excluding the effect of such nonrecurring items in each
period, income from continuing operations for 1999 was $44.4 million ($.65
diluted earnings per share) compared with $60.4 million ($.98 diluted earnings
per share) in 1998. On a comparable basis, the lower income from continuing
operations in 1999 was the result of lower investment income and, to a lesser
extent, lower operating income.
Sales for 1999 were $787.4 million compared with $784.6 million in 1998.
The increase in sales was attributable to product exchange arrangements pursuant
to which the Company sold butanediol, at cost, to other butanediol producers,
accounting for $15.3 million of sales, increased revenues in the Fine Chemicals
business ($14.7 million), the acquisition of Monsanto Company's Kelco Alginates
business (see Note 7 to Consolidated Financial Statements), which recorded sales
of $12.8 million in 1999 after the date of its acquisition, and higher sales in
the Pharmaceutical business. Such sales increases were offset by lower sales in
the Industrial business and in the Mineral Products and Personal Care business
segments. The overall sales increase was attributable to increased sales volumes
($51.9 million), offset by unfavorable pricing, principally in the Industrial
business, and the unfavorable effect ($5.4 million) of the stronger U.S. dollar
relative to other currencies in certain areas of the world. Sales in 1999
reflect slightly higher sales in the U.S., Europe and in the Asia-Pacific
region, partially offset by 10% lower sales in Latin America.
Operating income was $146.0 million in 1999 compared with $66.2 million in
1998. Excluding nonrecurring items in each year, operating income for 1999 was
$137.8 million compared with $150.8 million in 1998. The lower results in 1999
were attributable to lower gross margins as a result of lower pricing in
intermediates (including butanediol) and solvents and unabsorbed manufacturing
costs across all business segments that
F-2
<PAGE>
resulted from the Company's program to reduce inventory levels during the fourth
quarter of 1999. The results in 1999 were also impacted by lower operating
profits for the Mineral Products business segment, partially offset by lower
operating expenses that resulted from the Company's third quarter 1999 reduction
in corporate staff and other expense reduction efforts. Total selling, general
and administrative expenses decreased by 3% in 1999 and, as a percent of sales,
decreased from 19.8% in 1998 to 19.1% in 1999. Operating income in 1999
decreased in the U.S., Europe and Latin America, all due to the factors
discussed above, while the Asia-Pacific region experienced a slight growth in
operating income in 1999 over 1998.
Interest expense for 1999 was $78.6 million, a $3.0 million (4%) increase
over the $75.6 million recorded in 1998, with the increase due primarily to
higher average borrowings, partially offset by lower average interest rates.
Other income, net, comprises net investment income, foreign exchange
gains/losses resulting from the revaluation of foreign currency-denominated
accounts receivable and payable as a result of changes in exchange rates, and
other nonoperating and nonrecurring items of income and expense. Other income,
net, was $9.0 million in 1999 versus $35.1 million in 1998, with the decrease
principally reflecting $26.9 million lower net investment income.
Business Segment Review
A discussion of operating results for each of the Company's business
segments follows. The Company operates its Specialty Chemicals business through
three reportable business segments, in addition to the Minerals Products
segment. In 1999, the Company transferred its agricultural polymers and solvents
product lines from the Pharmaceutical, Agricultural and Beverage ("PAB") segment
to the Performance Chemicals, Fine Chemicals and Industrial segment.
Accordingly, prior year financial information for these two segments have been
restated to conform to the 1999 presentation. The effect on the years 1997 and
1998 was to reduce sales for the PAB segment by $58.1 and $52.7 million,
respectively, and reduce operating income by $5.5 and $8.6 million,
respectively, and increase sales and operating income for the Performance
Chemicals, Fine Chemicals and Industrial segment by like amounts. The PAB
segment has been renamed the Pharmaceutical, Food and Beverage segment and
includes the alginates business, which was acquired in October 1999. See Notes
15 and 16 to Consolidated Financial Statements for additional business segment
and geographic information.
Personal Care
The Personal Care segment provides products to the skin and hair care
markets. Sales in 1999 were $187.1 million compared with $189.4 million in 1998,
while operating income in 1999, including an $8.5 million pre-tax gain on the
sale of the pearlescent pigments business, a non-core product line, improved to
$45.7 million from $34.7 million in 1998. The lower sales in 1999 primarily
resulted from the sale of the pearlescent pigments business and lower average
pricing in both skin care and hair care. The sunscreen market continued to
experience lower average price levels in some products in 1999. In addition, the
skin care business experienced a decline in sales volumes to a major customer
who advised the Company that its application has been discontinued. These
factors combined to offset sales volume improvements due to growth in new
products and in preservatives.
Operating income, excluding the gain on the sale of the pearlescent
pigments business, improved by 7% in 1999 as the operating margin increased to
19.9% compared with 18.3% in 1998. The improvements reflected cost containment
in operating expenses, specifically selling and supply chain costs.
Pharmaceutical, Food and Beverage ("PFB")
Sales for the PFB segment were $177.3 million in 1999, including
$12.8 million in sales for the alginates business after the date of its
acquisition in October 1999, compared with $157.9 million in 1998. Excluding the
alginates business, sales for the Pharmaceutical and Beverage businesses
increased 4% to $164.5 million in 1999. The increased sales reflected sales
volume increases, primarily in the Asia-Pacific region and Europe and favorable
pricing in North America, partially offset by the unfavorable impact of the U.S.
dollar versus the Euro ($1.8 million).
F-3
<PAGE>
The increased sales in the PFB segment were principally attributable to
higher sales volumes in the Pharmaceutical business. The sales growth primarily
reflected increased volumes in the excipients and oral care markets and, to a
lesser extent, the denture adhesives market, with strong growth registered in
the Asia-Pacific region. Favorable pricing in the U.S. for PVP-Iodine and the
GANTREZ(R) product line also contributed to the sales growth.
Decreased sales in the Beverage business partially offset the sales gains
in the Pharmaceutical business. Beverage sales declined primarily due to lower
sales volumes, particularly in Latin America. The adverse impact of the stronger
U.S. dollar versus the Euro and competitive pricing pressures in Europe further
contributed to the sales decline.
Operating income for the PFB segment was $44.9 million in 1999, a 19%
improvement compared with $37.2 million in 1998, while operating margins
improved from 23.6% in 1998 to 25.3% in 1999. The improved results reflected the
higher sales volumes and favorable pricing in the Pharmaceutical business, as
well as favorable manufacturing and selling costs.
Performance Chemicals, Fine Chemicals and Industrial
Sales for the Performance Chemicals, Fine Chemicals and Industrial segment
were $335.7 million for 1999 compared with $342.8 million in 1998, while
operating income declined to $41.2 million in 1999 compared with $63.3 million
in 1998. The decrease in sales was attributable mainly to lower Industrial and
Performance Chemicals sales, partially offset by a 26% increase in Fine
Chemicals sales.
Sales for the Performance Chemicals business decreased by $4.8 million (5%)
in 1999, while operating income decreased by $1.0 million (6%). The primary
factor for the decline in sales was significantly lower volumes and lower
pricing for the solvent chemicals market in all regions, particularly in Europe.
Excluding the negative impact resulting from the solvents market, sales for the
Performance Chemicals business grew 10% in 1999. The growth in the non-solvents
markets was driven by new products and applications in Europe, combined with an
increase in the U.S. base business.
Sales for the Fine Chemicals business increased $14.7 million (26%) in
1999, while operating income improved $5.1 million (29%). The higher sales and
operating income in 1999 was primarily attributable to the increase in sales of
an intermediate to a pharmaceutical company. Sales of this product contributed
$32.2 million of sales and $17.4 million of gross margin in 1999. Sales and
operating income for the Fine Chemicals business will be significantly impacted
in the year 2000, as this customer has advised the Company that it will produce
this product in-house.
Sales for the Industrial business decreased by $17.0 million in 1999.
Excluding sales of $15.3 million from product exchange arrangements pursuant to
which the Company sold butanediol, at cost, to other butanediol producers, the
sales decline for the year was $32.3 million (17%), primarily resulting from
unfavorable selling prices and sales volume declines for butanediol and N-methyl
pyrrolidone and unfavorable pricing for tetrahydrofuran. As a result of such
sales decreases, the Industrial business experienced a 90% decrease in operating
profits in 1999.
Mineral Products
Sales for the Mineral Products segment in 1999 were $87.3 million, a $7.2
million (8%) decrease compared with sales of $94.5 million in 1998, while
operating income decreased $4.4 million (21%) to $16.1 million in 1999. The
lower sales and operating income resulted from a $5.3 million decrease in sales
to an affiliate, BMCA (see Note 14 to Consolidated Financial Statements),
resulting primarily from lower pricing and, to a lesser extent, lower volumes.
Sales to trade customers were down $1.9 million (6%) in 1999 due primarily to
the sale of the tennis court materials business in September 1998, which
accounted for $1.4 million of sales in 1998. During the fourth quarter of 1999,
the Mineral Products segment lost two major trade customers for colored roofing
granules, which together accounted for approximately 68% of Mineral Products
trade sales in 1999 and approximately 23% of total Mineral Products sales in
1999. Sales and operating income for the Mineral Products business will be
significantly impacted in the year 2000 as a result of the loss of these two
customers.
F-4
<PAGE>
RESULTS OF OPERATIONS
1998 Compared With 1997
The Company recorded income from continuing operations in 1998 of $2.8
million ($.05 diluted earnings per share) compared with $51.7 million ($.96
diluted earnings per share) in 1997. The results for 1998 reflected a
restructuring and impairment loss of $73.0 million and $12.8 million of charges
related to the Merger, and also included a $1.2 million pre-tax gain from the
sale of the Company's tennis court materials business. Excluding the effect of
such nonrecurring items, income from continuing operations for 1998 was $60.4
million ($.98 diluted earnings per share), with the increase attributable to
higher operating and other income, partially offset by higher interest expense.
Sales for 1998 were $784.6 million, an 11% increase compared with $709.0
million for 1997. The sales growth in 1998 was primarily attributable to the
Company's acquisition, effective April 1, 1998, of the remaining 50% interest in
its joint venture with Huls AG, GAF-Huls Chemie GmbH, now known as ISP Marl GmbH
("ISP Marl"), and to the acquisition of the Freetown fine chemicals facility
(see Note 7 to Consolidated Financial Statements), which together accounted for
$74.5 million of the increase. In addition, the sales increase was attributable
to increased sales volumes ($9.7 million), offset by the unfavorable effect
($9.6 million) of the stronger U.S. dollar relative to other currencies in
certain areas of the world. The higher sales in 1998 reflected increased sales
in the U.S., Europe (due to the sales of ISP Marl) and Latin America, partially
offset by lower sales in the Asia-Pacific region.
As discussed in Note 5 to Consolidated Financial Statements, the Company
recorded $73.0 million in 1998 for provisions for restructuring and impairment
loss, primarily related to its decision to shut down its butanediol production
unit at its Calvert City, Kentucky manufacturing facility. As a result of
significant adverse changes in the butanediol market, and in conjunction with
the decision to shut down the Calvert City butanediol production unit, the
Company also reviewed the recoverability of its butanediol production assets at
its Texas City and Seadrift, Texas facilities and, based on this review,
recognized an impairment loss of $16.6 million. The total charge related to the
above shutdown and impairment aggregated $59.3 million, including write-offs of
property, plant and equipment aggregating $38.7 million, the write-off of $13.1
million of goodwill related to the butanediol business and an accrual of $7.5
million for cash costs to be incurred, mainly for decommissioning, demolition
and remediation, and severance costs. In addition, also as a result of the
adverse changes in the butanediol market and as a result of the acquisition of
ISP Marl, the Company decided not to continue its plans to acquire or develop a
European manufacturing facility. Costs incurred in previous years for this
project aggregating $10.7 million were therefore deemed not recoverable and were
written off in 1998. Also, in the third quarter of 1998, the Company reserved
$3.0 million for the consolidation of offices in the Company's European
operations.
As a result of the Merger, the Company incurred $12.8 million of charges
against operating income in 1998, consisting of a $7.9 million charge in
connection with the termination of ISP Holdings' stock appreciation rights and
preferred stock option programs, a $2.6 million charge related to purchase
accounting adjustments and $2.2 million of other expenses relating to investment
banking, legal and other fees.
Operating income, before the impact of the $84.6 million of nonrecurring
items discussed above, was $150.8 million for 1998, a 10% increase over the
$137.7 million recorded in 1997. The improved results were primarily
attributable to higher operating income for the Performance Chemicals, Fine
Chemicals and Industrial business segment (up $25.9 million), mainly due to the
acquisitions of ISP Marl and the Freetown fine chemicals facility, and also due
to higher operating income for Mineral Products (up $3.5 million), partially
offset by lower results for Personal Care (down $9.3 million) and Pharmaceutical
and Beverage (down $3.9 million). See below for a further discussion of business
segment results. The overall operating results, in addition to the favorable
effect of the acquisitions, were favorably impacted by increased sales volumes,
partially offset by the adverse effect of the stronger U.S. dollar
($15.7 million) and 8% higher selling, general and administrative expenses due
primarily to higher distribution and marketing expenses. Selling, general and
administrative expenses as a percent of sales decreased from 20.3% in 1997 to
19.8% in 1998.
Of the $13.1 million increase in operating income, excluding the
nonrecurring items, domestic operating income increased by $3.3 million (10%)
due to increased sales volumes reflecting the acquisition of the Freetown
F-5
<PAGE>
fine chemicals facility and higher Mineral Products sales and, to a lesser
extent, slightly higher gross margins. Operating income for Europe increased
$13.0 million (20%) due mainly to the ISP Marl acquisition, partially offset by
the effect of the stronger U.S. dollar, while in the Asia-Pacific region,
operating income decreased by $5.5 million (24%) due to lower sales volumes.
Operating income for the Latin America region increased by $2.3 million (16%)
due to increased sales volumes and improved margins.
Interest expense for 1998 was $75.6 million, a $2.0 million (3%) increase
over the $73.6 million recorded in 1997, with the increase due primarily to
higher average borrowings.
Other income, net, was $35.1 million in 1998 compared with $34.2 million in
1997, as $1.8 million lower other nonoperating and nonrecurring expense items
were partially offset by $1.2 million lower net investment income.
Business Segment Review
Personal Care
Sales for the Personal Care segment were $189.4 million in 1998 compared
with $187.4 million in 1997, while operating income declined in 1998 to $34.7
million from $44.0 million in 1997. Sales volumes increased by $7.1 million in
1998, led by $4.0 million in sales of new products. The stronger U.S. dollar
adversely impacted sales by $3.1 million and, in addition, the sunscreen market
continued to experience lower average price levels in some products, which
offset volume improvements.
The decline in operating income in 1998 in the Personal Care segment was
attributable to a $4.7 million adverse impact of the stronger U.S. dollar,
unfavorable prices in skin care products, and $6.3 million higher selling,
general and administrative expenses. The latter was primarily the result of
increased expenses for new product development, marketing and development
expenses related to government regulations to reduce the emission of volatile
organic compounds (VOCs) in hairsprays to 55% levels, and, to a lesser extent,
higher distribution costs.
Pharmaceutical and Beverage ("P&B")
Sales for the P&B segment were $157.9 million in 1998 compared with $150.3
million in 1997, while operating income decreased to $37.2 million in 1998 from
$41.1 million in 1997. The increased sales reflected higher sales volumes ($2.5
million) and favorable pricing, offset by the adverse impact of the stronger
U.S. dollar ($3.7 million). The same factors impacted P&B's operating income,
with the decline in operating income reflecting a $6.2 million adverse impact of
the stronger U.S. dollar, mostly offset by favorable pricing and increased sales
volumes and by lower selling and distribution costs.
The Pharmaceutical business registered another year of strong growth,
primarily reflecting increased sales volumes in the oral care and excipients
markets. The effects of the economic slowdown in Asia were largely offset by
higher sales in Europe and North and South America. The growth in the oral care
market came primarily through increased sales of the GANTREZ(R) product line,
which has applications in both toothpaste and denture adhesives. In the
excipients market, increased revenues were generated through higher sales of
PLASDONES(R), which are polymers used as a drug tablet binder. Sales for 1998 in
the antiseptic area were slightly down from 1997.
In the Beverage business, the economic situation in Asia and in certain
parts of Eastern Europe had an unfavorable impact on sales, while sales in the
Latin America region continued to grow in 1998.
Performance Chemicals, Fine Chemicals and Industrial
The Performance Chemicals, Fine Chemicals and Industrial segment
experienced a 19% increase in sales in 1998, with sales increasing to $342.8
million from $288.1 million in 1997. Operating income improved to $63.3 million,
a 69% increase over the $37.4 million recorded in 1997, excluding the
restructuring and impairment loss previously discussed related to the butanediol
business. The sales increase was attributable to the acquisition of the
remaining 50% interest in ISP Marl and the acquisition of the Freetown fine
chemicals facility (see Note 7 to Consolidated Financial Statements), which
together accounted for $74.5 million of sales in 1998, and also
F-6
<PAGE>
reflected a substantial increase in the sales of pharmaceutical intermediates.
The results for ISP Marl are included in the Company's results on a consolidated
basis from the date of its acquisition, including sales of $53.0 million for
1998. Sales for Performance Chemicals in 1998 were 7% lower than in 1997 due to
weak economies in Asia and Eastern Europe. Pricing gains for Performance
Chemicals were more than offset by the adverse impact of the stronger U.S.
dollar.
The higher operating income for the Performance Chemicals, Fine Chemicals
and Industrial segment in 1998 was also primarily attributable to the
acquisitions of ISP Marl and the Freetown facility and to the impact of sales
volume increases, partially offset by unfavorable pricing, the adverse impact of
the stronger U.S. dollar and, to a lesser extent, unfavorable manufacturing
costs.
Mineral Products
Sales for the Mineral Products segment in 1998 were $94.5 million, a 14%
increase compared with $83.2 million in 1997, while operating income improved
21% to $20.5 million in 1998 compared with $17.0 million in 1997. The sales
growth resulted from an $11.5 million increase in sales to an affiliate, BMCA
(see Note 14 to Consolidated Financial Statements), resulting principally from
higher volumes and slightly higher pricing. Sales to trade customers were flat
due to consolidation in the roofing industry and plant closures at certain of
the Company's trade customers. The Company also sold its tennis court materials
business in 1998.
The improvement in operating income in 1998 resulted from the increased
sales volumes and cost containment controls, and, to a lesser extent, a $1.2
million pre-tax gain from the sale of the tennis court materials business.
LIQUIDITY AND FINANCIAL CONDITION
During 1999, the Company's net cash flow before financing activities was
$42.4 million, including $93.6 million of cash generated from operations, the
reinvestment of $109.0 million for capital programs and the acquisition of the
alginates business (see below and Note 7 to Consolidated Financial Statements),
$73.5 million of cash generated from the sale of the filters and pearlescent
pigments businesses, and the use of $15.7 million of cash for net purchases of
available-for-sale and held-to-maturity securities and other short-term
investments.
Cash from operations reflected a $15.6 million cash inflow from net sales
of trading securities. Cash invested in additional working capital totaled $11.9
million, primarily reflecting a $17.3 million increase in receivables, partially
offset by a $7.6 million decrease in inventories (excluding inventories acquired
in the acquisition of the alginates business) as a result of the Company's
program to reduce inventory levels during the fourth quarter of 1999.
Net cash used in financing activities in 1999 totaled $42.2 million,
reflecting the repayment of the Company's $200 million 9% Senior Notes in March
1999 and a $6.9 million reduction in short-term borrowings, partially offset by
a $162.4 million increase in borrowings under the Company's bank revolving
credit facility and $5.6 million of proceeds from the sale of the Company's
accounts receivable. In addition, financing activities included a $5.0 million
cash outlay for repurchases of common stock pursuant to the Company's repurchase
program. The Company announced in March 1999 that its Board of Directors had
approved the repurchase of an additional 1.5 million shares of its common stock.
This amount is in addition to the repurchase of one million shares, announced in
September 1998, which has been completed. The repurchased shares will be held
for general purposes, including the issuance of shares under the Company's stock
option plan.
As a result of the foregoing factors, cash and cash equivalents increased
by $0.2 million during 1999 to $23.3 million, excluding $397.2 million of
trading and available-for-sale securities and other short-term investments.
As of December 31, 1999, the Company's current maturities of long-term
debt, scheduled to be repaid during 2000, totaled $38.5 million, including a
$38.1 million mortgage obligation on its headquarters property.
In July 1996, the Company entered into a new five-year revolving credit
facility (the "Credit Agreement") with a group of banks, which provides for
loans of up to $400 million and letters of credit of up to $75 million
F-7
<PAGE>
(see Note 11 to Consolidated Financial Statements). As of December 31, 1999,
loans in the amount of $295.0 million and letters of credit in the amount of
$7.9 million were outstanding under the Credit Agreement.
Borrowings by the Company, including those under the Credit Agreement, are
subject to the application of certain financial covenants contained in such
agreement and in the indentures relating to the Company's 9% Senior Notes due
2003 and 9 3/4% Senior Notes due 2002 (collectively, the "Notes"). As of
December 31, 1999, the Company was in compliance with such covenants, and the
application of such covenants would not have restricted the amount available for
borrowing under the Credit Agreement. The Credit Agreement and the indentures
relating to the Notes limit the amount of cash dividends, purchases of treasury
stock, and other restricted payments (as defined) by the Company. See Note 11 to
Consolidated Financial Statements.
On January 27, 2000, the Company announced that it had notified Dexter
Corporation ("Dexter") of its intent to present at Dexter's Annual Meeting of
Shareholders scheduled to be held on April 27, 2000, and solicit proxies in
favor of, a series of resolutions designed to facilitate the Company's business
combination proposal. Under the proposal, as amended on March 23, 2000, Dexter
shareholders would receive at least $50 per share in cash, subject to the
execution of a mutually acceptable merger agreement. The Company has filed with
the Securities and Exchange Commission a preliminary proxy statement in
connection with Dexter's Annual Meeting. On March 23, 2000, the Company received
a binding commitment from a financial institution to provide, subject to
customary conditions, senior credit facilities in the aggregate amount of $1.825
billion to, among other things, finance the acquisition of Dexter. See also
Notes 2 and 18 to Consolidated Financial Statements.
In October 1999, the Company acquired substantially all of the assets of
the Kelco Alginates division of Monsanto Company. See Note 7 to Consolidated
Financial Statements.
For information with respect to income taxes, see Note 6 to Consolidated
Financial Statements.
Effective January 1, 1999, member states of the European Union converted to
a common currency, the Euro. This conversion has not had a material impact on
the Company's business, results of operations or financial condition. The
Company is currently billing customers in Euro if they so request, and this has
not had an impact on the Company's administrative systems.
The Company does not believe that inflation has had an effect on its
results of operations during the past three years. However, there can be no
assurance that the Company's business will not be affected by inflation in the
future.
The Company has received site designation from the New Jersey Hazardous
Waste Facilities Siting Commission for the construction of a hazardous waste
treatment, storage and disposal facility at its Linden, New Jersey property and
has received approval from the New Jersey Turnpike Authority for a direct access
ramp from the Turnpike to the site. If the Company is successful in securing the
necessary permits to construct and operate the hazardous waste facility, the
Company intends to develop and operate the facility in a separate subsidiary,
either on its own or in a joint venture with a suitable partner. The Company
estimates that the cost of constructing the facility will be approximately $100
million and, if approved, the facility is anticipated to be in operation three
years after commencement of construction. The Company anticipates utilizing
internally generated cash and/or seeking project or other independent financing
for this project. Accordingly, the Company would not expect such facility to
impact materially its liquidity or capital resources. The Company is also
investigating other development opportunities at this site.
The Company, together with other companies, is a party to a variety of
proceedings and lawsuits involving environmental matters. See Note 17 to
Consolidated Financial Statements for further information.
Market-Sensitive Instruments and Risk Management
The Company's investment strategy is to seek returns in excess of money
market rates on its available cash while minimizing market risks. There can be
no assurance that the Company will be successful in implementing such a
strategy. The Company invests primarily in international and domestic arbitrage
and securities of companies involved in acquisition or reorganization
transactions, including at times, common stock short positions which are offsets
against long positions in securities which are expected, under certain
circumstances,
F-8
<PAGE>
to be exchanged or converted into the short positions. With respect to its
equity positions, the Company is exposed to the risk of market loss. See Note 2
to Consolidated Financial Statements.
The Company enters into financial instruments in the ordinary course of
business in order to manage its exposure to market fluctuations in interest
rates, foreign currency rates and on its short-term investments. The financial
instruments the Company employs to reduce market risk include swaps, futures,
forwards and other hedging instruments. The financial instruments are subject to
strict internal controls and their use is primarily confined to the hedging of
the Company's debt, foreign currency exposure and short-term investment
portfolio. The counterparties to these financial instruments are major financial
institutions with high credit standings. The amounts subject to credit risk are
generally limited to the amounts, if any, by which the counterparties'
obligations exceed the obligations of the Company. The Company controls credit
risk through credit approvals, limits and monitoring procedures. The Company
does not anticipate nonperformance by counterparties to these instruments.
<TABLE>
<CAPTION>
DECEMBER 31, 1998 DECEMBER 31, 1999
------------------- ------------------
NOTIONAL FAIR NOTIONAL FAIR
AMOUNT VALUE AMOUNT VALUE
-------- ------ -------- -----
(MILLIONS)
<S> <C> <C> <C> <C>
Interest rate financial instruments.................................... $425.0 $(10.2) $100.0 $ 0.7
Foreign currency financial instruments................................. $ 90.8 $ (4.4) $ 57.4 $(0.3)
Equity-related financial instruments................................... $332.8 $ 0 $ 56.6 $ 0
</TABLE>
All of the financial instruments in the above table have a maturity of less
than one year, except that $100 million notional amount of interest rate swap
agreements, with a fair value of $0.7 million as of December 31, 1999, mature in
2002.
The objectives of the Company in utilizing interest rate swap agreements
are to lower funding costs, diversify sources of funding and manage interest
rate exposure. As of December 31, 1999, the Company had entered into interest
rate swap agreements with a notional value of $100 million in order to convert
to fixed rates $100 million of its exposure to floating interest rates. By
utilizing fixed to floating interest rate swap agreements, the Company reduced
its interest expense by $2.1, $1.7 and $0.3 million in 1997, 1998 and 1999,
respectively.
The Company enters into forward foreign exchange instruments with
off-balance-sheet risk in order to hedge a portion of both its borrowings
denominated in foreign currency and its firm or anticipated purchase commitments
related to the operations of its foreign subsidiaries. Forward contract
agreements require the Company and the counterparty to exchange fixed amounts of
U.S. dollars for fixed amounts of foreign currency on specified dates. All
forward contracts are in major currencies with highly liquid markets and mature
within one year. Hedging strategies are approved by senior management before
they are implemented.
As of December 31, 1998 and 1999, the U.S. dollar equivalent fair value of
outstanding forward foreign exchange contracts was $90.8 and $57.4 million,
respectively. The U.S. dollar equivalent fair value of foreign exchange
contracts outstanding as of December 31, 1998 and 1999, which were entered into
as a hedge of non-local currency intercompany loans, was $18.4 and $33.9
million, respectively, representing 100% of the Company's foreign currency
exposure with respect to such loans.
As of December 31, 1999, equity-related financial instruments employed by
the Company to reduce market risk include long contracts valued at $50.1 million
and short contracts valued at $6.5 million, both of which are marked-to-market
each month, with unrealized gains and losses included in the results of
operations. As such, there is no economic cost at December 31, 1999 to terminate
these instruments and therefore the fair market value is zero.
Year 2000 Compliance
During 1999, the Company completed a formal year 2000 program (the "Year
2000 Program") to address the potential issues relating to the inability of some
of its information technology ("IT") and non-IT equipment to accurately read and
process certain dates, including dates in the year 2000 and afterwards (the
"Year 2000 Issues"). As part of the Year 2000 Program, the Company also
requested information on the Year 2000 Issues of third parties significant to
the Company's business and, accordingly, developed contingency plans to minimize
F-9
<PAGE>
the impact of Year 2000 Issues on its business. The costs to complete the Year
2000 Program were not material to the Company's financial position or results of
operations. To date, the Company has not experienced any significant
consequences related to Year 2000 Issues, and the Company reasonably believes
that potential undiscovered Year 2000 Issues will not have a material effect on
its business, financial condition or results of operations.
* * *
FORWARD-LOOKING STATEMENTS
This Annual Report on Form 10-K contains both historical and
forward-looking statements. All statements other than statements of historical
fact are, or may be deemed to be, forward-looking statements within the meaning
of section 27A of the Securities Act of 1933 and section 21E of the Securities
Exchange Act of 1934. These forward-looking statements are only predictions and
generally can be identified by use of statements that include phrases such as
"believe," "expect," "anticipate," "intend," "plan," "foresee" or other words or
phrases of similar import. Similarly, statements that describe the Company's
objectives, plans or goals also are forward-looking statements. The Company's
operations are subject to certain risks and uncertainties that could cause
actual results to differ materially from those contemplated by the relevant
forward-looking statement. The forward-looking statements included herein are
made only as of the date of this Annual Report on Form 10-K and the Company
undertakes no obligation to publicly update such forward-looking statements to
reflect subsequent events or circumstances. No assurances can be given that
projected results or events will be achieved.
F-10
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
SELECTED FINANCIAL DATA
Set forth below are selected consolidated financial data of International
Specialty Products Inc. (the "Company"), formerly ISP Holdings Inc. ("ISP
Holdings"), and its subsidiaries. On July 15, 1998, International Specialty
Products Inc. ("Old ISP") merged (the "Merger") with and into ISP Holdings. In
connection with the Merger, ISP Holdings changed its name to International
Specialty Products Inc. The financial information presented herein for periods
prior to the Merger of Old ISP and ISP Holdings represent the results of the
former ISP Holdings. Prior to January 1, 1997, ISP Holdings was a wholly-owned
subsidiary of GAF Corporation ("GAF"). On January 1, 1997, GAF effected a series
of transactions that resulted in, among other things, the capital stock of ISP
Holdings being distributed to the stockholders of GAF. As a result of such
distribution, ISP ceased to be a direct or indirect subsidiary of GAF, and GAF's
subsidiaries are no longer included in the consolidated assets and liabilities
of ISP. The results of operations and assets and liabilities of GAF's
subsidiaries, as well as GAF Broadcasting Company, Inc. (whose assets were sold
in August 1996), have been classified as "Discontinued Operations" within the
Selected Financial Data below for all periods presented prior to January 1,
1997. In October 1999, the Company sold the stock of its Filter Products
subsidiaries (see Note 3 to Consolidated Financial Statements). Accordingly, the
results of operations and assets and liabilities of the Filter Products
subsidiaries have been classified as a "Discontinued Operation" within the
Consolidated Financial Statements for all periods presented.
<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31,
--------------------------------------------------------------------
1995 1996 1997 1998 1999
------------ ------------ ------------ ------------ ------------
(DOLLARS IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
<S> <C> <C> <C> <C> <C>
Operating Data:
Net sales................................ $ 651,834 $ 676,951 $ 708,971 $ 784,616 $ 787,356
Gross profit............................. 258,593 283,186 295,199 321,105 304,959
Operating income......................... 123,599 135,784 137,689 66,177 145,978
Interest expense......................... 33,091 38,333 73,612 75,564 78,552
Income from continuing operations before
income taxes and extraordinary
losses................................ 102,605 116,388 104,219 27,168 76,454
Income from continuing operations before
extraordinary losses.................. 52,848 60,683 51,702 2,779 49,632
Net income............................... 32,828 53,933 54,005 4,812 74,930
Income from continuing operations per
common share:
Basic.................................... $ .98 $ 1.13 $ .96 $ .05 $ .72
Diluted.................................. $ .98 $ 1.13 $ .96 $ .05 $ .72
Other Data:
Gross profit margin...................... 39.7% 41.8% 41.6% 40.9% 38.7%
Operating margin......................... 19.0% 20.1% 19.4% 8.4% 18.5%
Depreciation............................. $ 35,533 $ 37,801 $ 41,236 $ 49,272 $ 48,590
Goodwill amortization.................... 13,223 13,200 13,294 15,025 16,344
Capital expenditures and
acquisitions.......................... 37,138 51,411 67,674 163,850 108,955
<CAPTION>
DECEMBER 31,
--------------------------------------------------------------------
1995 1996 1997 1998 1999
------------ ------------ ------------ ------------ ------------
(THOUSANDS)
<S> <C> <C> <C> <C> <C>
Balance Sheet Data:
Total working capital.................... $ 290,001 $ 476,846 $ 322,080 $ 406,654 $ 438,083
Total assets............................. 1,460,382 1,600,114 1,483,977 1,763,870 1,835,308
Long-term debt less current
maturities ........................... 280,254 834,284 798,762 896,095 820,141
Stockholders' equity (deficit)........... (1,707) 42,653 261,841 501,723 587,261
</TABLE>
F-11
<PAGE>
REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS
To International Specialty Products Inc.:
We have audited the accompanying consolidated balance sheets of
International Specialty Products Inc. (a Delaware corporation) and subsidiaries
as of December 31, 1998 and 1999, and the related consolidated statements of
income, stockholders' equity and cash flows for each of the three years in the
period ended December 31, 1999. These financial statements and the schedule
referred to below are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements and
schedule based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above, appearing on
pages F-13 to F-44 of this Form 10-K, present fairly, in all material respects,
the financial position of International Specialty Products Inc. and subsidiaries
as of December 31, 1998 and 1999, and the results of their operations and their
cash flows for each of the three years in the period ended December 31, 1999, in
conformity with generally accepted accounting principles.
Our audits were made for the purpose of forming an opinion on the basic
financial statements taken as a whole. The schedule appearing on page S-1 of
this Form 10-K is presented for purposes of complying with the Securities and
Exchange Commission's rules and is not part of the basic financial statements.
This schedule has been subjected to the auditing procedures applied in the audit
of the basic financial statements and, in our opinion, fairly states in all
material respects the financial data required to be set forth therein in
relation to the basic financial statements taken as a whole.
ARTHUR ANDERSEN LLP
Roseland, New Jersey
February 28, 2000
F-12
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
CONSOLIDATED STATEMENTS OF INCOME
<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31,
----------------------------------
1997 1998 1999
---------- ---------- ----------
(THOUSANDS, EXCEPT PER SHARE
AMOUNTS)
<S> <C> <C> <C>
Net sales................................................................. $ 708,971 $ 784,616 $ 787,356
Cost of products sold..................................................... (413,772) (463,511) (482,397)
Selling, general and administrative....................................... (144,216) (155,257) (150,768)
Provision for restructuring, staff reduction and impairment loss.......... -- (73,049) (410)
Merger-related expenses................................................... -- (12,786) --
Gain on sale of assets.................................................... -- 1,189 8,541
Goodwill amortization..................................................... (13,294) (15,025) (16,344)
---------- ---------- ----------
Operating income.......................................................... 137,689 66,177 145,978
Interest expense.......................................................... (73,612) (75,564) (78,552)
Equity in earnings of joint venture....................................... 5,909 1,455 --
Other income, net......................................................... 34,233 35,100 9,028
---------- ---------- ----------
Income from continuing operations before income taxes..................... 104,219 27,168 76,454
Income taxes.............................................................. (37,825) (14,110) (26,822)
Minority interest in income of subsidiary................................. (14,692) (10,279) --
---------- ---------- ----------
Income from continuing operations......................................... 51,702 2,779 49,632
---------- ---------- ----------
Discontinued operation:
Income from discontinued operation, net of income taxes................. 2,303 2,033 1,769
Gain on sale of discontinued operation, net of income taxes of
$12,725.............................................................. -- -- 23,529
---------- ---------- ----------
Income from discontinued operation........................................ 2,303 2,033 25,298
---------- ---------- ----------
Net income................................................................ $ 54,005 $ 4,812 $ 74,930
---------- ---------- ----------
---------- ---------- ----------
Earnings per common share:
Basic:
Income from continuing operations.................................... $ .96 $ .05 $ .72
Income from discontinued operation................................... .04 .03 .37
---------- ---------- ----------
Net income........................................................... $ 1.00 $ .08 $ 1.09
---------- ---------- ----------
---------- ---------- ----------
Diluted:
Income from continuing operations.................................... $ .96 $ .05 $ .72
Income from discontinued operation................................... .04 .03 .37
---------- ---------- ----------
Net income........................................................... $ 1.00 $ .08 $ 1.09
---------- ---------- ----------
---------- ---------- ----------
Weighted average number of common and common equivalent shares
outstanding:
Basic................................................................... 53,833 60,971 68,536
---------- ---------- ----------
---------- ---------- ----------
Diluted................................................................. 53,833 61,278 68,685
---------- ---------- ----------
---------- ---------- ----------
</TABLE>
The accompanying Notes to Consolidated Financial Statements are an integral part
of these statements.
F-13
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
CONSOLIDATED BALANCE SHEETS
<TABLE>
<CAPTION>
DECEMBER 31,
------------------------
1998 1999
---------- ----------
(THOUSANDS)
<S> <C> <C>
ASSETS
Current Assets:
Cash and cash equivalents........................................................... $ 23,130 $ 23,309
Investments in trading securities................................................... 67,333 10,395
Investments in available-for-sale securities........................................ 233,625 344,905
Investments in held-to-maturity securities.......................................... 12,287 --
Other short-term investments........................................................ 41,708 41,900
Accounts receivable, trade, less reserve of $2,494 and $3,411....................... 74,839 82,201
Accounts receivable, other.......................................................... 20,649 23,410
Receivable from related parties, net................................................ 7,769 16,901
Inventories......................................................................... 129,050 151,775
Net current assets of discontinued operation........................................ 18,514 --
Other current assets................................................................ 19,197 20,569
---------- ----------
Total Current Assets.............................................................. 648,101 715,365
Property, plant and equipment, net.................................................... 547,555 570,218
Excess of cost over net assets of businesses acquired,
net of accumulated amortization of $133,344 and $149,688............................ 526,928 510,578
Net noncurrent assets of discontinued operation....................................... 5,724 --
Other assets.......................................................................... 35,562 39,147
---------- ----------
Total Assets.......................................................................... $1,763,870 $1,835,308
---------- ----------
---------- ----------
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Short-term debt..................................................................... $ 87,937 $ 82,531
Current maturities of long-term debt................................................ 583 38,543
Accounts payable.................................................................... 59,784 63,852
Accrued liabilities................................................................. 83,684 86,350
Income taxes........................................................................ 9,459 6,006
---------- ----------
Total Current Liabilities......................................................... 241,447 277,282
---------- ----------
Long-term debt less current maturities................................................ 896,095 820,141
---------- ----------
Deferred income taxes................................................................. 60,282 89,796
---------- ----------
Other liabilities..................................................................... 64,323 60,828
---------- ----------
Commitments and Contingencies.........................................................
Stockholders' Equity:
Preferred stock, $.01 par value per share; 20,000,000
shares authorized: no shares issued............................................... -- --
Common stock, $.01 par value per share; 300,000,000
shares authorized: 69,546,456 shares issued....................................... 695 695
Additional paid-in capital............................................................ 489,285 486,137
Treasury stock, at cost--735,744 and 754,199 shares................................... (8,388) (7,344)
Retained earnings..................................................................... 44,892 119,822
Accumulated other comprehensive loss.................................................. (24,761) (12,049)
---------- ----------
Total Stockholders' Equity........................................................ 501,723 587,261
---------- ----------
Total Liabilities and Stockholders' Equity............................................ $1,763,870 $1,835,308
---------- ----------
---------- ----------
</TABLE>
The accompanying Notes to Consolidated Financial Statements are an integral part
of these statements.
F-14
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31,
--------------------------------------
1997 1998 1999
---------- ---------- ----------
(THOUSANDS)
<S> <C> <C> <C>
Cash and cash equivalents, beginning of year............................ $ 17,477 $ 20,137 $ 23,130
---------- ---------- ----------
Cash provided by (used in) operating activities:
Net income............................................................ 54,005 4,812 74,930
Adjustments to reconcile net income to net cash provided by operating
activities:
Income from discontinued operation................................. (2,303) (2,033) (25,298)
Gain on sale of assets............................................. -- (1,189) (8,541)
Provision for restructuring, staff reduction and impairment loss... -- 73,049 410
Depreciation....................................................... 41,236 49,272 48,590
Goodwill amortization.............................................. 13,294 15,025 16,344
Deferred income taxes.............................................. 28,570 (6,816) 6,064
Unrealized (gains) losses on trading securities and other
short-term investments........................................... (9,539) 1,484 (6,778)
(Increase) decrease in working capital items.......................... (17,080) 2,842 (11,851)
Purchases of trading securities....................................... (196,513) (223,062) (209,649)
Proceeds from sales of trading securities............................. 119,864 272,027 225,291
(Increase) decrease in other assets................................... 2,210 3,136 (513)
Increase in other liabilities......................................... 9,702 128 503
(Increase) decrease in receivable from related parties................ 1,112 (3,645) (9,132)
Change in cumulative translation adjustment........................... (6,238) 2,975 (19,367)
Change in minority interest in subsidiary............................. 13,552 9,730 --
Other, net............................................................ 1,328 (6,608) 7,261
---------- ---------- ----------
Net cash provided by continuing operations............................ 53,200 191,127 88,264
Net cash provided by discontinued operation........................... 455 1,315 5,293
---------- ---------- ----------
Net cash provided by operating activities............................... 53,655 192,442 93,557
---------- ---------- ----------
Cash provided by (used in) investing activities:
Capital expenditures and acquisitions................................. (67,674) (163,850) (108,955)
Proceeds from sale-leaseback transaction.............................. -- 56,050 --
Proceeds from sale of assets.......................................... -- 2,400 11,533
Proceeds from sale of discontinued operation.......................... -- -- 62,000
Purchases of available-for-sale securities............................ (301,207) (671,842) (432,782)
Purchases of held-to-maturity securities.............................. (1,623) (12,287) (3,459)
Purchases of other short-term investments............................. -- (10,000) (5,600)
Proceeds from sales of available-for-sale securities.................. 344,408 477,014 395,659
Proceeds from held-to-maturity securities............................. 3,289 311 15,746
Proceeds from sales of other short-term investments................... -- -- 14,716
---------- ---------- ----------
Net cash used in investing activities................................... (22,807) (322,204) (51,142)
---------- ---------- ----------
Cash provided by (used in) financing activities:
Proceeds (repayments) from sale of accounts receivable................ -- (4,951) 5,558
Increase (decrease) in short-term debt................................ 16,794 48,861 (6,866)
Increase (decrease) in borrowings under revolving credit facility..... (35,425) 97,600 162,400
Repayments of long-term debt.......................................... (153) (643) (200,378)
Repurchases of common stock........................................... -- (9,326) (4,987)
Subsidiary's repurchases of common stock.............................. (10,240) -- --
Other, net............................................................ 836 1,214 2,037
---------- ---------- ----------
Net cash provided by (used in) financing activities..................... (28,188) 132,755 (42,236)
---------- ---------- ----------
Net change in cash and cash equivalents................................. 2,660 2,993 179
---------- ---------- ----------
Cash and cash equivalents, end of year.................................. $ 20,137 $ 23,130 $ 23,309
---------- ---------- ----------
---------- ---------- ----------
</TABLE>
F-15
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS--(CONTINUED)
<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31,
--------------------------------------
1997 1998 1999
---------- ---------- ----------
(THOUSANDS)
<S> <C> <C> <C>
Supplemental Cash Flow Information:
Effect on cash from (increase) decrease in working capital items*:
Accounts receivable................................................... $ (9,849) $ 11,127 $ (17,276)
Inventories........................................................... (10,822) (12,290) 7,627
Other current assets.................................................. (2,438) 823 156
Accounts payable...................................................... 2,338 8,674 3,972
Accrued liabilities................................................... 4,473 (6,910) (1,616)
Income taxes.......................................................... (782) 1,418 (4,714)
---------- ---------- ----------
Net effect on cash from (increase) decrease in working capital items.... $ (17,080) $ 2,842 $ (11,851)
---------- ---------- ----------
---------- ---------- ----------
Cash paid during the period for:
Interest (net of amount capitalized).................................. $ 71,512 $ 76,589 $ 83,948
Income taxes paid (refunded) (including taxes paid pursuant to the Tax
Sharing Agreement)................................................. (3,554) 20,471 23,957
Acquisition of remaining 50% interest in GAF-Huls Chemie GmbH joint
venture, net of $23,732 cash acquired**:
Fair market value of assets acquired.................................. $ 48,003
Purchase price of acquisition......................................... 23,381
----------
Liabilities assumed................................................... $ 24,622
----------
----------
Acquisition of Kelco Alginates business, net of $269 cash acquired:
Fair market value of assets acquired.................................. $ 41,619
Purchase price of acquisition......................................... 39,731
----------
Liabilities assumed................................................... $ 1,888
----------
----------
</TABLE>
- ------------------
* Working capital items exclude cash and cash equivalents, short-term
investments, short-term debt, receivables from related parties and net
current assets of discontinued operations. Working capital acquired in
connection with acquisitions is reflected within "Capital expenditures and
acquisitions." The effects of reclassifications between noncurrent and
current assets and liabilities are excluded from the amounts shown above. In
addition, the increase in accounts receivable shown above does not reflect
the cash proceeds from the sale of the Company's domestic trade accounts
receivable (see Note 8); such proceeds are reflected in cash from financing
activities.
** The Company had a 50% equity interest in the cash held by the joint venture
prior to the acquisition, which was classified within "Other assets" on the
Consolidated Balance Sheet.
The accompanying Notes to Consolidated Financial Statements are an integral part
of these statements.
F-16
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
<TABLE>
<CAPTION>
CAPITAL
STOCK AND ACCUMULATED RETAINED
ADDITIONAL TREASURY OTHER EARNINGS
PAID-IN STOCK COMPREHENSIVE (ACCUMULATED
CAPITAL AT COST INCOME (LOSS) DEFICIT)
---------- -------- ------------- ------------
(THOUSANDS)
<S> <C> <C> <C> <C>
Balance, December 31, 1996........................................ $ 46,426 $ -- $ 10,152 $ (13,925)
Comprehensive income, year ended December 31, 1997:
Net income.................................................... -- -- -- 54,005
Other comprehensive income (loss), net of tax:
Unrealized holding gains, net of income taxes of $7,849....... -- -- 16,467 --
Less: Reclassification adjustment for gains included in net
income, net of income taxes of $4,781....................... -- -- 10,834 --
---------
Unrealized gains on available-for-sale securities............. -- -- 5,633 --
Translation adjustment........................................ -- -- (6,238) --
Effect of Separation Transactions on components of accumulated
other comprehensive income (loss)........................... -- -- (155) --
Minimum pension liability adjustment.......................... -- -- (582) --
Comprehensive income............................................
Effect of Separation Transactions............................... 165,840 -- -- --
Effect of purchases of treasury stock........................... (1,851) -- -- --
Effect of exercises of subsidiary's stock options............... 1,945 -- -- --
Effect of subsidiary's issuances of stock and options as
incentives.................................................... 591 -- -- --
-------- -------- --------- ----------
Balance, December 31, 1997........................................ $212,951 $ -- $ 8,810 $ 40,080
Comprehensive income (loss), year ended December 31, 1998:
Net income.................................................... -- -- -- 4,812
Other comprehensive income (loss), net of tax:
Unrealized holding losses, net of income tax benefit of
$600........................................................ -- -- (5,546) --
Less: Reclassification adjustment for gains included in net
income, net of income taxes of $13,322...................... -- -- 26,782 --
---------
Unrealized losses on available-for-sale securities............ -- -- (32,328) --
Translation adjustment........................................ -- -- 2,975 --
Effect of the Merger on components of accumulated other
comprehensive loss.......................................... -- -- (196) --
Minimum pension liability adjustment.......................... -- -- (4,022) --
Comprehensive loss..............................................
Repurchases of common stock of ISP Holdings..................... -- (1,312) -- --
Effect of the Merger............................................ 275,982 1,312 -- --
Repurchases of common stock--816,300 shares..................... -- (9,326) -- --
Issuances under stock option plan--80,556 shares................ -- 938 -- --
Excess of proceeds over cost of treasury stock issued........... 1,570 -- -- --
Effect of exercises of subsidiary's stock options............... (2,019) -- -- --
Effect of issuances of stock options as incentives.............. 1,496 -- -- --
-------- -------- --------- ----------
Balance, December 31, 1998........................................ $489,980 $(8,388) $ (24,761) $ 44,892
Comprehensive income, year ended December 31, 1999:
Net income.................................................... -- -- -- 74,930
Other comprehensive income, net of tax:
Unrealized holding gains, net of income taxes of $12,054...... -- -- 27,949 --
Less: Reclassification adjustment for gains included in net
income, net of income taxes of $2,544....................... -- -- 2,068 --
---------
Unrealized gains on available-for-sale securities............. -- -- 25,881 --
---------
Translation adjustment........................................ -- -- (19,367) --
Less: Reclassification adjustment for translation adjustment
included in net income, net of income tax effect of $521.... -- -- (1,483) --
---------
Net translation adjustment.................................... -- -- (17,884) --
Minimum pension liability adjustment.......................... -- -- 4,715 --
Comprehensive income............................................
Repurchases of common stock--629,000 shares..................... -- (4,987) -- --
Issuances under stock option plan--291,946 shares............... -- 2,931 -- --
Excess of cost of treasury stock issued over proceeds........... (890) -- -- --
Stock issued pursuant to Executive purchase agreement--318,599
shares........................................................ (3,100) 3,100 -- --
Effect of issuances of stock options as incentives.............. 842 -- -- --
-------- -------- --------- ----------
Balance, December 31, 1999........................................ $486,832 $(7,344) $ (12,049) $ 119,822
-------- -------- --------- ----------
-------- -------- --------- ----------
<CAPTION>
COMPREHENSIVE
INCOME (LOSS)
-------------
<S> <C>
Balance, December 31, 1996........................................
Comprehensive income, year ended December 31, 1997:
Net income.................................................... $ 54,005
---------
Other comprehensive income (loss), net of tax:
Unrealized holding gains, net of income taxes of $7,849....... 16,467
Less: Reclassification adjustment for gains included in net
income, net of income taxes of $4,781....................... 10,834
---------
Unrealized gains on available-for-sale securities............. 5,633
Translation adjustment........................................ (6,238)
Effect of Separation Transactions on components of accumulated
other comprehensive income (loss)........................... (155)
Minimum pension liability adjustment.......................... (582)
---------
Comprehensive income............................................ $ 52,663
---------
---------
Effect of Separation Transactions...............................
Effect of purchases of treasury stock...........................
Effect of exercises of subsidiary's stock options...............
Effect of subsidiary's issuances of stock and options as
incentives....................................................
Balance, December 31, 1997........................................
Comprehensive income (loss), year ended December 31, 1998:
Net income.................................................... $ 4,812
---------
Other comprehensive income (loss), net of tax:
Unrealized holding losses, net of income tax benefit of
$600........................................................ (5,546)
Less: Reclassification adjustment for gains included in net
income, net of income taxes of $13,322...................... 26,782
---------
Unrealized losses on available-for-sale securities............ (32,328)
Translation adjustment........................................ 2,975
Effect of the Merger on components of accumulated other
comprehensive loss.......................................... (196)
Minimum pension liability adjustment.......................... (4,022)
---------
Comprehensive loss.............................................. $ (28,759)
---------
---------
Repurchases of common stock of ISP Holdings.....................
Effect of the Merger............................................
Repurchases of common stock--816,300 shares.....................
Issuances under stock option plan--80,556 shares................
Excess of proceeds over cost of treasury stock issued...........
Effect of exercises of subsidiary's stock options...............
Effect of issuances of stock options as incentives..............
Balance, December 31, 1998........................................
Comprehensive income, year ended December 31, 1999:
Net income.................................................... $ 74,930
---------
Other comprehensive income, net of tax:
Unrealized holding gains, net of income taxes of $12,054...... 27,949
Less: Reclassification adjustment for gains included in net
income, net of income taxes of $2,544....................... 2,068
---------
Unrealized gains on available-for-sale securities............. 25,881
---------
Translation adjustment........................................ (19,367)
Less: Reclassification adjustment for translation adjustment
included in net income, net of income tax effect of $521.... (1,483)
---------
Net translation adjustment.................................... (17,884)
Minimum pension liability adjustment.......................... 4,715
---------
Comprehensive income............................................ $ 87,642
---------
---------
Repurchases of common stock--629,000 shares.....................
Issuances under stock option plan--291,946 shares...............
Excess of cost of treasury stock issued over proceeds...........
Stock issued pursuant to Executive purchase agreement--318,599
shares........................................................
Effect of issuances of stock options as incentives..............
Balance, December 31, 1999........................................
</TABLE>
The accompanying Notes to Consolidated Financial Statements are an integral part
of these statements.
F-17
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1. FORMATION OF THE COMPANY AND MERGER OF INTERNATIONAL SPECIALTY PRODUCTS
INC. INTO ISP HOLDINGS INC.
On July 15, 1998, International Specialty Products Inc. ("Old ISP") merged
(the "Merger") with and into ISP Holdings Inc. ("ISP Holdings"). In connection
with the Merger, ISP Holdings changed its name to International Specialty
Products Inc. (the "Company"). In the Merger, each outstanding share of Old
ISP's common stock, other than those held by ISP Holdings, was converted into
one share of common stock of the Company, and the outstanding shares of Old
ISP's common stock which were held by ISP Holdings were converted into an
aggregate of 53,833,333 shares (or approximately 78%) of the outstanding shares
of common stock of the Company. The financial statements presented herein for
periods prior to the Merger represent the results of the former ISP Holdings.
As a result of the Merger, the Company incurred $12.8 million of charges
against operating income in 1998, consisting of a $7.9 million charge in
connection with the termination of ISP Holdings' stock appreciation rights and
preferred stock option programs, a $2.6 million charge related to purchase
accounting adjustments and $2.2 million of other expenses relating to investment
banking, legal and other fees.
Prior to January 1, 1997, ISP Holdings was a wholly-owned subsidiary of GAF
Corporation ("GAF"). ISP Holdings was formed on August 6, 1996 and 10 shares of
its common stock were issued to GAF in exchange for all of the capital stock of
G-I Holdings Inc. ("G-I Holdings"), which resulted in G-I Holdings becoming a
direct wholly-owned subsidiary of ISP Holdings.
On January 1, 1997, GAF effected a series of transactions (the "Separation
Transactions") that resulted in, among other things, the capital stock of ISP
Holdings being distributed to the stockholders of GAF. As a result of such
distribution, ISP Holdings and Old ISP are no longer direct or indirect
subsidiaries of GAF. Conversely, the assets and liabilities of the other
wholly-owned subsidiaries of G-I Holdings are no longer included in the
consolidated assets and liabilities of the Company.
The Company is engaged principally in the manufacture and sale of a wide
range of specialty chemicals and mineral products. See Notes 15 and 16 for a
description of and financial information relating to the Company's business
segments and foreign and domestic operations.
NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Principles of Consolidation
All subsidiaries are consolidated and intercompany transactions have been
eliminated.
Financial Statement Estimates
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make certain estimates.
Actual results could differ from those estimates. In the opinion of management,
the financial statements herein contain all adjustments necessary to present
fairly the financial position and the results of operations and cash flows of
the Company for the periods presented. The Company has a policy to review the
recoverability of long-lived assets and identify and measure any potential
impairments. The Company does not anticipate any changes in management estimates
that would have a material impact on operations, liquidity or capital resources.
Short-term Investments
For securities classified as "trading" (including short positions),
unrealized gains and losses are reflected in the results of operations. For
securities classified as "available-for-sale," unrealized gains (losses), net of
income tax effect, are included in a separate component of stockholders' equity,
"Accumulated other comprehensive loss," and amounted to $(24.0) and
$1.8 million as of December 31, 1998 and 1999, respectively. Investments
classified as "held-to-maturity" securities are carried at amortized cost in the
Consolidated Balance Sheets.
F-18
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES--(CONTINUED)
Included in "Investments in available-for-sale securities" at December 31,
1998 and 1999, respectively, is a $136.3 and $149.5 million investment (based on
market value) in Life Technologies, Inc. Such investment represents
approximately 14% of the outstanding common stock of Life Technologies, Inc. at
December 31, 1999. Included in "Investments in available-for-sale securities" at
December 31, 1999 is a $91.4 million investment (based on market value) in
Dexter Corporation ("Dexter"). Such investment represents approximately 10% of
the outstanding common stock of Dexter at December 31, 1999. See Note 18.
"Other income, net," includes $46.7, $43.2 and $17.9 million of net
realized and unrealized gains on securities in 1997, 1998 and 1999,
respectively. The determination of cost in computing realized gains and losses
is based on the specific identification method.
As of December 31, 1998 and 1999, the market value of the Company's equity
securities held long was $320.7 and $359.2 million, respectively, and the
Company had $82.4 and $56.8 million, respectively, of short positions in common
stocks, based on market value. As of December 31, 1998, the market value of the
Company's held-to-maturity securities was $12.3 million. The Company enters into
equity-related financial instruments with off-balance-sheet risk as a means to
manage its exposure to market fluctuations on its short-term investments. As of
December 31, 1999, the value of equity-related long contracts was $50.1 million,
while the value of equity-related short contracts was $6.5 million, both of
which are marked-to-market each month, with unrealized gains and losses included
in the results of operations. The market values referred to above are based on
quotations as reported by various stock exchanges and major broker/dealers. With
respect to its investments in securities, the Company is exposed to the risk of
market loss.
"Other short-term investments" are investments in limited partnerships
which are accounted for by the equity method. Gains and losses are reflected in
"Other income, net." Liquidation of partnership interests generally require a 30
to 45 day notice period.
Cash and cash equivalents include cash on deposit and debt securities
purchased with original maturities of three months or less.
Inventories
Inventories are stated at the lower of cost or market. The LIFO (last-in,
first-out) method is utilized to determine cost for a substantial portion of the
Company's domestic inventories. All other inventories are determined principally
based on the FIFO (first-in, first-out) method.
Property, Plant and Equipment
Property, plant and equipment is stated at cost less accumulated
depreciation. Depreciation is computed principally on the straight-line method
based on the estimated economic lives of the assets. The Company uses an
economic life of 10-20 years for land improvements, 40 years for buildings, and
3-20 years for machinery and equipment, which includes furniture and fixtures.
Certain interest charges are capitalized during the period of construction as
part of the cost of property, plant and equipment.
Foreign Exchange Contracts
The Company enters into forward foreign exchange instruments with
off-balance-sheet risk in order to hedge a portion of both its borrowings
denominated in foreign currency and its firm or anticipated purchase commitments
related to the operations of foreign subsidiaries. Gains and losses on
instruments used to hedge firm purchase commitments are deferred, and
amortization is included in the measurement of the foreign currency transactions
hedged. Gains and losses on instruments used to hedge anticipated purchases are
recognized within "Other income, net."
F-19
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES--(CONTINUED)
Forward contract agreements require the Company and the counterparty to
exchange fixed amounts of U.S. dollars for fixed amounts of foreign currency on
specified dates. The market value of such contracts varies with changes in the
market exchange rates. The Company is exposed to credit loss in the event of
nonperformance by the counterparties to the forward contract agreements.
However, the Company does not anticipate nonperformance by the counterparties.
The Company does not generally require collateral or other security to support
these financial instruments.
As of December 31, 1998 and 1999, the U.S. dollar equivalent fair value of
outstanding forward foreign exchange contracts was $90.8 and $57.4 million,
respectively, and the amount of net unrealized losses on such instruments was
$4.4 and $0.3 million, respectively. All forward contracts are in major
currencies with highly liquid markets and mature within one year. The Company
uses quoted market prices obtained from major financial institutions to
determine the market value of its outstanding forward exchange contracts. In
addition, the U.S. dollar equivalent fair value of foreign exchange contracts
outstanding as of December 31, 1998 and 1999, which were entered into as a hedge
of non-local currency intercompany loans, was $18.4 and $33.9 million,
respectively, representing 100% of the Company's foreign currency exposure with
respect to such loans.
The Company continually monitors its risk from the effects of foreign
currency fluctuations on its operations and on the derivative products used to
hedge its risk. The Company utilizes real-time, on-line foreign exchange data
and news as well as evaluation of economic information provided by financial
institutions. Mark-to-market valuations are made on a regular basis. Hedging
strategies are approved by senior management before being implemented.
Foreign Currency Translation
Assets and liabilities of foreign subsidiaries, other than those located in
highly inflationary countries, are translated at year-end exchange rates. The
effects of these translation adjustments are reported in a separate component of
stockholders' equity, "Accumulated other comprehensive loss," and amounted to
$4.0 and $(13.9) million as of December 31, 1998 and 1999, respectively. Income
and expenses are translated at average exchange rates prevailing during the
year. Exchange gains and losses arising from transactions denominated in a
currency other than the functional currency of the entity involved, and
translation adjustments of subsidiaries in countries with highly inflationary
economies, are included in "Other income, net."
Excess of Cost Over Net Assets of Businesses Acquired ("Goodwill")
Goodwill, which arose principally from the 1989 management-led buyout of
the predecessor company to the Company's former parent company, GAF, and as a
result of the Merger (see Note 1), is amortized on the straight-line method over
a period of approximately 40 years. The Company believes that the goodwill is
recoverable. To determine if goodwill is recoverable, the Company compares the
net carrying amount to undiscounted projected cash flows of the underlying
businesses to which the goodwill pertains. If goodwill is not recoverable, the
Company would record an impairment based on the difference between the net
carrying amount and fair value.
Debt Issuance Costs
Debt issuance costs are amortized to expense over the life of the related
debt.
Interest Rate Swaps
Gains (losses) on interest rate swap agreements ("swaps") are deferred and
amortized as a reduction (increase) of interest expense over the remaining life
of the debt issue with respect to which the swaps were entered.
F-20
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES--(CONTINUED)
Research and Development
Research and development costs are charged to operations as incurred and
amounted to $26.9, $25.9 and $23.0 million for 1997, 1998 and 1999,
respectively.
Earnings per Common Share
In February 1997, the Financial Accounting Standards Board (the "FASB")
issued Statement of Financial Accounting Standards ("SFAS") No. 128, "Earnings
per Share," which requires the Company to present Basic Earnings per Share and
Diluted Earnings per Share. Earnings per share data for all periods prior to the
Merger are calculated based on the 53,833,333 shares of the Company's common
stock held by ISP Holdings' stockholders. For periods subsequent to the Merger,
"Basic Earnings per Share" are calculated based on the total weighted average
number of shares of the Company's common stock outstanding during the period.
"Diluted Earnings per Share" for periods subsequent to the Merger give effect to
all potential dilutive common shares outstanding during the period under the
Company's 1991 Incentive Plan for Key Employees and Directors (see Note 13).
Investment in Joint Venture
Prior to April 1, 1998, the Company had a 50% equity ownership in GAF-Huls
Chemie GmbH, now known as ISP Marl GmbH ("ISP Marl"), a joint venture which
operated a chemical manufacturing plant in Germany, and was accounted for by the
equity method. Effective April 1, 1998, the Company acquired the remaining 50%
interest in ISP Marl (see Note 7). Dividends received by the Company from the
joint venture totaled $6.3 and $8.1 million for 1997 and 1998, respectively.
Environmental Liability
The Company, together with other companies, is a party to a variety of
proceedings and lawsuits involving environmental matters. The Company estimates
that its liability in respect of such environmental matters, and certain other
environmental compliance expenses, as of December 31, 1999, is $22.5 million,
before reduction for insurance recoveries reflected on its balance sheet of
$11.1 million. The Company's liability is reflected on an undiscounted basis.
See Note 17 for further discussion with respect to environmental liabilities and
estimated insurance recoveries.
Accumulated Other Comprehensive Income (Loss)
In June 1997, the FASB issued SFAS No. 130, "Reporting Comprehensive
Income," which establishes standards for reporting comprehensive income and its
components in annual and interim financial statements. In the Company's case,
Comprehensive Income includes net income, unrealized gains and losses from
investments in available-for-sale securities, net of income tax effect, foreign
currency translation adjustments, and minimum pension liability adjustments. The
Company has chosen to disclose Comprehensive Income (Loss) in the Consolidated
Statements of Stockholders' Equity.
F-21
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES--(CONTINUED)
Changes in the components of "Accumulated other comprehensive income
(loss)" for the years 1997, 1998 and 1999 are as follows:
<TABLE>
<CAPTION>
UNREALIZED CUMULATIVE
GAINS (LOSSES) FOREIGN MINIMUM ACCUMULATED
ON AVAILABLE- CURRENCY PENSION OTHER
FOR-SALE TRANSLATION LIABILITY COMPREHENSIVE
SECURITIES ADJUSTMENT ADJUSTMENT INCOME (LOSS)
-------------- ---------- ---------- -------------
(THOUSANDS)
<S> <C> <C> <C> <C>
Balance, December 31, 1996.................... $ 3,082 $ 7,153 $ (83) $ 10,152
Change for the year 1997...................... 4,925 (5,768) (499) (1,342)
-------- -------- -------- ---------
Balance, December 31, 1997.................... $ 8,007 $ 1,385 $ (582) $ 8,810
Change for the year 1998...................... (32,044) 2,606 (4,133) (33,571)
-------- -------- -------- ---------
Balance, December 31, 1998.................... $(24,037) $ 3,991 $ (4,715) $ (24,761)
Change for the year 1999...................... 25,881 (17,884) 4,715 12,712
-------- -------- -------- ---------
Balance, December 31, 1999.................... $ 1,844 $(13,893) $ -- $ (12,049)
-------- -------- -------- ---------
-------- -------- -------- ---------
</TABLE>
New Accounting Standard
In June 1998, the FASB issued SFAS No. 133, "Accounting for Derivative
Instruments and Hedging Activities." SFAS No. 133 establishes accounting and
reporting standards requiring that every derivative instrument be recorded in
the balance sheet as either an asset or liability measured at its fair value.
SFAS No. 133 requires that changes in a derivative's fair value be recognized
currently in earnings unless specific hedge accounting criteria are met. Special
accounting for qualifying hedges allows a derivative's gains and losses to
offset related results on the hedged item in the income statement.
SFAS No. 133, as amended by SFAS No. 137, is effective for fiscal years
beginning after June 15, 2000, but may be adopted earlier. The Company has not
yet determined the effect of adoption of SFAS No. 133 and has not determined the
timing or method of adoption of the statement. Adoption of SFAS No. 133 could
increase volatility in earnings and other comprehensive income.
Reclassifications
Certain reclassifications have been made to conform to the 1999
presentation.
NOTE 3. DISCONTINUED OPERATION
On October 1, 1999, the Company sold the stock of its Filter Products
subsidiaries to Hayward Industrial Products, Inc. for a purchase price of $62
million. The gain on disposal was $23.5 million, after income taxes of $12.7
million. Accordingly, the Filter Products business segment is reported as a
discontinued operation, and the Consolidated Financial Statements have been
reclassified to report separately the operating results of the Filter Products
business segment. The Company's prior year financial statements have been
restated to reflect continuing operations.
F-22
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
NOTE 3. DISCONTINUED OPERATION--(CONTINUED)
Summary operating results for the Filter Products business are as follows:
<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31,
-----------------------------
1997 1998 1999
------- ------- -------
(THOUSANDS)
<S> <C> <C> <C>
Net sales.................................................... $40,237 $39,322 $28,730
------- ------- -------
------- ------- -------
Income before income taxes................................... $ 3,615 $ 3,248 $ 2,726
Income taxes................................................. (1,312) (1,215) (957)
------- ------- -------
Net income................................................... $ 2,303 $ 2,033 $ 1,769
------- ------- -------
------- ------- -------
</TABLE>
<TABLE>
<CAPTION>
DECEMBER 31,
1998
------------
(THOUSANDS)
<S> <C>
Assets:
Current assets...................................................... $ 20,260
Other noncurrent assets............................................. 5,731
--------
Total Assets.......................................................... $ 25,991
--------
--------
Liabilities:
Current liabilities................................................. $ 1,746
Other noncurrent liabilities........................................ 7
--------
Total Liabilities..................................................... $ 1,753
--------
--------
</TABLE>
NOTE 4. DISPOSITION OF ASSETS
In September 1998, the Company sold its tennis court materials business
that was part of the Mineral Products business segment, which resulted in a
pre-tax gain of $1.2 million. The tennis court materials business accounted for
$1.4 million of sales in 1998. As a result, the sale did not have a material
impact on the Company's results of operations for the year 1999.
On April 2, 1999, the Company sold its pearlescent pigments business, a
non-core product line that was part of the Personal Care business segment, which
resulted in a pre-tax gain of $8.5 million. The pearlescent pigments product
line accounted for $4.9 million of the Company's net sales in 1998. As a result,
the sale did not have a material impact on the Company's results of operations
for the year 1999.
NOTE 5. PROVISION FOR RESTRUCTURING, STAFF REDUCTION AND IMPAIRMENT LOSS
The Company announced in January 1999 that it was shutting down its
butanediol production unit at its Calvert City, Kentucky manufacturing facility.
The decision to shut down this production unit, the Company's highest-cost
butanediol production, resulted from significant adverse changes in the
butanediol market and the Company's acquisition of the remaining 50% interest in
ISP Marl (see Note 7). Accordingly, the Company recorded a one-time
restructuring charge against operating income in 1998 of $42.7 million, as
detailed below.
In conjunction with the decision to shut down the butanediol production
unit in Calvert City, the Company also reviewed its butanediol production assets
at its Texas City and Seadrift, Texas manufacturing facilities to determine if
the carrying amount of such assets was recoverable. As a result of determining
that the expected undiscounted cash flows of the assets was less than their
carrying amount, the Company recognized an impairment loss of $16.6 million in
1998 to write down these assets to fair value.
Prior to acquiring the remaining 50% interest in ISP Marl, the Company
intended to acquire or develop a European manufacturing facility to meet the
needs of the Company's European business. Costs incurred in
F-23
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
NOTE 5. PROVISION FOR RESTRUCTURING, STAFF REDUCTION AND IMPAIRMENT
LOSS--(CONTINUED)
previous years for this project totaled $10.7 million and were included in
"Construction in progress" at December 31, 1997. Such costs represented site
evaluation, engineering, infrastructure and future technology. Based on the
Company's decision to discontinue this project as no longer needed due to the
adverse changes in the butanediol market and the ISP Marl acquisition, these
costs were no longer recoverable and were written off in the fourth quarter of
1998.
In the third quarter of 1998, the Company reserved $3.0 million for the
consolidation of offices in its European operations, consisting of $0.5 million
for severance related to 52 terminated employees in the sales and marketing,
finance and accounting, and the supply chain departments, $1.7 million for lease
obligations and $0.8 million for the relocation of headquarters operations and
other related expenses. This program was completed in 1999.
The components of the $73.0 million provision for restructuring and
impairment loss are as follows:
<TABLE>
<CAPTION>
(MILLIONS)
----------
<S> <C>
Write-off of Calvert City production assets.............................. $ 22.1
Impairment loss on Texas City and Seadrift assets........................ 16.6
Write-off of goodwill related to the butanediol business................. 13.1
Write-off of fixed asset costs related to the terminated European
expansion project...................................................... 10.7
Accrual for decommissioning, demolition and remediation costs............ 4.7
Accrual for severance costs.............................................. 0.9
Accrual for costs related to the termination of raw material contracts
and other related costs................................................ 1.9
Accrual for consolidation of European offices............................ 3.0
------
Total provision.......................................................... $ 73.0
------
------
</TABLE>
Of the total $70.0 million provision recorded in the fourth quarter of
1998, $7.5 million represented cash costs to be incurred, including severance
costs of $0.9 million for 41 terminated employees who were operators and
supervisors in the butanediol production unit that was shut down. During 1999,
$4.8 million of costs were charged to this accrual, principally for
decommissioning activities and severance. In 1999, the Company reversed $1.9
million of such previously recorded restructuring reserves, representing an
excess demolition reserve of $0.8 million and $1.1 million of other reserves,
mainly for raw material contract terminations, which were no longer required.
The total restructuring reserve balance as of December 31, 1999 was $0.8
million, principally for demolition and severance costs to be incurred in the
first half of 2000. The Company expects this program to be completed by June
2000.
As a result of the write-off of property, plant and equipment and goodwill,
the Company's depreciation expense has been lowered by approximately $4.5
million per year and goodwill amortization has been lowered by approximately
$0.4 million per year.
In the third quarter of 1999, the Company implemented a staff reduction
program impacting corporate and worldwide executive and administrative staff
positions. As a result, a total of 79 positions were eliminated in 1999 through
normal attrition or termination, for which the Company recorded a pre-tax
provision for severance of $2.3 million. The applicable severance reserve
remaining as of December 31, 1999 was $0.5 million.
F-24
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
NOTE 6. INCOME TAXES
Income tax (provision) benefit for continuing operations consists of the
following:
<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31,
--------------------------------
1997 1998 1999
-------- -------- --------
(THOUSANDS)
<S> <C> <C> <C>
Federal:
Current............................................................ $ (2,233) $ (370) $ (1,342)
Deferred........................................................... (27,832) 6,598 (10,403)
-------- -------- --------
Total Federal........................................................ (30,065) 6,228 (11,745)
-------- -------- --------
Foreign:
Current............................................................ (4,772) (19,106) (16,830)
Deferred........................................................... -- -- 5,185
-------- -------- --------
Total foreign................................................... (4,772) (19,106) (11,645)
-------- -------- --------
State and local:
Current............................................................ (2,250) (1,450) (2,586)
Deferred........................................................... (738) 218 (846)
-------- -------- --------
Total state and local........................................... (2,988) (1,232) (3,432)
-------- -------- --------
Income tax provision................................................. $(37,825) $(14,110) $(26,822)
-------- -------- --------
-------- -------- --------
</TABLE>
The differences between the income tax provision computed by applying the
statutory Federal income tax rate to pre-tax income, and the income tax
provision reflected in the Consolidated Statements of Income are as follows:
<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31,
--------------------------------
1997 1998 1999
-------- -------- --------
(THOUSANDS)
<S> <C> <C> <C>
Statutory tax provision.............................................. $(36,477) $ (9,509) $(26,746)
Impact of:
Foreign operations................................................. 2,500 2,022 4,388
State and local taxes, net of Federal benefits..................... (1,942) (801) (2,231)
Nondeductible goodwill amortization................................ (4,611) (9,858) (5,723)
Percentage depletion............................................... 1,680 1,929 1,943
Other, net......................................................... 1,025 2,107 1,547
-------- -------- --------
Income tax provision................................................. $(37,825) $(14,110) $(26,822)
-------- -------- --------
-------- -------- --------
</TABLE>
F-25
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
NOTE 6. INCOME TAXES--(CONTINUED)
The components of the net deferred tax liability are as follows:
<TABLE>
<CAPTION>
DECEMBER 31,
--------------------
1998 1999
-------- --------
(THOUSANDS)
<S> <C> <C>
Deferred tax liabilities related to:
Property, plant and equipment........................................ $ 95,776 $ 96,444
Other................................................................ (9,540) 30,290
-------- --------
Total deferred tax liabilities......................................... 86,236 126,734
-------- --------
Deferred tax assets related to:
Expenses not yet deducted for tax purposes........................... (12,323) (20,185)
Deferred income...................................................... (499) (67)
Carryover AMT and R&D credits........................................ (7,802) (11,347)
Other................................................................ (15,682) (18,095)
-------- --------
Total deferred tax assets.............................................. (36,306) (49,694)
-------- --------
Net deferred tax liability............................................. 49,930 77,040
Deferred tax assets reclassified to other current assets............... 10,352 12,756
-------- --------
Noncurrent deferred tax liability...................................... $ 60,282 $ 89,796
-------- --------
-------- --------
</TABLE>
The Company was a party to tax sharing agreements with members of the GAF
consolidated group (the "GAF Group"). As a result of the Separation
Transactions, the Company is no longer included in the consolidated Federal
income tax returns of GAF, and therefore, such tax sharing agreements are no
longer applicable with respect to the tax liabilities of the Company for periods
subsequent to the Separation Transactions. The Company remains obligated,
however, with respect to tax liabilities imposed or that may be imposed for
periods prior to the Separation Transactions. Among other things, those tax
sharing agreements provide for the sharing of the GAF Group's consolidated tax
liability based on each member's share of the tax as if such member filed on a
separate basis. Accordingly, a payment of tax would be made to GAF equal to the
Company's allocable share of the GAF Group's consolidated tax liability.
Alternatively, the Company would be entitled to refunds if losses or other
attributes reduce the GAF Group's consolidated tax liability. Moreover, foreign
tax credits generated by the Company not utilized by GAF will be refunded by GAF
or its subsidiary to the Company, if such credits expire unutilized upon
termination of the statute of limitations for the year of expiration.
Furthermore, those tax sharing agreements provide for an indemnification to the
Company for any tax liability attributable to another member of the GAF Group.
On September 15, 1997, GAF received a notice from the Internal Revenue
Service (the "IRS") of a deficiency in the amount of $84.4 million (after taking
into account the use of net operating losses and foreign tax credits otherwise
available for use in later years) in connection with the formation in 1990 of
Rhone-Poulenc Surfactants and Specialties, L.P. (the "surfactants partnership"),
a partnership in which a subsidiary of GAF, GAF Fiberglass Corporation ("GFC"),
held an interest. The claim of the IRS for interest and penalties, after taking
into account the effect on the use of net operating losses and foreign tax
credits, could result in GAF incurring liabilities significantly in excess of
the deferred tax liability of $131.4 million that it recorded in 1990 in
connection with this matter. GAF has advised the Company that it believes that
it will prevail in this matter, although there can be no assurance in this
regard. The Company believes that the ultimate disposition of this matter will
not have a material adverse effect on its business, financial position or
results of operations. GAF and certain subsidiaries of GAF have agreed to
jointly and severally indemnify the Company against any tax liability associated
with the surfactants partnership, which the Company would be severally liable
for, together with GAF and several current and former subsidiaries of GAF,
should GAF be unable to satisfy such liability. See Note 17.
F-26
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
NOTE 7. ACQUISITIONS
In February 1998, the Company acquired Polaroid Corporation's Freetown,
Massachusetts fine chemicals facility. In connection with the acquisition, the
Company entered into a sale-leaseback arrangement for the facility's equipment
with a third party. The lease has been accounted for as an operating lease, with
an initial term of four years and, at the Company's option, up to three one-year
renewal periods. As part of the acquisition transaction, the Company entered
into a long-term supply and license agreement with Polaroid for the imaging
chemicals and polymers manufactured at the facility and used by Polaroid in its
instant film business. The results of the Freetown facility are included in the
Company's financial statements from the date of its acquisition and were not
material to 1998 operations.
Effective April 1, 1998, the Company acquired the remaining 50% interest in
ISP Marl, its joint venture with Huls AG. ISP Marl consists of a manufacturing
facility that produces primarily butanediol and tetrahydrofuran. As part of the
transaction, the Company also acquired Huls' production facility that supplies
ISP Marl with acetylene, its primary raw material. The results of ISP Marl are
included in the Company's financial statements on a consolidated basis from the
date of its acquisition, including sales of $53.0 million for 1998.
On October 15, 1999, the Company acquired substantially all of the assets
of the Kelco Alginates division of Monsanto Company, including manufacturing
facilities in San Diego, California and Girvan, Scotland, a research facility in
Tadworth, England and equity investments in three seaweed processing joint
ventures in Ireland, Iceland and Tasmania. The alginates business manufactures
sodium alginate, propylene glycol alginate and other alginate derivatives. Algin
is a naturally occurring hydrocolloid, derived from brown seaweed, and is used
in food, pharmaceutical and industrial applications. The results of the
alginates business, including sales of $12.8 million for 1999, are included in
the Company's financial statements from the date of its acquisition and were not
material to 1999 operations.
NOTE 8. SALE OF ACCOUNTS RECEIVABLE
In June 1993, the Company sold its domestic trade accounts receivable,
without recourse, for a maximum of $25 million in cash to be made available to
the Company based on eligible domestic receivables outstanding from time to
time. The agreement under which the Company sells its domestic trade accounts
receivable was renewed each year through 1998 for one-year periods on
substantially the same terms and conditions, and the maximum purchase amount was
increased in January 1998 to provide for up to $33 million in cash. In June
1999, the agreement was extended through May 2000, and the maximum purchase
amount was increased to provide for up to $36 million in cash. The excess of
accounts receivable sold over the net proceeds received is included in "Accounts
receivable, other." The effective cost to the Company varies with LIBOR or
commercial paper rates and is included in "Other income, net" and amounted to
$1.8, $1.8 and $2.5 million in 1997, 1998 and 1999, respectively.
F-27
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
NOTE 9. INVENTORIES
At December 31, 1998 and 1999, $61.8 and $47.7 million, respectively, of
domestic inventories were valued using the LIFO method. Inventories comprise the
following:
<TABLE>
<CAPTION>
DECEMBER 31,
--------------------
1998 1999
-------- --------
(THOUSANDS)
<S> <C> <C>
Finished goods........................................................ $ 83,068 $110,248
Work in process....................................................... 23,736 18,457
Raw materials and supplies............................................ 25,526 25,735
-------- --------
Total............................................................... 132,330 154,440
Less LIFO reserve..................................................... (3,280) (2,665)
-------- --------
Inventories........................................................... $129,050 $151,775
-------- --------
-------- --------
</TABLE>
NOTE 10. PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment comprises the following:
<TABLE>
<CAPTION>
DECEMBER 31,
--------------------
1998 1999
-------- --------
(THOUSANDS)
<S> <C> <C>
Land and land improvements............................................ $ 74,057 $ 76,111
Buildings and building equipment...................................... 90,330 99,800
Machinery and equipment............................................... 492,335 586,831
Construction in progress.............................................. 96,623 75,879
-------- --------
Total............................................................... 753,345 838,621
Less accumulated depreciation......................................... (205,790) (268,403)
-------- --------
Property, plant and equipment, net.................................... $547,555 $570,218
-------- --------
-------- --------
</TABLE>
See Note 17 for information regarding capital leases.
NOTE 11. LONG-TERM DEBT AND LINES OF CREDIT
Long-term debt comprises the following:
<TABLE>
<CAPTION>
DECEMBER 31,
--------------------
1998 1999
-------- --------
(THOUSANDS)
<S> <C> <C>
9% Senior Notes due 2003.............................................. $324,378 $324,508
9 3/4% Senior Notes due 2002.......................................... 199,871 199,871
9% Senior Notes due 1999.............................................. 200,000 --
Borrowings under revolving credit facility............................ 132,600 295,000
Obligation on mortgaged property, due 2000............................ 38,125 38,125
Obligations under capital leases (Note 17)............................ 1,317 945
Other................................................................. 387 235
-------- --------
Total long-term debt................................................ 896,678 858,684
Less current maturities............................................... (583) (38,543)
-------- --------
Long-term debt less current maturities................................ $896,095 $820,141
-------- --------
-------- --------
</TABLE>
F-28
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
11. LONG-TERM DEBT AND LINES OF CREDIT--(CONTINUED)
In October 1996, the Company issued $325 million principal amount of
9% Senior Notes due 2003 (the "9% Senior Notes"). The net cash proceeds of
$317.2 million were utilized to consummate a cash tender offer for all of G-I
Holdings' Senior Discount Notes and Series B Senior Discount Notes due 1998.
In October 1996, the Company consummated an offer to exchange (the
"Exchange Offer") $1,000 principal amount of 9 3/4% Senior Notes due 2002 (the
"9 3/4% Senior Notes") for each $1,000 principal amount of G-I Holdings'
Series B 10% Senior Notes due 2006 (the "10% Notes"). Pursuant to the Exchange
Offer, an aggregate amount of $199.9 million of 9 3/4% Senior Notes were issued
to the former holders of the 10% Notes.
Holders of the 9% Senior Notes and the 9 3/4% Senior Notes (collectively,
the "Notes") have the right to require the Company to purchase the Notes at a
price of 101% of their principal amount, and the Company has the right to redeem
the Notes at their principal amount plus the Applicable Premium (as defined),
together with any accrued and unpaid interest, in the event of a Change of
Control (as defined). Under the indentures relating to the Notes, the incurrence
of additional debt and the issuance of preferred stock by the Company would be
restricted unless, subject to certain exceptions, the ratio of consolidated
income before income taxes, interest, depreciation and amortization expense to
the consolidated interest expense (as defined) for the most recently completed
four fiscal quarters is at least 2 to 1. For the four quarters ended
December 31, 1999, the Company was in compliance with such test.
In connection with the issuance of the 9% Senior Notes which matured on
March 1, 1999 (the "9% Notes"), the Company entered into interest rate swap
agreements ("swaps") with banks in an aggregate notional principal amount of
$200 million. In 1993, the Company terminated the swaps, resulting in gains of
$25.1 million, and entered into new swaps. The gains were deferred and were
amortized as a reduction of interest expense over the remaining life of the
9% Notes. During 1997, the Company entered into five-year swaps with banks in
the aggregate notional principal amount of $100 million in order to fix a
portion of its interest expense and reduce its exposure to floating interest
rates. These swaps require the Company to pay a fixed rate and receive LIBOR for
a period of five years. In 1998, the Company entered into forward-starting swaps
in the aggregate notional principal amount of $125 million in order to convert
to fixed rates $125 million of its exposure to floating interest rates. Such
swaps matured on March 1, 1999. Based on the fair value of the outstanding swaps
at December 31, 1998 and 1999, the Company would have incurred gains (losses) of
$(10.2) and $0.7 million, respectively, representing the estimated amount that
would be payable or receivable by the Company if the swaps were terminated at
such dates.
The Company may be considered to be at risk, to the extent of the costs of
replacing such swaps at current market rates, in the event of nonperformance by
counterparties. However, since the counterparties are major financial
institutions, the credit ratings of which are continually monitored by the
Company, the risk of such nonperformance is considered by the Company to be
remote.
In July 1996, the Company entered into a new five-year revolving credit
facility (the "Credit Agreement") with a group of banks, which provides for
loans of up to $400 million and letters of credit of up to $75 million.
Borrowings under the Credit Agreement bear interest at a floating rate (6.60% on
December 31, 1999) based on the banks' base rate, federal funds rate, Eurodollar
rate or a competitive bid rate (which may be based on LIBOR or money market
rates), at the option of the Company. As of December 31, 1999, letters of credit
in the amount of $7.9 million were outstanding under the Credit Agreement.
F-29
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
11. LONG-TERM DEBT AND LINES OF CREDIT--(CONTINUED)
The Company has a $38.1 million mortgage obligation, due April 2000, on its
headquarters property. Interest on the mortgage is at a floating rate based on
LIBOR.
Borrowings by the Company, including those under the Credit Agreement, are
subject to the application of certain financial covenants contained in such
agreement and in the indentures relating to the Notes. As of December 31, 1999,
the Company was in compliance with such covenants, and the application of such
covenants would not have restricted the amount available for borrowing under the
Credit Agreement. The Credit Agreement and the indentures relating to the Notes
also limit the amount of cash dividends, purchases of treasury stock, and other
restricted payments (as defined) by the Company. As of December 31, 1999, under
the most restrictive of such limitations, the Company could have paid dividends
and other restricted payments of up to $112.4 million.
The Credit Agreement and the indentures relating to the Notes contain
additional affirmative and negative covenants, including restrictions on liens,
investments, transactions with affiliates, sale-leaseback transactions, and
mergers and transfers of all or substantially all of the assets of the Company
or its subsidiaries. The Credit Agreement also provides for a default if there
is a change in control (as defined) of the Company.
The Company believes that the fair value of its non-public variable rate
indebtedness approximates the book value of such indebtedness because the
interest rates on such indebtedness are at floating short-term rates. The Credit
Agreement also provides for adjustments to the interest rate if there is a
change in the credit rating of the Company. With respect to the Company's
publicly traded debt securities, the Company has obtained estimates of fair
values from an independent source believed to be reliable. The estimated fair
value of the 9% Senior Notes as of December 31, 1998 and 1999 was $341.4 and
$318.8 million, respectively, and the estimated fair value of the 9 3/4% Senior
Notes as of December 31, 1998 and 1999 was $212.4 and $200.4 million,
respectively. The estimated fair value of the 9% Notes as of December 31, 1998
was $201.0 million.
The aggregate maturities of long-term debt as of December 31, 1999 for the
next five years are as follows:
<TABLE>
<CAPTION>
(THOUSANDS)
-----------
<S> <C>
2000......................................................... $ 38,543
2001......................................................... 295,346
2002......................................................... 200,040
2003......................................................... 324,755
2004......................................................... --
</TABLE>
In the above table, 2000 maturities include the $38.1 million mortgage
obligation. Maturities in 2001 include the $295.0 million of borrowings
outstanding under the Credit Agreement as of December 31, 1999, based on the
expiration of the Credit Agreement in July 2001. Maturities in 2002 include the
$199.9 million of 9 3/4% Senior Notes. Maturities in 2003 include the
$324.5 million of 9% Senior Notes, based on their accreted value as of
December 31, 1999.
At December 31, 1999, the Company's foreign subsidiaries had total
available short-term lines of credit aggregating $17.5 million, of which
$9.6 million were unused. The weighted-average interest rate on the Company's
short-term borrowings as of December 31, 1998 and 1999 was 5.5% and 5.7%,
respectively.
F-30
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
NOTE 12. BENEFIT PLANS
Eligible, full-time employees of the Company are covered by various benefit
plans, as described below.
Defined Contribution Plan
The Company provides a defined contribution plan for eligible employees.
The Company contributes up to 7% of participants' compensation (any portion of
which can be contributed, at the participants' option, in the form of the
Company's common stock at a $.50 per share discount from the market price on the
date of contribution), and also contributes fixed amounts, ranging from $50 to
$750 per year depending on age, to the accounts of participants who are not
covered by a Company-provided postretirement medical benefit plan. The aggregate
contributions by the Company were $7.0, $8.0 and $8.1 million for 1997, 1998 and
1999, respectively.
Defined Benefit Plans
The Company provides a noncontributory defined benefit retirement plan for
certain hourly employees in the U.S. (the "Hourly Retirement Plan"). Benefits
under this plan are based on stated amounts for each year of service. The
Company's funding policy is consistent with the minimum funding requirements of
ERISA.
ISP Marl provides a noncontributory defined benefit retirement plan for its
hourly and salaried employees (the "ISP Marl Plan"). Benefits under this plan
are based on average earnings over each employee's career with the Company.
The Company's net periodic pension cost (income) for the Hourly Retirement
Plan and the ISP Marl Plan included the following components:
<TABLE>
<CAPTION>
ISP MARL
PLAN
HOURLY RETIREMENT PLAN ------------
--------------------------------
YEAR ENDED
YEAR ENDED DECEMBER 31, DECEMBER 31,
-------------------------------- ------------
1997 1998 1999 1998 1999
-------- -------- -------- ---- ----
(THOUSANDS)
<S> <C> <C> <C> <C> <C>
Service cost.......................................... $ 284 $ 313 $ 310 $140 $176
Interest cost......................................... 1,481 1,586 1,678 172 236
Expected return on plan assets........................ (2,152) (2,366) (2,314) -- --
Amortization of actuarial losses...................... -- -- 215 -- 12
Amortization of unrecognized prior service cost....... 174 174 174 12 11
-------- -------- -------- ---- ----
Net periodic pension cost (income).................... $ (213) $ (293) $ 63 $324 $435
-------- -------- -------- ---- ----
-------- -------- -------- ---- ----
</TABLE>
The following tables set forth, for the years 1998 and 1999,
reconciliations of the beginning and ending balances of the benefit obligation,
fair value of plan assets, funded status, amounts recognized in the Consolidated
Balance Sheets and changes in Accumulated Other Comprehensive Loss related to
the Hourly Retirement Plan and the ISP Marl Plan:
F-31
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
NOTE 12. BENEFIT PLANS--(CONTINUED)
<TABLE>
<CAPTION>
HOURLY RETIREMENT PLAN ISP MARL PLAN
----------------------- --------------------
DECEMBER 31, DECEMBER 31,
----------------------- --------------------
1998 1999 1998 1999
------- ------- -------- --------
(THOUSANDS)
<S> <C> <C> <C> <C>
Change in benefit obligation:
Benefit obligation at beginning of year............ $21,718 $24,015 $ 2,359 $ 3,378
Service cost....................................... 313 310 140 176
Interest cost...................................... 1,586 1,678 172 236
Actuarial (gains) losses........................... 1,298 (1,574) 707 6
Benefits paid...................................... (900) (1,000) -- --
------- ------- -------- --------
Benefit obligation at end of year.................. 24,015 23,429 3,378 3,796
------- ------- -------- --------
Change in plan assets:
Fair value of plan assets at beginning of year..... 21,426 21,008 -- --
Actual return on plan assets....................... (358) 2,602 -- --
Employer contributions............................. 840 1,051 -- --
Benefits paid...................................... (900) (1,000) -- --
------- ------- -------- --------
Fair value of plan assets at end of year........... 21,008 23,661 -- --
------- ------- -------- --------
Reconciliation of funded status:
Funded status...................................... (3,007) 232 (3,378) (3,796)
Transition obligation.............................. -- -- 228 159
Unrecognized prior service cost.................... 1,236 1,062 -- 515
Unrecognized actuarial losses...................... 4,715 2,637 -- --
------- ------- -------- --------
Net amount recognized in Consolidated Balance
Sheets.......................................... $ 2,944 $ 3,931 $ (3,150) $ (3,122)
------- ------- -------- --------
------- ------- -------- --------
Amounts recognized in Consolidated Balance Sheets:
Prepaid (accrued) benefit cost..................... $(3,007) $ 3,931 $ (3,150) $ (3,122)
Intangible asset................................... 1,236 -- -- --
Accumulated other comprehensive loss............... 4,715 -- -- --
------- ------- -------- --------
Net amount recognized.............................. $ 2,944 $ 3,931 $ (3,150) $ (3,122)
------- ------- -------- --------
------- ------- -------- --------
Change for the year in accumulated other
comprehensive loss:
Change in intangible asset......................... $ 174 $ 1,236 -- --
Change in additional minimum liability............. 3,849 (5,951) -- --
------- -------
Total.............................................. $ 4,023 $(4,715) -- --
------- -------
------- -------
</TABLE>
In determining the projected benefit obligation, the weighted-average
assumed discount rate was 7% and 7.75% for 1998 and 1999, respectively, for the
Hourly Retirement Plan, and was 6% and 6.5%, respectively, for the ISP Marl
Plan. The expected long-term rate of return on assets, used in determining net
periodic pension cost (income) for the Hourly Retirement Plan, was 11% for 1998
and 1999.
The Company also provides a nonqualified defined benefit retirement plan
for certain key employees. Expense accrued for this plan was $0.6, $1.0 and
$0.9 million for 1997, 1998 and 1999, respectively.
F-32
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
NOTE 12. BENEFIT PLANS--(CONTINUED)
Postretirement Medical and Life Insurance
The Company generally does not provide postretirement medical and life
insurance benefits, although it subsidizes such benefits for certain employees
and certain retirees. Such subsidies were reduced or ended as of January 1,
1997.
The net periodic postretirement benefit cost included the following
components:
<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31,
--------------------------
1997 1998 1999
------ ------ ------
(THOUSANDS)
<S> <C> <C> <C>
Service cost...................................................... $ 4 $ 6 $ 7
Interest cost..................................................... 752 619 608
Amortization of unrecognized prior service cost................... (179) (179) (179)
------ ------ ------
Net periodic postretirement benefit cost.......................... $ 577 $ 446 $ 436
------ ------ ------
------ ------ ------
</TABLE>
The following table sets forth, for the years 1998 and 1999,
reconciliations of the beginning and ending balances of the postretirement
benefit obligation, funded status and amounts recognized in the Consolidated
Balance Sheets related to postretirement medical and life insurance benefits:
<TABLE>
<CAPTION>
DECEMBER 31,
---------------------
1998 1999
--------- --------
(THOUSANDS)
<S> <C> <C>
Change in benefit obligation:
Benefit obligation at beginning of year............................. $ 10,324 $ 9,249
Service cost........................................................ 6 7
Interest cost....................................................... 619 608
Actuarial gains..................................................... (968) (1,393)
Benefits paid....................................................... (732) (831)
--------- --------
Benefit obligation at end of year................................... 9,249 7,640
--------- --------
Change in plan assets:
Fair value of plan assets at beginning of year...................... -- --
Employer contributions.............................................. 732 831
Benefits paid....................................................... (732) (831)
--------- --------
Fair value of plan assets at end of year............................ -- --
--------- --------
Reconciliation of funded status:
Funded status....................................................... (9,249) (7,640)
Unrecognized prior service cost..................................... (1,154) (975)
Unrecognized actuarial (gains) losses............................... 185 (1,209)
--------- --------
Net amount recognized in Consolidated Balance Sheets as accrued
benefit cost..................................................... $ (10,218) $ (9,824)
--------- --------
--------- --------
</TABLE>
For purposes of calculating the accumulated postretirement benefit
obligation, the following assumptions were made. Retirees as of December 31,
1999 who were formerly salaried employees (with certain exceptions) were assumed
to receive a Company subsidy of $700 to $1,000 per year. For retirees over age
65, this subsidy may be replaced by participation in a managed care program.
With respect to retirees who were formerly hourly employees, most such retirees
are subject to a $5,000 per person lifetime maximum benefit. Subject to such
lifetime maximum, an 11% and 6% annual rate of increase in the Company's per
capita cost of providing postretirement medical benefits was assumed for 1999
for such retirees under and over age 65, respectively. To
F-33
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
NOTE 12. BENEFIT PLANS--(CONTINUED)
the extent that the lifetime maximum benefits have not been reached, the
foregoing rates were assumed to decrease gradually to an ultimate rate of 7% and
6%, respectively, by the year 2003 and remain at that level thereafter. The
weighted-average assumed discount rate used in determining the accumulated
postretirement benefit obligation was 7% and 7.75% for 1998 and 1999,
respectively.
The health care cost trend rate assumption has an effect on the amounts
reported. To illustrate, increasing the assumed health care cost trend rates by
one percentage point in each year would increase the accumulated postretirement
benefit obligation as of December 31, 1998 and 1999 by $419,000 and $346,000,
respectively, and the aggregate of the service and interest cost components of
the net periodic postretirement benefit cost for the years 1998 and 1999 by
$30,000 and $25,000, respectively. A decrease of one percentage point in each
year would decrease the accumulated postretirement benefit obligation as of
December 31, 1998 and 1999 by $373,000 and $308,000, respectively, and the
aggregate of the service and interest cost components of the net periodic
postretirement benefit cost for the years 1998 and 1999 by $27,000 and $22,000,
respectively.
NOTE 13. STOCK OPTION PLANS AND STOCK APPRECIATION RIGHTS
The 1991 Incentive Plan for Key Employees and Directors, as amended (the
"Plan"), authorizes the grant of options to purchase a maximum of 9,000,000
shares of the Company's common stock. In June 1999, the Company's Board of
Directors approved an amendment to the Plan, subject to stockholder approval,
increasing the number of shares as to which options may be granted under the
Plan to 13,000,000. The Compensation Committee of the Board of Directors (the
"Committee") determines the exercise price and vesting schedule of options
granted under the Plan. In 1997, 1998 and 1999, the Company granted options to
certain employees to purchase 264,344, 2,029,301 and 369,230 shares,
respectively, of the Company's common stock at exercise prices ranging from
$1.50 to $5.00 below the fair market value of such shares on the date of grant.
The difference between the exercise price and the fair market value of such
shares on the date of grant is recognized as compensation expense over the
vesting period of 2 1/2 to 5 years. Compensation expense for such options was
$0.7, $1.9 and $0.8 million in 1997, 1998 and 1999, respectively. All other
employee options granted under the Plan have a term of nine years, have an
exercise price equal to the fair market value of such shares on the date of
grant and become exercisable at a rate determined by the Committee at the time
of grant. Special vesting rules apply to options granted to non-employee
directors.
The Company has elected the disclosure-only provisions of SFAS No. 123,
"Accounting for Stock-Based Compensation," and applies APB Opinion No. 25 and
related interpretations in accounting for the Plan. If the Company had elected
to recognize compensation cost based on the fair value of awards under the Plan
at grant dates, the Company's pro forma net income for the years 1997, 1998 and
1999 would have been $51.8, $2.2 and $71.2 million, respectively, and pro forma
basic earnings per share would have been $.96, $.04 and $1.04, respectively. The
SFAS No. 123 method of accounting has not been applied to options granted prior
to January 1, 1995, and the resulting pro forma compensation expense may not be
indicative of pro forma expense in future years.
The fair value of the Company's stock options used to compute pro forma net
income and earnings per share is the estimated present value at the date of
grant using the Black-Scholes option-pricing model with the following
weighted-average assumptions: risk-free interest rate of 6%; expected life of 6
years; expected volatility of 24%; and dividend yield of 0%.
F-34
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
NOTE 13. STOCK OPTION PLANS AND STOCK APPRECIATION RIGHTS--(CONTINUED)
The following is a summary of transactions pertaining to the Plan:
<TABLE>
<CAPTION>
YEAR ENDED YEAR ENDED YEAR ENDED
DECEMBER 31, 1997 DECEMBER 31, 1998 DECEMBER 31, 1999
------------------ ------------------ -------------------
WEIGHTED WEIGHTED WEIGHTED
AVERAGE AVERAGE AVERAGE
SHARES EXERCISE SHARES EXERCISE SHARES EXERCISE
(000'S) PRICE (000'S) PRICE (000'S) PRICE
------ -------- ------ -------- ------- --------
<S> <C> <C> <C> <C> <C> <C>
Outstanding, January 1............................... 5,014 $ 9.32 4,733 $ 9.68 6,989 $12.06
Granted.............................................. 515 11.99 3,117 15.05 3,468 9.47
Exercised............................................ (306) 8.08 (351) 7.70 (292) 7.03
Forfeited............................................ (490) 9.37 (510) 11.19 (2,137) 12.78
------ ------ -------
Outstanding, December 31............................. 4,733 9.68 6,989 12.06 8,028 10.93
------ ------ -------
------ ------ -------
Options exercisable, December 31..................... 1,294 8.37 2,190 10.63 3,162 10.81
------ ------ -------
------ ------ -------
</TABLE>
Based on calculations using the Black-Scholes option-pricing model, the
weighted-average fair value of options granted in 1997, 1998 and 1999 under the
Plan for which the exercise price equaled the fair market value of such shares
on the date of grant was $4.17, $4.40 and $2.91 per share, respectively, and
such weighted-average fair value of options granted in 1997, 1998 and 1999 for
which the exercise price was less than the fair market value of such shares on
the date of grant was $7.93, $6.42 and $5.64 per share, respectively.
The following is a summary of the status of stock options outstanding and
exercisable under the Plan as of December 31, 1999:
<TABLE>
<CAPTION>
STOCK OPTIONS
OUTSTANDING STOCK OPTIONS
--------------------------------- EXERCISABLE
WEIGHTED ------------------
WEIGHTED AVERAGE WEIGHTED
AVERAGE REMAINING AVERAGE
RANGE OF SHARES EXERCISE CONTRACTUAL SHARES EXERCISE
EXERCISE PRICES (000'S) PRICE LIFE (000'S) PRICE
- --------------------------------------------------- ------ -------- ----------- ------ --------
<S> <C> <C> <C> <C> <C>
$ 3.781--$ 5.875................................... 425 $ 4.95 4.72 years 109 $ 5.88
$ 5.876--$ 8.938................................... 1,490 7.55 4.01 years 1,138 7.31
$ 8.939--$13.313................................... 4,268 10.70 7.25 years 1,295 11.76
$13.314--$18.625................................... 1,845 15.58 7.43 years 620 16.10
------ ------
Total.............................................. 8,028 10.93 6.55 years 3,162 10.81
------ ------
------ ------
</TABLE>
ISP Holdings issued options in 1996 to certain employees to purchase
138,983 shares of ISP Holdings' redeemable convertible preferred stock
("Preferred Stock"), exercisable at a price of $111.44 per share. Each share of
Preferred Stock was convertible, at the holder's option, into shares of common
stock of ISP Holdings at a formula price based on the sum of the determined
initial Book Value (as defined) plus interest on such Book Value at a specified
rate. The options vested over seven years, subject to earlier vesting under
certain circumstances including in connection with a change of control.
ISP Holdings also issued stock appreciation rights ("SARs") in 1996 related
to 27,748 shares of ISP Holdings' common stock. The SARs represented the right
to receive a cash payment based upon the appreciation in value of the specified
number of shares of common stock of ISP Holdings over the sum of the determined
initial Book Value (as defined) per share of common stock of ISP Holdings plus
interest on such Book Value at a specified rate. The SARs vested over a
five-year period, subject to earlier vesting under certain circumstances
including in connection with a change of control. Compensation expense related
to SARs was $1.3 million for 1997.
F-35
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
NOTE 13. STOCK OPTION PLANS AND STOCK APPRECIATION RIGHTS--(CONTINUED)
As a result of the Merger (see Note 1), ISP Holdings' Preferred Stock
option and SAR programs were terminated, and the Company charged $7.9 million
against operating income for cash payments made in 1998 for amounts vested at
that time. Additional expenses totaling $3.1 million may be recorded over the
remaining vesting period from the date of the Merger through 2003, including
$0.8 million expensed in 1998 after the Merger and $0.9 million in 1999.
NOTE 14. RELATED PARTY TRANSACTIONS
Included in the Consolidated Balance Sheets are the following receivable
balances with related parties, which arise from operating transactions between
the Company and its affiliates, including the sales of mineral products and the
management agreement, as discussed below:
<TABLE>
<CAPTION>
DECEMBER 31,
-----------------
1998 1999
------ -------
(THOUSANDS)
<S> <C> <C>
Building Materials Corporation of America ("BMCA")....................... $5,853 $15,037
GAF/G-I Holdings/G Industries Corp....................................... 1,836 1,350
Other.................................................................... 80 514
------ -------
Receivable from related parties, net..................................... $7,769 $16,901
------ -------
------ -------
</TABLE>
BMCA, an indirect subsidiary of GAF and an affiliate of the Company, and
its subsidiaries purchase all of their colored roofing granules requirements
from the Company under a requirements contract, except for the requirements of
their California and Oregon roofing plants and a portion of the requirements of
their Indiana roofing plant, which are supplied by a third party. Effective
January 1, 1999, this contract was amended to cover, among other things,
purchases of colored roofing granules by BMCA's subsidiaries. This contract is
subject to annual renewal, unless terminated by either party to such agreement.
In 1999, BMCA and its subsidiaries purchased a total of $57.3 million of mineral
products from the Company, representing 7.3% of the Company's total net sales
and 65.7% of the Company's net sales of mineral products. Sales by the Company
to BMCA and its subsidiaries totaled $51.1 and $62.6 million for 1997 and 1998,
respectively. The receivable from BMCA and its subsidiaries for sales of mineral
products as of December 31, 1998 and 1999 was $5.6 and $2.9 million,
respectively.
Pursuant to a management agreement (the "Management Agreement"), the
Company has provided certain general management, administrative, legal,
telecommunications, information and facilities services to certain of its
affiliates, including GAF, BMCA, G-I Holdings and GFC. Charges by the Company
for providing such services aggregated $5.6, $5.1 and $6.1 million for 1997,
1998 and 1999, respectively, and are reflected as reductions of "Selling,
general and administrative" expense. Such charges consist of management fees and
other reimbursable expenses attributable to, or incurred by the Company for the
benefit of, the respective parties, which are based on an estimate of the costs
the Company incurs to provide such services. The receivable from such affiliates
for management fees as of December 31, 1998 and 1999 was $1.7 and $3.1 million,
respectively. Effective January 1, 2000, the term of the Management Agreement
was extended through the end of 2000, and the management fees payable thereunder
were increased. In addition, the Management Agreement was amended to provide
that the Company pay to G-I Holdings lease payments due to a subsidiary of G-I
Holdings for the use of one of the Company's sales offices. The Company and BMCA
also allocate a portion of the management fees payable by BMCA under the
Management Agreement to separate lease payments for the use of BMCA's
headquarters. Based on the services provided by the Company in 1999 under the
Management Agreement, the aggregate amount payable to the Company under the
Management Agreement for 2000, net of the lease payments to G-I Holdings, is
expected to be approximately $6.1 million.
In September 1999, the Company granted its President and Chief Executive
Officer the right to purchase, and such officer purchased, 318,599 shares of its
common stock held in treasury for a purchase price of $9.563
F-36
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
NOTE 14. RELATED PARTY TRANSACTIONS--(CONTINUED)
per share, or an aggregate of $3.047 million. Pursuant to the purchase
agreement, the Company loaned such officer $3.047 million to purchase the shares
of common stock, which loan is evidenced by a recourse promissory note. The
recourse promissory note bears interest at the rate of 6% per annum. The
principal amount of the note is payable in four installments starting in June
2001 through January 2004. However, if such officer remains continuously
employed by the Company through each installment date, the principal amount due
on such installment date will be forgiven. As the loan is forgiven, compensation
expense will be recorded. The Company has accounted for this loan as a reduction
of "Additional paid-in capital." The difference between the market value of the
shares issued of $9.563 per share and the average cost per share in treasury of
$9.73 per share, amounting to $53,000, was also reflected as a reduction of
"Additional paid-in capital."
NOTE 15. BUSINESS SEGMENT INFORMATION
SFAS No. 131, "Disclosures about Segments of an Enterprise and Related
Information," establishes standards for companies to report information about
operating segments in annual financial statements, based on the approach that
management utilizes to organize the segments within the Company for management
reporting and decision making.
The Company is a leading multinational manufacturer of a broad spectrum of
specialty chemicals and mineral products. In addition to the Mineral Products
business segment, the Company operates its Specialty Chemicals business through
three reportable business segments, organized based upon the markets for their
products and the internal management of the Company, as follows:
Personal Care products serve as critical ingredients in the formulation of
many well-known skin care, hair care, toiletry and cosmetic products. Skin care
ingredients include sunscreen actives, waterproofing agents, preservatives,
emollients and moisturizers. Hair care ingredients include a number of specially
formulated fixative resins for hairsprays, mousses and gels, as well as
thickeners and stabilizers for shampoos and conditioners.
Pharmaceutical, Food and Beverage products are sold to these three
government-regulated industries. In the pharmaceutical market, the Company's
products serve as key ingredients in prescription and over-the-counter tablets,
injectable prescription drugs and serums, cough syrups, antiseptics, toothpastes
and denture adhesives. The Company's food products are comprised of the
alginates business which was acquired in October 1999 (see Note 7). Algin is a
naturally occurring hydrocolloid, derived from brown seaweed, and is used in
food, pharmaceutical and industrial applications. The Company's specialty
polymers serve the beverage market by assuring the clarity and extending the
shelf life of beer, wine and fruit juices.
Performance Chemicals, Fine Chemicals and Industrial. The Company's
Performance Chemicals business includes acetylene-based polymers, vinyl ether
monomers, and advanced materials for consumer, agricultural and industrial
applications. The Company's acetylene-based chemistry produces a number of
performance polymers for use in a wide range of industrial markets including
coatings, agricultural, imaging, detergents, electronics and metalworking. The
Performance Chemicals business also includes inert ingredients for the
agricultural industry, where the Company's solvents and polymers are used for
the formulation of safer and more effective crop treatment products. The Company
manufactures a broad range of highly specialized Fine Chemicals which are sold
to the pharmaceutical, biotechnology, agricultural and imaging markets,
including bulk pharmaceuticals, pharmaceutical intermediates, and pheromones for
use in insect population measurement and control. The Company's Industrial
business markets several intermediate and solvent products, such as butanediol,
tetrahydrofuran (THF) and N-methyl pyrrolidone (NMP), which are sold primarily
to industrial markets for use in high performance plastics, lubricating oil and
chemical processing, electronics cleaning, and coatings.
Mineral Products. The Company manufactures ceramic-coated colored roofing
granules that are sold primarily to the North American roofing industry for use
in the production of asphalt roofing shingles.
F-37
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
NOTE 15. BUSINESS SEGMENT INFORMATION--(CONTINUED)
The following segment data are presented based on the Company's internal
management reporting system for the four reportable business segments. The
Company evaluates segment performance based on operating income. Therefore, the
measure of profit or loss that is reported to management for each segment is
operating income. Interest expense, other income items and income taxes are not
allocated to the business segments for management reporting. At this time, the
Company's internal management reporting system does not report assets by segment
for the three specialty chemicals reportable segments (Personal Care;
Pharmaceutical, Food and Beverage; and Performance Chemicals, Fine Chemicals and
Industrial), as many of the Company's plant assets are utilized by several of
the segments. Therefore, the following asset-related segment data are presented
only for Specialty Chemicals and Mineral Products.
In 1999, the Company transferred its agricultural polymers and solvents
product lines from the Pharmaceutical, Agricultural and Beverage ("PAB") segment
to the Performance Chemicals, Fine Chemicals and Industrial segment.
Accordingly, prior year financial information for these two segments have been
reclassified to conform to the 1999 presentation. The effect on the years 1997
and 1998 was to reduce sales for the PAB segment by $58.1 and $52.7 million,
respectively, and reduce operating income by $5.5 and $8.6 million,
respectively, and increase sales and operating income for the Performance
Chemicals, Fine Chemicals and Industrial segment by like amounts. The PAB
segment has been renamed the Pharmaceutical, Food and Beverage segment, and
encompasses the alginates business which was acquired in October 1999 (see Note
7), including sales in 1999 after the date of its acquisition of $12.8 million.
Sales of Mineral Products to BMCA and its subsidiaries in 1997, 1998 and
1999 accounted for 61.5%, 66.2% and 65.7%, respectively, of the Company's net
sales of Mineral Products, representing 7.2%, 8.0% and 7.3%, respectively, of
the Company's total net sales. No other customer accounted for more than 5% of
the Company's total net sales in 1997, 1998 or 1999.
F-38
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
NOTE 15. BUSINESS SEGMENT INFORMATION--(CONTINUED)
<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31,
-------------------------------
1997 1998 1999
--------- --------- ---------
(MILLIONS)
<S> <C> <C> <C>
Net sales:
Personal Care................................................................ $ 187.4 $ 189.4 $ 187.1
Pharmaceutical, Food and Beverage............................................ 150.3 157.9 177.3
Performance Chemicals, Fine Chemicals and Industrial......................... 288.1 342.8 335.7
--------- --------- ---------
Total Specialty Chemicals................................................. 625.8 690.1 700.1
Mineral Products(1).......................................................... 83.2 94.5 87.3
--------- --------- ---------
Net sales...................................................................... $ 709.0 $ 784.6 $ 787.4
--------- --------- ---------
--------- --------- ---------
Operating income:
Personal Care(2)............................................................. $ 44.0 $ 34.7 $ 45.7
Pharmaceutical, Food and Beverage............................................ 41.1 37.2 44.9
Performance Chemicals, Fine Chemicals and Industrial......................... 37.4 63.3 41.2
--------- --------- ---------
Total Specialty Chemicals................................................. 122.5 135.2 131.8
Mineral Products(2).......................................................... 17.0 20.5 16.1
--------- --------- ---------
Total segment operating income............................................ 139.5 155.7 147.9
Unallocated corporate office expenses........................................ (1.8) (3.7) (1.5)
Provision for restructuring, staff reduction and impairment loss(3).......... -- (73.0) (0.4)
Merger-related expenses...................................................... -- (12.8) --
--------- --------- ---------
Total operating income.................................................... 137.7 66.2 146.0
Interest expense and other, net................................................ (33.5) (39.0) (69.5)
--------- --------- ---------
Income from continuing operations before income taxes.......................... $ 104.2 $ 27.2 $ 76.5
--------- --------- ---------
--------- --------- ---------
Assets:
Specialty Chemicals(4)....................................................... $ 985.7 $ 1,050.3 $ 1,182.0
Mineral Products............................................................. 155.2 157.6 153.3
General Corporate(5)......................................................... 319.6 531.8 500.0
Net assets of discontinued operation......................................... 23.5 24.2 --
--------- --------- ---------
Total assets................................................................... $ 1,484.0 $ 1,763.9 $ 1,835.3
--------- --------- ---------
--------- --------- ---------
Capital expenditures and acquisitions:
Specialty Chemicals.......................................................... $ 56.3 $ 153.8 $ 101.5
Mineral Products............................................................. 11.2 10.1 7.5
Unallocated corporate office................................................. 0.2 -- --
--------- --------- ---------
Total.......................................................................... $ 67.7 $ 163.9 $ 109.0
--------- --------- ---------
--------- --------- ---------
Depreciation and goodwill amortization:
Specialty Chemicals.......................................................... $ 44.0 $ 50.3 $ 53.1
Mineral Products............................................................. 10.1 11.8 11.4
Unallocated corporate office................................................. 0.4 2.2 0.4
--------- --------- ---------
Total.......................................................................... $ 54.5 $ 64.3 $ 64.9
--------- --------- ---------
--------- --------- ---------
</TABLE>
- ------------------
(1) Includes sales to BMCA and its subsidiaries of $51.1, $62.6 and
$57.3 million for 1997, 1998 and 1999, respectively.
(2) Personal Care operating income for the year 1999 includes a pre-tax gain of
$8.5 million from the sale of the pearlescent pigments product line. Mineral
Products operating income for the year 1998 includes a pre-tax gain of
$1.2 million from the sale of its tennis court materials business. See
Note 4.
(3) Of the $73.0 million restructuring and impairment loss in 1998, $70.0
million related to the Performance Chemicals, Fine Chemicals and Industrial
business segment. The remaining $3.0 million provision related to the
consolidation of European offices and affects all business segments except
Mineral Products.
(Footnotes continued on next page)
F-39
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
NOTE 15. BUSINESS SEGMENT INFORMATION--(CONTINUED)
(Footnotes continued from previous page)
(4) Identifiable assets of Specialty Chemicals as of December 31, 1997 include
the Company's 50% ownership of ISP Marl. See Notes 2 and 7.
(5) General Corporate assets primarily represent the Company's investments in
trading, available-for-sale and held-to-maturity securities and other
short-term investments, which are held for general corporate purposes and
are not allocated to business segments.
NOTE 16. GEOGRAPHIC INFORMATION
Financial information set forth below for foreign operations represent
sales and long-lived assets (property, plant and equipment) of foreign-based
subsidiaries. Net sales are attributed to countries based on the location of
customers and reflect the Company's internal management reporting system.
<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31,
-------------------------------
1997 1998 1999
--------- --------- ---------
(MILLIONS)
<S> <C> <C> <C>
Net sales:
North America:
United States................................................................... $ 370.7 $ 407.5 $ 410.5
Canada.......................................................................... 13.9 16.4 16.9
--------- --------- ---------
Total North America........................................................... 384.6 423.9 427.4
--------- --------- ---------
Europe:
Germany(1)...................................................................... 32.1 84.4 89.0
United Kingdom.................................................................. 35.0 34.6 39.8
France.......................................................................... 20.5 21.2 17.3
Italy........................................................................... 16.0 15.7 15.9
Switzerland..................................................................... 14.0 12.4 7.7
Other European countries........................................................ 62.9 64.4 64.4
--------- --------- ---------
Total Europe.................................................................. 180.5 232.7 234.1
--------- --------- ---------
Asia-Pacific:
Japan........................................................................... 36.8 26.3 24.7
China........................................................................... 11.9 9.4 12.7
Australia....................................................................... 11.2 11.0 11.5
Taiwan.......................................................................... 13.5 13.3 9.6
Other Asia-Pacific countries.................................................... 32.0 27.0 30.4
--------- --------- ---------
Total Asia-Pacific............................................................ 105.4 87.0 88.9
--------- --------- ---------
Latin America:
Brazil.......................................................................... 13.0 14.7 12.7
Mexico.......................................................................... 9.8 12.1 12.3
Other Latin American countries.................................................. 15.7 14.2 12.0
--------- --------- ---------
Total Latin America........................................................... 38.5 41.0 37.0
--------- --------- ---------
Total net sales...................................................................... $ 709.0 $ 784.6 $ 787.4
--------- --------- ---------
--------- --------- ---------
</TABLE>
F-40
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
NOTE 16. GEOGRAPHIC INFORMATION--(CONTINUED)
<TABLE>
<CAPTION>
DECEMBER 31,
-------------------------------
1997 1998 1999
--------- --------- ---------
(MILLIONS)
<S> <C> <C> <C>
Property, plant and equipment, net:
United States...................................................................... $ 499.4 $ 476.4 $ 504.8
Germany(2)......................................................................... 0.3 53.5 48.0
All other foreign countries........................................................ 13.9 17.7 17.4
--------- --------- ---------
Total property, plant and equipment, net............................................. $ 513.6 $ 547.6 $ 570.2
--------- --------- ---------
--------- --------- ---------
</TABLE>
- ------------------
(1) Net sales for Germany for 1997 do not include sales of the ISP Marl joint
venture, which was accounted for by the equity method prior to the Company's
acquisition, effective April 1, 1998, of the remaining 50% interest in ISP
Marl. See Notes 2 and 7.
(2) The Company's other principal long-lived asset in Germany as of
December 31, 1997 was the 50% ownership of ISP Marl of $34.3 million. See
Notes 2 and 7.
Approximately 48% of the Company's sales in 1999 were in foreign countries
which are subject to currency exchange rate fluctuation risks. See Note 2 for a
discussion of the Company's policy to manage these risks. Certain countries in
which the Company has sales are subject to additional risks, including high
rates of inflation, exchange controls, government expropriation and general
instability.
NOTE 17. COMMITMENTS AND CONTINGENCIES
Asbestos Litigation Against GAF
GAF Corporation has advised that, as of December 31, 1999, it was
defending approximately 115,000 pending alleged asbestos-related bodily injury
claims relating to the inhalation of asbestos fiber ("Asbestos Claims"), having
received notice of approximately 43,100 new Asbestos Claims during 1999. GAF has
advised that the Center for Claims Resolution ("CCR"), a non-profit organization
set up to administer and handle asbestos-related personal injury claims against
the participating companies and in which GAF Corporation was a member,
terminated GAF's membership, effective January 17, 2000. GAF has advised the CCR
that such termination was unauthorized and that it intends to take appropriate
measures to protect its rights to pursue claims against the CCR and its member
companies arising out of this improper termination and for other improper
actions. The disputes between GAF and the CCR are the subject of pending
Alternative Dispute Proceedings.
GAF Corporation has confirmed that it has experienced a significant
increase in the rate of new Asbestos Claims, principally involving claimants
without any asbestos-related impairment, and amounts demanded to settle such
claims. GAF anticipates that these trends could well continue for the
foreseeable future, and that the percentage of Asbestos Claims filed by
individuals with no physical impairment will remain high. GAF has advised that
it expects an increasingly adverse litigation environment in particular
jurisdictions. GAF believes that these trends and the CCR's termination of GAF's
membership resulted from, or were induced by, in no small part, retaliatory
actions taken by asbestos lawyers against GAF in connection with GAF's active
support of proposed legislation currently pending in Congress to address the
national asbestos litigation crisis. GAF has advised that depending upon whether
such trends continue, whether other retaliatory actions are taken, the ultimate
resolution of the disputes between GAF and the CCR, and whether the proposed
legislation currently pending in Congress is enacted into law, its financial
condition could be materially adversely affected by one or more of these
factors.
F-41
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
NOTE 17. COMMITMENTS AND CONTINGENCIES--(CONTINUED)
GAF Corporation has stated that it is committed to effecting a
comprehensive resolution of Asbestos Claims, and that it is exploring options to
accomplish this resolution, including the support of the proposed Congressional
legislation, but there can be no assurance that these efforts will be
successful.
Neither the Company nor the assets or operations of the Company, which was
operated as a division of a corporate predecessor of GAF prior to July 1986,
have been involved in the manufacture or sale of asbestos products. The Company
believes that it should have no legal responsibility for damages in connection
with asbestos-related claims. Should GAF, however, be unable to satisfy
judgments against it in asbestos-related lawsuits, its judgment creditors might
seek to enforce their judgments against the assets of GAF and, in that regard,
seek to recapture assets distributed by GAF, including assets distributed in the
Separation Transactions. Although the Company does not believe any such action
to unwind the Separation Transactions would be successful, there can be no
assurance in that regard. If a creditor were successful in recapturing assets
distributed in the Separation Transactions, such creditor could seek to enforce
any asbestos-related judgment against GAF's assets, including the capital stock
of the Company, and such enforcement could result in a change of control of the
Company. See Note 11 for a discussion of the Credit Agreement.
The Company has been advised by GAF Corporation and Samuel J. Heyman, its
Chairman of the Board, that in January 2000, an action was commenced against
Mr. Heyman, individually, in the United States District Court for the Southern
District of New York by a purported class of persons who hold an
asbestos-related personal injury claim against GAF Corporation or who have
become holders of such a claim arising out of asbestos exposure before
January 1, 1997. The action alleges, among other things, that the distribution
by GAF of the capital stock of the Company in the Separation Transactions was
without fair consideration and a fraudulent conveyance. The action seeks, among
other things, to set aside such distribution and to require Mr. Heyman to return
to GAF the capital stock of the Company held by him as well as an unspecified
amount of damages. GAF Corporation and Mr. Heyman have advised that they believe
this action is being funded by a consortium of asbestos lawyers as part of the
retaliatory actions described above and is without merit. Mr. Heyman has advised
that he intends to vigorously oppose this action.
Environmental Litigation
The Company, together with other companies, is a party to a variety of
proceedings and lawsuits involving environmental matters ("Environmental
Claims"), in which recovery is sought for the cost of cleanup of contaminated
sites, a number of which Environmental Claims are in the early stages or have
been dormant for protracted periods.
The Company estimates that its liability in respect of all Environmental
Claims (including those relating to its closed Linden, New Jersey plant
described below), as of December 31, 1999, is approximately $22.5 million,
before reduction for insurance recoveries reflected on the Company's balance
sheet (discussed below) of $11.1 million that relate to both past expenses and
estimated future liabilities ("estimated recoveries"). The gross environmental
liability is included within "Accrued liabilities" and "Other liabilities," and
the estimated recoveries are included within "Other assets."
In the opinion of the Company's management, the resolution of the
Environmental Claims should not be material to the business, liquidity, results
of operations, cash flows or financial position of the Company. However, adverse
decisions or events, particularly as to the liability and the financial
responsibility of the Company's insurers and of the other parties involved at
each site and their insurers, could cause the Company to increase its estimate
of its liability in respect of such matters. It is not currently possible to
estimate the amount or range of any additional liability.
After considering the relevant legal issues and other pertinent factors,
the Company believes that it will receive the estimated recoveries and the legal
expenses incurred on the Company's behalf and that the recoveries could be well
in excess of the current estimated liability for all Environmental Claims,
although there can be no
F-42
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
NOTE 17. COMMITMENTS AND CONTINGENCIES--(CONTINUED)
assurances in this regard. The Company believes it is entitled to substantially
full defense and indemnity under its insurance policies for most Environmental
Claims, although the Company's insurers have not affirmed a legal obligation
under the policies to provide indemnity for such claims.
In March 1995, GAF commenced litigation on behalf of itself and its
predecessors, successors, subsidiaries and related corporate entities seeking
amounts substantially in excess of the estimated recoveries. While the Company
believes that its claims are meritorious, there can be no assurance that the
Company will prevail in its efforts to obtain amounts equal to, or in excess of,
the estimated recoveries.
In June 1989, the Company entered into a Consent Order with the New Jersey
Department of Environmental Protection ("NJDEP") requiring the development of a
remediation plan for its closed Linden, New Jersey plant and the maintenance of
financial assurances (currently $7.5 million) to guarantee the Company's
performance. This Consent Order does not address any potential natural resource
damage claims. In April 1993, NJDEP issued orders which require the prevention
of discharge of contaminated groundwater and stormwater from the site and the
elimination of other potential exposure concerns. The Company believes, although
there can be no assurance, that, taking into account its plans for development
of the site, it can comply with the NJDEP order at a cost of no more than
$7.5 million.
Lease Commitments
Leases for certain equipment at the Company's mineral products plants are
accounted for as capital leases and are included in "Property, plant and
equipment, net," at December 31, 1998 and 1999 in the amount of $2.2 and $1.9
million, respectively. The Company also has operating leases related to the
sale-leaseback transaction discussed in Note 7 and for transportation,
production and data processing equipment and for various buildings. Rental
expense on operating leases was $9.7, $15.1 and $17.3 million for 1997, 1998 and
1999, respectively. Future minimum lease payments for properties which were held
under long-term noncancelable leases as of December 31, 1999 were as follows:
<TABLE>
<CAPTION>
CAPITAL OPERATING
LEASES LEASES
------- ---------
(THOUSANDS)
<S> <C> <C>
2000......................................................................................... $ 434 $ 9,917
2001......................................................................................... 341 8,803
2002......................................................................................... 145 7,731
2003......................................................................................... 140 6,987
2004......................................................................................... -- 6,325
Later years.................................................................................. -- 3,948
------- -------
Total minimum payments....................................................................... 1,060 $43,711
-------
-------
Less interest included above................................................................. 115
-------
Present value of net minimum lease payments.................................................. $ 945
-------
-------
</TABLE>
Other Matters
The Company has received site designation from the New Jersey Hazardous
Waste Facilities Siting Commission for the construction of a hazardous waste
treatment, storage and disposal facility at its Linden, New Jersey property and
has received approval from the New Jersey Turnpike Authority for a direct access
ramp from the Turnpike to the site. If the Company is successful in securing the
necessary permits to construct and operate the hazardous waste facility, the
Company intends to develop and operate the facility in a separate subsidiary,
either on its own or in a joint venture with a suitable partner. The Company
estimates that the cost of constructing the facility will be approximately $100
million and, if approved, the facility is anticipated to be in operation three
F-43
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(CONTINUED)
NOTE 17. COMMITMENTS AND CONTINGENCIES--(CONTINUED)
years after commencement of construction. The Company anticipates utilizing
internally generated cash and/or seeking project or other independent financing
for this project. Accordingly, the Company would not expect such facility to
impact materially its liquidity or capital resources. The Company is also
investigating other development opportunities at this site.
See Note 6 for information regarding additional contingencies.
NOTE 18. SUBSEQUENT EVENT
On January 27, 2000, the Company announced that it had notified Dexter of
its intent to present at Dexter's 2000 Annual Meeting of Shareholders, and
solicit proxies in favor of, a series of resolutions designed to facilitate the
Company's business combination proposal. Under the proposal, as amended on March
23, 2000, Dexter shareholders would receive at least $50 per share in cash,
subject to the execution of a mutually acceptable merger agreement.
The proposals include increasing the number of seats on Dexter's Board of
Directors from ten to seventeen, and electing ten Company nominees (including
eight nominees independent of the Company) to Dexter's Board who are committed
to considering and pursuing the Company's proposal, or a superior proposal. The
Company is also proposing a bylaw amendment and a shareholder resolution
requiring the removal of Dexter's "poison pill" in favor of offers for all
shares of at least $50 per share in cash.
The Company commenced a lawsuit in federal court in Connecticut on
January 27, 2000 to, among other things, declare valid the Company's proposed
resolutions, invalidate the "poison pill" and Dexter's supermajority bylaw
voting requirement and order Dexter's Annual Meeting to be held no later than
April 30, 2000.
F-44
<PAGE>
INTERNATIONAL SPECIALTY PRODUCTS INC.
SUPPLEMENTARY DATA (UNAUDITED)
QUARTERLY FINANCIAL DATA (UNAUDITED)
<TABLE>
<CAPTION>
1998 BY QUARTER 1999 BY QUARTER
--------------------------------- ---------------------------------
FIRST SECOND THIRD FOURTH FIRST SECOND THIRD FOURTH
------ ------ ------ ------ ------ ------ ------ ------
(MILLIONS)
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Net sales...................................... $191.1 $209.6 $197.5 $186.4 $201.6 $193.2 $188.2 $204.4
Cost of products sold.......................... 113.5 120.1 115.4 114.5 119.4 111.4 106.9 144.7
------ ------ ------ ------ ------ ------ ------ ------
Gross profit................................... $ 77.6 $ 89.5 $ 82.1 $ 71.9 $ 82.2 $ 81.8 $ 81.3 $ 59.7
------ ------ ------ ------ ------ ------ ------ ------
------ ------ ------ ------ ------ ------ ------ ------
Operating income (loss)(1)..................... $ 37.0 $ 46.5 $ 25.3 $(42.6) $ 46.8 $ 38.5 $ 38.5 $ 22.2
------ ------ ------ ------ ------ ------ ------ ------
------ ------ ------ ------ ------ ------ ------ ------
Income (loss) from continuing operations before
income taxes................................. $ 30.5 $ 37.1 $ 17.8 $(58.2) $ 17.7 $ 25.0 $ 23.5 $ 10.3
Income tax (provision) benefit................. (11.1) (14.1) (6.7) 17.8 (6.2) (8.8) (8.3) (3.6)
Minority interest in income of subsidiary...... (4.2) (5.0) (1.1) -- -- -- -- --
------ ------ ------ ------ ------ ------ ------ ------
Income (loss) from continuing operations....... 15.2 18.0 10.0 (40.4) 11.5 16.2 15.2 6.7
------ ------ ------ ------ ------ ------ ------ ------
Discontinued operation:
Income from discontinued operation, net of
income taxes.............................. 0.5 1.0 0.3 0.2 0.5 0.9 0.4 --
Gain on sale of discontinued operation, net
of income taxes........................... -- -- -- -- -- -- 24.5 (1.0)
------ ------ ------ ------ ------ ------ ------ ------
Income (loss) from discontinued operation...... 0.5 1.0 0.3 0.2 0.5 0.9 24.9 (1.0)
------ ------ ------ ------ ------ ------ ------ ------
Net income (loss).............................. $ 15.7 $ 19.0 $ 10.3 $(40.2) $ 12.0 $ 17.1 $ 40.1 $ 5.7
------ ------ ------ ------ ------ ------ ------ ------
------ ------ ------ ------ ------ ------ ------ ------
Earnings per common share(2):
Basic:
Income (loss) from continuing
operations.............................. $ .28 $ .33 $ .15 $ (.58) $ .16 $ .24 $ .23 $ .10
Income (loss) from discontinued
operation............................... .01 .02 -- -- .01 .01 .36 (.02)
------ ------ ------ ------ ------ ------ ------ ------
Net income (loss)......................... $ .29 $ .35 $ .15 $ (.58) $ .17 $ .25 $ .59 $ .08
------ ------ ------ ------ ------ ------ ------ ------
------ ------ ------ ------ ------ ------ ------ ------
Diluted:
Income (loss) from continuing
operations.............................. $ .28 $ .33 $ .15 $ (.58) $ .16 $ .24 $ .23 $ .10
Income (loss) from discontinued
operation............................... .01 .02 -- -- .01 .01 .36 (.02)
------ ------ ------ ------ ------ ------ ------ ------
Net income (loss)......................... $ .29 $ .35 $ .15 $ (.58) $ .17 $ .25 $ .59 $ .08
------ ------ ------ ------ ------ ------ ------ ------
------ ------ ------ ------ ------ ------ ------ ------
</TABLE>
- ------------------
(1) Operating income for the third quarter of 1998 reflects $12.8 million of
merger-related expenses and $3.0 million of restructuring charges related to
the consolidation of offices in the Company's European operations. Operating
income (loss) for the fourth quarter of 1998 reflects $70.0 million of
restructuring and impairment losses. See Note 5 to Consolidated Financial
Statements. Operating income for the first quarter of 1999 reflects a
pre-tax gain of $8.5 million from the sale of the Company's pearlescent
pigments business. See Note 4 to Consolidated Financial Statements.
(2) Earnings per share are calculated separately for each quarter and the full
year. Accordingly, annual earnings per share will not necessarily equal the
total of the quarters. Earnings per share for all periods prior to the
Merger are calculated based on the 53,833,333 shares of the Company's common
stock held by ISP Holdings' stockholders. See Note 1 to Consolidated
Financial Statements.
F-45
<PAGE>
SCHEDULE II
INTERNATIONAL SPECIALTY PRODUCTS INC.
VALUATION AND QUALIFYING ACCOUNTS
YEAR ENDED DECEMBER 31, 1997
(THOUSANDS)
<TABLE>
<CAPTION>
BALANCE CHARGED TO BALANCE
JANUARY 1, COSTS AND DECEMBER 31,
DESCRIPTION 1997 EXPENSES DEDUCTIONS 1997
- -------------------------------------------------------------- ---------- ---------- ---------- ------------
<S> <C> <C> <C> <C>
Valuation and Qualifying Accounts Deducted from
Assets to Which They Apply:
Allowance for doubtful accounts.......................... $ 2,710 $ 338 $ 439(a) $ 2,609
Reserve for inventory market valuation................... 11,657 7,631 5,703(a) 13,585
</TABLE>
YEAR ENDED DECEMBER 31, 1998
(THOUSANDS)
<TABLE>
<CAPTION>
BALANCE CHARGED TO BALANCE
JANUARY 1, COSTS AND DECEMBER 31,
DESCRIPTION 1998 EXPENSES DEDUCTIONS OTHER 1998
- ------------------------------------------------------ ---------- ---------- ---------- ----- ------------
<S> <C> <C> <C> <C> <C>
Valuation and Qualifying Accounts Deducted from
Assets to Which They Apply:
Allowance for doubtful accounts.................. $ 2,609 $ 78 $ 291(a) $ 98(b) $ 2,494
Reserve for inventory market valuation........... 13,585 15,410 7,762(a) 127(b) 21,360
Reserves for restructuring....................... -- 10,503 1,161 -- 9,342
</TABLE>
YEAR ENDED DECEMBER 31, 1999
(THOUSANDS)
<TABLE>
<CAPTION>
BALANCE CHARGED TO BALANCE
JANUARY 1, COSTS AND DECEMBER 31,
DESCRIPTION 1999 EXPENSES DEDUCTIONS 1999
- -------------------------------------------------------------- ---------- ---------- ---------- ------------
<S> <C> <C> <C> <C>
Valuation and Qualifying Accounts Deducted from
Assets to Which They Apply:
Allowance for doubtful accounts.......................... $ 2,494 $2,026 $ 1,109(a) $ 3,411
Reserve for inventory market valuation................... 21,360 5,063 11,275(a) 15,148
Reserves for restructuring and staff reduction........... 9,342 2,273(c) 10,291(d) 1,324
</TABLE>
- ------------------
Notes:
(a) Represents write-off of uncollectible accounts net of recoveries, and the
effects of foreign currency translation.
(b) Represents balance acquired in acquisitions.
(c) Reflects a reserve established for a staff reduction program in 1999 (see
Note 5 to Consolidated Financial Statements).
(d) Includes $1,863 of excess reserves which were reversed and credited to the
Consolidated Statement of Income (see Note 5 to Consolidated Financial
Statements).
S-1
<PAGE>
EXHIBIT INDEX
<TABLE>
<CAPTION>
EXHIBIT
NUMBER DESCRIPTIONS
- ------ ---------------------------------------------------------------------------------------------------------
<S> <C>
3.1 -- Amended and Restated Certificate of Incorporation of ISP (incorporated by reference to Exhibit 4.1 to
Post-Effective Amendment No. 1 of Form S-8 to the Registration Statement on Form S-4 of ISP
(Registration No. 333-53709) (the "ISP Registration Statement")).
3.2 -- By-laws of ISP (incorporated by reference to Exhibit 99.2 to the ISP Registration Statement).
4.1 -- 9% Note Indenture, dated as of October 18, 1996, between ISP Holdings and The Bank of New York, as
trustee (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-4 of ISP
Holdings (Registration No. 333-17827) (the "Holdings Registration Statement")).
4.2 -- 9 3/4% Note Indenture, dated as of October 18, 1996, between ISP Holdings and The Bank of New York, as
trustee (incorporated by reference to Exhibit 4.2 to the Holdings Registration Statement).
10.1 -- Amended and Restated Management Agreement, dated as of January 1, 1999, among GAF Corporation, G-I
Holdings Inc., G Industries Corp., Merick Inc., GAF Fiberglass Corporation, ISP, GAF Building
Materials Corporation, GAF Broadcasting Company, Inc., Building Materials Corporation of America and
ISP Opco Holdings Inc. (the "Management Agreement") (incorporated by reference to Exhibit 10.1 to
BMCA's Annual Report on Form 10-K for the fiscal year ended December 31, 1998).
10.2 -- Amendment No. 1 to the Management Agreement, dated as of January 1, 2000.
10.3 -- Indemnification Agreement, dated as of October 18, 1996, among GAF Corporation, G-I Holdings Inc., ISP
Holdings, G Industries Corp. and GAF Fiberglass Corporation (incorporated by reference to
Exhibit 10.7 to the Holdings Registration Statement).
10.4 -- Tax Sharing Agreement, dated as of January 1, 1997, among ISP Holdings, International Specialty
Products Inc. and certain subsidiaries of International Specialty Products Inc. (incorporated by
reference to Exhibit 10.8 to the Holdings Registration Statement).
</TABLE>
<PAGE>
<TABLE>
<S> <C>
10.5 -- Non-Qualified Retirement Plan Letter Agreement (incorporated by reference to Exhibit 10.11 to the
Registration Statement on Form S-1 of International Specialty Products Inc. (Registration
No. 33-40351)).*
10.6 -- International Specialty Products Inc. 1991 Incentive Plan for Key Employees and Directors, as amended
(incorporated by reference to Exhibit 4.3 to Post-Effective Amendment No. 1 on Form S-8 to the ISP
Registration Statement).*
10.7 -- Agreement, dated July 30, 1993, between International Specialty Products Inc. and Carl R. Eckardt
(incorporated by reference to Exhibit 10.16 to the Registration Statement on Form S-4 of G-I Holdings
Inc. (Registration No. 33-72220)).*
10.8 -- Letter Agreement, dated September 29, 1999, between International Specialty Products Inc. and Sunil
Kumar (incorporated by reference to Exhibit 10 to the ISP Quarterly Report on Form 10-Q for the
fiscal quarter ended October 3, 1999).*
10.9 -- Compensation and Indemnification Agreement among Charles M. Diker, Burt Manning and ISP, dated
October 10, 1997 (incorporated by reference to Exhibit 10.23 to the ISP Registration Statement).*
10.10 -- Consulting Agreement, dated November 23, 1999, between Carl R. Eckardt and ISP.*
10.11 -- Agreement and Plan of Merger between ISP Holdings and International Specialty Products Inc., dated as
of March 30, 1998 (incorporated by reference to Exhibit A to Amendment No. 2 to ISP Holdings Schedule
13D with respect to the common stock of International Specialty Products Inc. filed with the
Securities and Exchange Commission on April 1, 1998).
21 -- Subsidiaries of ISP.
23 -- Consent of Arthur Andersen LLP.
27 -- Financial Data Schedule for fiscal year 1999, which is submitted electronically to the Securities and
Exchange Commission for information only.
</TABLE>
- ------------------
* Management and/or compensation plan or arrangement.
<PAGE>
AMENDMENT No. 1, dated as of January 1, 2000, to AMENDED AND RESTATED
MANAGEMENT AGREEMENT, dated as of January 1, 1999 (the "Agreement"), by and
among GAF Corporation ("GAF"), G-I Holdings Inc. ("G-I Holdings"), G Industries
Corp. ("Industries"), Merick Inc. ("Merick"), GAF Fiberglass Corporation
(formerly known as GAF Chemicals Corporation) ("GFC"), International Specialty
Products Inc. (formerly known as ISP Holdings Inc.) ("New ISP"), GAF Building
Materials Corporation ("Building Materials"), GAF Broadcasting Company, Inc.
("Broadcasting"), Building Materials Corporation of America ("BMCA"), and ISP
Opco Holdings Inc. (the "Company"), as assignee of International Specialty
Products Inc.
WHEREAS, in accordance with Section 7 of the Agreement, the parties
desire to adjust the management fees payable to the Company under the Agreement,
effective January 1, 2000, in order to reflect the costs to the Company of
providing services thereunder and the costs to a subsidiary of G-I Holdings for
providing certain office space to a subsidiary of the Company; and
WHEREAS, the parties desire to extend the term of the Agreement;
NOW, THEREFORE, the parties hereby amend the Agreement as follows:
1. Section 1 of the Agreement is hereby amended to extend the
Term until December 31, 2000.
2. Section 3 of the Agreement is amended to read in its
entirety as follows:
"In consideration of the Company providing Services hereunder,
(i) each of the corporations listed below shall pay to the
Company a management fee (the "Management Fee") at the
following respective rates for the year ending December 31,
2000: BMCA (on behalf of itself and its subsidiaries) -
$3,707,000; G-I Holdings (on behalf of itself and its
subsidiaries other than BMCA and BMCA's subsidiaries) -
$608,000 and New ISP - $109,463; and (ii) BMCA shall pay to
the Company a fee for the Company's provision to BMCA of
treasury, acquisition and investment management services
("Financial Services Fee") at the annual rate of $1,120,000
for the year ended December 31, 2000. The Management Fee and
the Financial Services Fee shall be payable quarterly in
arrears.
<PAGE>
In addition to the Management Fee and the Financial Services
Fee, BMCA shall pay to a wholly-owned subsidiary of the
Company sublease payments pursuant to and in accordance with
the Sublease between BMCA and such subsidiary, the form of
which is attached as Exhibit A hereto and made a part hereof.
The Company, on behalf of its subsidiary as tenant under the
Lease attached hereto as Exhibit B and made a part hereof (the
"Lease), shall pay or cause to be paid to G-I Holdings the
lease payments due and payable under the Lease, as the Company
shall be reimbursed by such subsidiary for all such lease
payments made on its behalf. Such lease payments shall be paid
to G-I Holdings by way of offsetting the Management Fee and
other amounts due and payable to the Company by G-I Holdings
on behalf of itself and its subsidiaries (including the
landlord under the Lease) under the Agreement.
3. In all other respects, the Agreement as previously amended
shall remain in full force and effect.
4. This Amendment is subject to the approval of the Board of
Directors of the Company.
2
<PAGE>
IN WITNESS WHEREOF, the parties have executed this Amendment on the
date and year first above written.
<TABLE>
<S> <C>
GAF CORPORATION G-I HOLDINGS INC.
By: /s/ Susan B. Yoss By: /s/ Susan B. Yoss
----------------- -----------------
Name: Susan B. Yoss Name: Susan B. Yoss
Title: Senior Vice President, Title: Senior Vice President,
Chief Financial Officer and Chief Financial Officer and
Treasurer Treasurer
G INDUSTRIES CORP. MERICK INC.
By: /s/ Susan B. Yoss By: /s/ Susan B. Yoss
----------------- -----------------
Name: Susan B. Yoss Name: Susan B. Yoss
Title: Senior Vice President, Title: Senior Vice President and
Chief Financial Officer and Treasurer
Treasurer
GAF FIBERGLASS CORPORATION INTERNATIONAL SPECIALTY PRODUCTS INC.
By: /s/ Susan B. Yoss By: /s/ Randall R. Lay
----------------- ------------------
Name: Susan B. Yoss Name: Randall R. Lay
Title: Senior Vice President, Title: Executive Vice President and
Chief Financial Officer and Chief Financial Officer
Treasurer
GAF BUILDING MATERIALS CORPORATION GAF BROADCASTING COMPANY, INC.
By: /s/ Susan B. Yoss By: /s/ Susan B. Yoss
----------------- -----------------
Name: Susan B. Yoss Name: Susan B. Yoss
Title: Senior Vice President, Title: Senior Vice President and
Chief Financial Officer and Treasurer
Treasurer
BUILDING MATERIALS CORPORATION ISP OPCO HOLDINGS INC.
OF AMERICA
By: /s/ William C. Lang By: /s/ Randall R. Lay
------------------- -------------------
Name: William C. Lang Name: Randall R. Lay
Title: Executive Vice President, Title: Executive Vice President and
Chief Financial Officer and Chief Financial Officer
Chief Administrative Officer
</TABLE>
3
<PAGE>
November 23, 1999
Carl R. Eckardt
[Address]
Re: Consulting Agreement
Dear Carl:
This letter sets forth the Consulting Agreement between International
Specialty Products Inc. (as defined in Paragraph 16 of the General Release
Agreement to which this Consulting Agreement is attached and made a part) and
you for certain consulting services as described below, referring to you as
"Consultant" and to this Company as "ISP".
1. Consulting Services. During the Term of this Consulting Agreement,
Consultant shall provide ISP with Consulting Services (referred to hereinafter
as "Services") which shall include providing administrative and managerial
advice, cooperating with ISP and responding to reasonable inquiries and requests
for information by ISP in connection with any matters in which Consultant was
involved during employment with ISP, and the management of the Linden project
and such other projects as may be designated by the President and Chief
Executive Officer. Such Services shall be performed in Wayne, New Jersey and at
other locations as mutually agreed upon. ISP, through its designated
representative, will request Services when needed and Consultant agrees to use
his best efforts to meet such requests. At ISP's request, Consultant shall
provide Services for two to four days per month during the Term of this
Consulting Agreement. Consultant acknowledges and agrees he shall be providing
the Services pursuant to this Consulting Agreement as an independent contractor
and that this Consulting Agreement does not and is not intended to create any
employer-employee relationship between Consultant and ISP. As such, Consultant
acknowledges that he is not eligible to participate and waives any claims he may
have to any type of benefits offered to full-time employees of ISP, its
affiliates or subsidiaries, except for any benefit expressly required by law
(e.g., COBRA continuation coverage) or except as expressly provided in the
General Release Agreement executed by Eckardt to which this Consulting Agreement
is attached and made a part.
2. Designated Representative. In rendering the Services, Consultant
(unless notified to the contrary in writing by ISP) shall report to Sunil Kumar,
President and Chief Executive Officer of ISP.
3. Compensation. ISP shall pay Consultant $7,600.00 per month during
the Term of this Consulting Agreement. Consultant shall be available during the
Term of this Consulting Agreement to provide such Services to ISP for up to four
(4) days per month as requested by ISP. A work day shall consist of 8.0 hours,
exclusive of meals and breaks. No other payments will be made by ISP to
Consultant for Services performed without ISP's prior written request. However,
if ISP desires Services in excess of four (4) days per month, and Consultant
desires to provide such additional Services, ISP shall pro rate the monthly rate
set forth in this Paragraph 3 for each additional working day.
4. Term. The term of this Consulting Agreement shall commence on
November 20, 1999 and shall terminate at midnight on November 19, 2001, unless
<PAGE>
earlier terminated by mutual written agreement of the Parties hereto. The Term
of this Consulting Agreement shall not be extended after its expiration on
November 19, 2001 unless both ISP and Eckardt otherwise agree in writing.
5. General Conditions. The attached General Conditions for Consulting
Agreements are a part of this Consulting Agreement.
6. Miscellaneous. The terms and conditions of the "General Release
Agreement" by and between ISP and Consultant, to which this Consulting Agreement
is attached, are not changed in any manner by this Consulting Agreement.
Please indicate your agreement to the terms and conditions stated in
this Consulting Agreement by signing and returning this letter to Sunil Kumar,
President and Chief Executive Officer, 1361 Alps Road, Building 8, Wayne, New
Jersey 07470.
Very truly yours,
/s/ Sunil Kumar
Sunil Kumar
President and
Chief Executive Officer
ACCEPTED AND AGREED TO:
/s/ Carl R. Eckardt
- -------------------------
Carl R. Eckardt
Date: December 16, 1999
--
2
<PAGE>
GENERAL CONDITIONS
FOR ISP
CONSULTING AGREEMENTS
1. Confidential Relationship. Consultant shall forever keep confidential and
shall not use except in the performance of Services any proprietary
technical or business information of ISP or its affiliates which
Consultant has heretofore obtained or may obtain during the term of this
Consulting Agreement as well as any proprietary technical or business
information of third parties which is made available to Consultant in
connection with Consultant's work hereunder.
2. Proprietary Rights. The work product of Consultant's Services, whether of
a business or technical nature, and any writings, discoveries or
inventions made or conceived during the course of or resulting from the
Services, shall be promptly communicated to and be the property of ISP.
Consultant shall perform all lawful acts requested by ISP to:
(i) perfect title therein in ISP or its nominee; and
(ii) enable ISP or its nominee to obtain and maintain copyright,
patent or other legal protection therefor anywhere in the
world.
3. Reimbursement for Expenses. ISP shall reimburse Consultant for all
reasonable travel and lodging expenses Consultant incurs at ISP's request
in the performance of Services hereunder and for any other disbursements
by Consultant that ISP authorizes in advance. Consultant shall not receive
compensation for travel time, except to the extent Services are actually
performed during such time. Air travel, if required, shall be by coach or
economy class and must be arranged through ISP's travel department. All
travel expenses must be in accordance with ISP's Travel Policy. Consultant
shall submit an Invoice at the end of any month in which Services are
performed including full supporting documentation including a receipt for
any expenditure over $25.00.
4. Complete Compensation. Consultant agrees that the payments set forth in
this Consulting Agreement are full and complete compensation for all
Services performed, for all obligations assumed and for all inventions,
improvements, patent rights and copyrights assigned hereunder.
5. Conflict of Interest. Consultant represents that Consultant has no
obligation to any other party which is inconsistent with Consultant's
obligations under this Consulting Agreement and that Consultant shall not,
in the performance of this Consulting Agreement, breach any obligations
that Consultant has to others. Consultant agrees not to perform any
services for others that would create a conflict of interest with
Consultant's obligations under this Consulting Agreement or would
otherwise violate any other legal or contractual obligation to ISP
including but not limited to the obligations set forth in the
Confidentiality, Invention and Non-Competition Agreement he signed as a
condition of employment with ISP.
6. Notices. Any notices, payments or statements to be sent under this
Consulting Agreement shall be sent to Consultant at the address to which
this letter is directed and to ISP at its address above (to the attention
of its designated representative) or at such other address as a party may
designate in writing.
3
<PAGE>
7. Independent Contractor. Consultant shall perform this Agreement solely as
an independent contractor and not as ISP's agent or employee. Consultant
has no authority to make any statement, representation or commitment of
any kind or to take any action binding upon ISP without ISP's prior
written authorization. Consultant will not be entitled to any benefits
that ISP makes available to its employees and ISP will not withhold from
compensation payable under this Agreement any income, social security, or
other taxes. Consultant will not be entitled to any benefits that ISP
makes available to its employees and ISP will not withhold any amount
attributable to payments hereunder for any benefit program or for any
local, state, municipal, federal or national tax purpose, and the
Consultant shall be solely responsible for fulfilling all such tax
obligations, including without limitation any salary, wage or payroll
taxes or any other costs based on employment and/or payroll, including
without limitation any form of social security, unemployment insurance,
disability benefits, workers compensation, severance payments, pension,
health, life or any other employee benefits or insurance, and/or any other
local state, municipal, federal or national taxes or levies otherwise
imposed in connection with the fee paid Consultant hereunder except as
expressly provided in the General Release Agreement to which these
Conditions are attached and made a part.
8. Indemnity. (i) Because Consultant is an independent contractor, any
personal injury or property damage suffered by Consultant or Consultant's
employees in the course of performing Services under this Agreement will
be Consultant's sole responsibility. ISP will not carry any insurance or
otherwise provide for the protection of Consultant or any employee of
Consultant. Consultant shall indemnify, defend and hold harmless ISP, its
affiliates, and their respective directors, officers, employees, and
agents from all liabilities, damages and expenses and claims for damages,
suits, proceedings, recoveries, judgments, costs, losses, penalties, fines
or executions, (including, but not limited to, litigation costs and
expenses and reasonable attorneys' fees, as well as such costs, fees, and
expenses as may be incurred by ISP, its affiliates and/or their respective
directors, officers, employees, and/or agents in establishing their rights
to indemnification hereunder) which may be made, had, brought or recovered
from ISP, its affiliates and/or their respective directors, officers,
employees, and/or agents, by reason of or on account of, or which may
arise out of or result from, Consultant's performance, non-performance, or
improper performance of Consulting Services under this Agreement,
Consultant's willful misconduct or misrepresentation, or from any breach
by Consultant of this Agreement or Consultant's failure to comply with
ISP's instructions or directions.
(ii) ISP shall indemnify, defend and hold Consultant harmless, from all
liabilities, damages and expenses and claims for damages, suits,
proceedings, recoveries, judgments, costs, losses, penalties, fines, or
executions (including, but not limited to, litigation costs and expenses
and reasonable attorneys' fees, as well as such costs, fees and expenses
as may be incurred by Consultant in establishing his rights to
indemnification hereunder) which may be made, had, brought or recovered
from Consultant by reason of or on account of, or which may arise out of
or result from, Consultant's performance of Consulting Services under this
Agreement; provided, however, ISP shall not be obligated to indemnify
Consultant for Consultant's gross negligence, willful misconduct or
misrepresentation, or from any breach by Consultant of this Agreement or
Consultant's failure to comply with ISP's instructions or directions.
(iii) Any other provisions contained herein to the contrary
notwithstanding, Consultant and ISP agree that the indemnification
provisions set forth in this Condition 8, shall indefinitely survive the
4
<PAGE>
expiration or earlier termination of this Agreement and remain in effect
with respect to any occurrence or claim arising out of or in connection
with this Agreement.
9. Laws and Regulations. Consultant shall comply with all applicable laws and
governmental regulations. Consultant is not expected or authorized to take
any action in the name of or otherwise on behalf of ISP which would
violate applicable laws or governmental regulations.
10. Changes. This Agreement may be changed only by a written amendment signed
by both parties.
11. Survival of Obligations. The obligations set forth in Conditions 1 and 2
above shall survive the termination of this Consulting Agreement to the
extent indicated therein.
12. Assignment. Consultant shall not assign this Consulting Agreement and will
not delegate or subcontract any of the Services without the prior written
consent of ISP.
13. Governing Law. The construction, interpretation and performance of this
Agreement shall be governed by the laws of New Jersey and any action to
enforce any rights hereunder shall only be commenced and prosecuted in the
State of New Jersey.
5
<PAGE>
Exhibit 21
INTERNATIONAL SPECIALTY PRODUCTS INC.
LIST OF SUBSIDIARIES
STATE OF
COMPANY INCORPORATION
- ------- -------------
Belleville Realty Corp. Delaware
ISP Opco Holdings Inc. Delaware
Bluehall Incorporated Delaware
Verona Inc. Delaware
International Specialty Products Funding Corporation Delaware
ISP Alginates Inc. Delaware
ISP Environmental Services Inc. Delaware
ISP Management Company, Inc. Delaware
ISP Minerals Inc. Delaware
ISP Mineral Products Inc. Delaware
ISP Realty Corporation Delaware
ISP Real Estate Company, Inc. Delaware
ISP Technologies Inc. Delaware
ISP Chemicals Inc. Delaware
ISP Fine Chemicals Inc. Delaware
ISP Freetown Fine Chemicals Inc. Delaware
ISP Newark Inc. Delaware
ISP Van Dyk Inc. Delaware
ISP Investments Inc. Delaware
ISP Global Technologies Inc. Delaware
ISP International Corp. Delaware
ISP (Puerto Rico) Inc. Delaware
ISP Andina, C.A. Venezuela
ISP Argentina S.A. Argentina
ISP Asia Pacific Pte Ltd. Singapore
ISP (Australasia) Pte Ltd. Australia
ISP (Belgium) N.V. Belgium
ISP (Belgium) International N.V. Belgium
ISP do Brasil Ltda. Brazil
ISP (Canada) Inc. Canada
ISP Ceska Republika Spol, S.R.O. Czech. Rep.
ISP (China) Limited China
ISP Colombia Ltda. Colombia
ISP Freight Service N.V. Belgium
ISP Global Operations (Barbados) Inc. Barbados
ISP Global Technologies (Belgium) S.A. Belgium
ISP Global Technologies (Germany) Holding GmbH Germany
ISP Customer Service GmbH Germany
ISP Global Technologies Deutschland GmbH Germany
International Specialty Products ISP (France) S.A. France
ISP Holdings (U.K.) Ltd. United Kingdom
ISP Alginates (U.K.) Ltd. United Kingdom
ISP (Great Britain) Co. Ltd. United Kingdom
<PAGE>
ISP (Hong Kong) Limited Hong Kong
ISP Ireland(1) Ireland
ISP (Italia) S.r.l. Italy
ISP (Japan) Ltd. Japan
ISP (Korea) Limited Korea
ISP Marl Holdings GmbH Germany
ISP Acetylene GmbH Germany
ISP Marl GmbH Germany
ISP Mexico, S.A. de C.V. Mexico
ISP (Norden) A.B. Sweden
ISP (Osterreich) G.m.b.h. Austria
ISP (Polska) Sp.z. o.p. Poland
ISP Sales (Barbados) Inc. Barbados
ISP Sales (U.K.) Limited Ireland
ISP (Singapore) Pte Ltd. Singapore
ISP (Switzerland) A.G. Switzerland
ISP (Thailand) Co., Ltd. Thailand
Chemfields Pharmaceuticals Private Limited(2) India
- ---------------------
(1) 25% owned by ISP (Italia) S.r.l.; 75% owned by International
Specialty Products ISP (France) S.A.
(2) 50.1% owned by ISP Global Technologies Inc.
<PAGE>
Exhibit 23
CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS
As independent public accountants, we hereby consent to the incorporation of our
report dated February 28, 2000, included in this Form 10-K, into International
Specialty Products Inc.'s previously filed Registration Statement on Form S-4
File No. 333-53709 and Registration Statements on Form S-8 File Nos. 333-60469
and 333-62359.
ARTHUR ANDERSEN LLP
Roseland, New Jersey
March 29, 2000
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
1999 ANNUAL REPORT ON FORM 10-K OF INTERNATIONAL SPECIALTY PRODUCTS INC.
AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> YEAR
<FISCAL-YEAR-END> DEC-31-1999
<PERIOD-START> JAN-01-1999
<PERIOD-END> DEC-31-1999
<CASH> 23,309
<SECURITIES> 355,300
<RECEIVABLES> 82,201
<ALLOWANCES> 3,411
<INVENTORY> 151,775
<CURRENT-ASSETS> 715,365
<PP&E> 570,218
<DEPRECIATION> 268,403
<TOTAL-ASSETS> 1,835,308
<CURRENT-LIABILITIES> 277,282
<BONDS> 820,141
0
0
<COMMON> 695
<OTHER-SE> 586,566
<TOTAL-LIABILITY-AND-EQUITY> 1,835,308
<SALES> 787,356
<TOTAL-REVENUES> 787,356
<CGS> 482,397
<TOTAL-COSTS> 482,397
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 78,552
<INCOME-PRETAX> 76,454
<INCOME-TAX> 26,822
<INCOME-CONTINUING> 49,632
<DISCONTINUED> 25,298
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 74,930
<EPS-BASIC> 1.09
<EPS-DILUTED> 1.09
</TABLE>
